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Adverse drug reactions (ADRs) are an important healthcare problem frequently associated with 
significant morbidity, hospitalisation and mortality. Globally, the prevalence of ADR-related 
hospitalisation and mortality vary from 0.2% to 54.5% and 0.1% to 10.0%, respectively. Severe 
ADRs are important reason for admission to intensive care unit and extensions of hospital stay 
in approximately one-fifth of overall ADR-related admissions. Overall, the rates of ADR-
related hospital admissions and mortality are comparable between developed and developing 
countries. However, there are marked differences between developed and developing countries 
with regard to the nature of the ADRs implicated in hospital admissions and the mortality rate. 
In addition, there are some important differences in risk factors contributing to ADR-related 
hospital admissions and mortality due to the differences in population socio-demographics, 
disease characteristics, drug therapy used, healthcare systems and ethnic origins.  
In Ethiopia, a developing country, there are number of factors thought to increase the risk of 
ADR-related hospital admission. These include, but are not limited to, a greater proportion of 
patients who take anti-tubercular (anti-TB) drugs and antiretroviral therapy (ART), a high 
prevalence of malnutrition and anaemia, a higher prevalence of concomitant anti-TB drugs and 
ART use, and widespread use of traditional remedies. In addition, there is a higher proportion 
of the slow acetylator phenotype among patients on ART and anti-TB drugs that increases 
susceptibility to ADRs. There is growing attention to chronic disease management with new 
and complex therapies in ambulatory care clinics, where there are higher rates of drug-related 
problems and irrational use of medicines that could lead to drug-related harm. Unlike 
developed countries, there is substantial all-cause mortality rate among patients presenting to 
emergency departments, a high rate of mortality among HIV/TB co-infected patients on drug 





there are increasing rates of concurrent infectious and non-communicable diseases demanding 
multiple medications with potential drug interactions.  
The majority of studies focussing on risk factors for ADR-related hospitalisation and mortality 
have been conducted in developed countries. In Ethiopia, to our knowledge, there are no studies 
reporting on the prevalence and risk factors associated with ADR-related hospitalisation, or the 
mortality rate attributable to ADRs in patients presenting to hospital. The limited information 
available in the Ethiopian setting, the presence of multiple factors suspected to increase the risk 
of ADR-related admissions and evidence of a substantial burden of ADR-related admissions 
and mortality in other settings provided the impetus for this study. Determining the magnitude 
of ADR-related hospitalisation and mortality and identifying factors contributing to ADRs for 
community-based patients are crucial in understanding the extent of the problem and 
developing preventive strategies to decrease the clinical and economic burden. Therefore, the 
main aims of the body of work presented in this thesis were to identify ADRs responsible for 
ADR-related hospital admissions; investigate the medications and other risk factors associated 
with the ADRs; and to determine their severity, preventability, clinical presentation and 
outcomes. 
Due to the absence of similar studies in Ethiopian patients, we began by reviewing the existing 
literature on the prevalence and contributing factors of ADR-related hospitalisations in 
developed and developing countries. From 43 relevant publications identified through 
systematic review, the median (with interquartile range (IQR)) prevalence of ADR-related 
hospitalisations in developed and developing countries were 6.3% (3.3-11.0%) and 5.5% (1.1-
16.9%), respectively. Similarly, the median proportions of ADR-related mortality in developed 
and developing countries were 1.7% (0.7-4.8%) and 1.8% (0.8-8.0%), respectively. Older age, 





associated with an increased risk for ADR-related hospitalisation in both settings, while 
HIV/AIDS was implicated in developing countries only. The majority of ADRs were 
preventable in both settings, highlighting the importance of improving medication use, 
particularly in vulnerable patient groups such as the elderly, patients with multiple 
comorbidities and, in developing countries, with HIV/AIDS.  
Following review of existing literature, a prospective observational study determined the 
prevalence of ADR-related hospitalisation, characterised the ADR types and their 
preventability, characterised the implicated medications and identified predictors of ADR-
related hospitalisation. This was determined through detailed review of medical records, 
laboratory tests and patient interviews followed by causality assessment by the Naranjo 
algorithm and expert consensus. Of 1,001 patients included, 103 (10.3%) were deemed to have 
experienced an ADR-related admission. Common ADRs responsible for hospitalisation were 
hepatotoxicity (35, 29.4%) followed by acute kidney injury (27, 22.7%) and electrolyte 
disturbances (hypokalaemia and hypocalcaemia) (13, 10.9%). The drug classes most frequently 
involved in ADRs were anti-TB drugs (36 patients, 35.0%), followed by ART (22 patients, 
21.4%) and diuretics (19 patients, 18.4%). Body mass index (BMI) <18.5 kg/m2 (adjusted odd 
ratio [AOR]=1.69; 95% confidence interval [CI]=1.10-2.62), pre-existing renal disease 
(AOR=2.84; 95% CI=1.38-5.85), pre-existing liver disease (AOR=2.61; 95% CI=1.38-4.96), 
number of comorbidities ≥4 (AOR=2.09; 95% CI=1.27-3.44), number of drugs ≥6 (AOR=2.02; 
95% CI=1.26-3.25) and history of previous ADRs (AOR=24.27; 95% CI=11.29-52.17) were 
found to be independent predictors of ADR-related hospitalisation in an ADR risk prediction 
model with an area under the receiver operator curve of 79.0% (95% CI 73.9%-84.1%). Most 





Another component of a prospective observational study determined the prevalence of 
mortality attributable to ADRs in patients presenting to hospital, and identified drugs and 
factors associated with ADR-related mortality. Of 1,001 patients, 15 (1.5%, 95% CI=0.80-
2.30%) died. Deaths were primarily due to suspected drug-induced hepatotoxicity (7 patients, 
43.8%) followed by acute kidney injury (4 patients, 25.0%). Anti-TB drugs and ART together 
were implicated in 60% of the deaths. A bivariate comparison showed patients who died with 
ADRs were more likely to have pre-existing liver disease (40.0% vs. 7.0%; 95% CI=8.1-
57.8%), a history of ADRs (40% vs. 1.4%; 95% CI=13.8-63.4%), a low BMI (17.6 ± 2.1 vs. 
20.0 ± 2.9; 95% CI=0.9-3.9), exposure to anti-TB drugs (46.7% vs. 18.9%; 95% CI=2.3-53.1%) 
and ART (40.0 % vs. 7.7%; 95% CI=7.5-57.2%), a higher mean (±SD) number of medications 
(7.1 ± 3.3 vs. 3.8 ± 2.1; 95% CI=2.2-4.4), and Charlson Comorbidity Index (3.9 ± 2.9 vs. 1.6 
± 1.8; 95% CI=1.4-3.2) than surviving patients without ADRs.  
Findings from a series of analyses in a prospective observational study led us to further 
characterise the clinical patterns and severity of drug-induced hepatotoxicity (DIH), which was 
the commonest ADR implicated in hospitalisation and mortality. In this sub-study, 674 patients 
with documented previous medical history and regular medication prior to hospital admission 
and at least one set of liver function tests were included. Of 674 patients, 35 (5.2%) were 
deemed to have been hospitalised due to DIH, of whom, 22 (62.9%) exhibited a cholestatic 
pattern, 8 (22.9%) a hepatocellular pattern and 5 (14.3%) a mixed pattern. The most frequent 
drug classes implicated were anti-TB drugs (21 patients, 60.0%) followed by ART (12 patients, 
34.3%). More than two-thirds of the DIH cases (24, 68.6%) were severe or fatal, were mainly 
caused by anti-TB drugs (15, 42.9%), ART (4, 11.4%) or concomitant anti-TB/ART (6, 17.1%).  
Our studies provided several novel findings regarding hospitalisation and mortality related to 





in adults is an important public health problem, with a significant number of fatal ADRs in 
patients presenting to hospital. Commonly used drugs, such as anti-TB drugs, ART and 
cardiovascular agents, causing well-known reactions are the most frequently occurring ADRs 
in patients presenting to hospital, suggesting that strategies for their prevention should be 
identifiable. Conversely, the ADR-related hospitalisation risk prediction model demonstrated 
some ability to identify patients at higher risk for ADRs, such as patients with lower BMI, 
previous ADR history, renal and liver diseases, multiple comorbidities and medications. This 
was further augmented by an ADR preventability assessment using Schumock and Thornton’s 
criteria, in which the majority of the ADRs were preventable provided these risk factors were 
reviewed and monitored closely. Therefore, consideration of the independent risk factors for 
ADRs identified in this study, by medical practitioners during assessment of patients at 
emergency and chronic care centres, might help distinguish patients who are at higher risk of 
ADR-related hospitalisation. 
More research is needed into intervention strategies to help reduce ADR-related hospitalisation 
and mortality. However, key areas that demand urgent interventions based on our study 
findings include patients taking anti-TB drugs (isoniazid and pyrazinamide) and ART 
(tenofovir, efavirenz and nevirapine), with a special focus on patients with malnutrition, 
previous ADR history, and pre-existing renal and liver diseases. Patients with cardiovascular 
disorders taking furosemide, enalapril, atorvastatin, warfarin and heparin also require special 
consideration. Given our findings that the majority of events occurred in patients receiving 
treatment for infectious and non-communicable chronic diseases, ADR risk assessment and 
intervention strategies should focus on these groups of patients to minimise the occurrence of 
preventable ADR-related hospitalisation and mortality in Ethiopia, noting that measuring the 





In summary, this thesis has provided the most robust estimate of the extent and nature of the 
burden of ADR-related hospital admission and mortality in Ethiopian patients. Given the 
overburdening of the growing healthcare system with ADR-related hospitalisation and 
mortality, urgent work is required to:  
• investigate the impacts of genetics, malnutrition, and chronic infectious and non-
communicable diseases on the acquisition and outcomes of ADRs; 
• develop robust methods for prevention of the occurrence of ADRs in the future; and 
• evaluate the impact of ADR prevention strategies with the ultimate goal of preventing or 
reducing the risk of acquiring ADRs, improving patient outcomes and minimising ADR-
related costs to the healthcare system. 
Considering the significant problem of ADR-related admissions and mortality, and the lack of 
universally accepted standardised methods for assessing ADR causality, type, severity and 
preventability, there is a need to develop robust standardised methods in order to accurately 
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"Our figures show approximately four and one half million hospital admissions annually due 
to the adverse reactions to drugs."  Milton Silverman, M.D. (Professor of Pharmacology, 
University of California) 
1.1 Background 
The safe use of drugs is plausibly the single most important criteria that a regulatory authority 
within a given country has to ensure in order to protect the public health and the integrity of its 
healthcare system (1). In principle, the safety profile of a medicine is derived primarily from 
early phase adverse event data of randomised controlled trials (RCTs), which typically includes 
relatively small numbers of patients and normally has a short duration (2). RCTs are useful for 
detecting common adverse drug reactions (ADRs) that will occur with exposure to a drug and 
they may explain some serious ADRs (2). However, RCTs are less likely to be able to reveal 
rare ADRs, delayed ADRs that occur with prolonged use, delayed ADRs that occur after drug 
cessation, ADRs in special populations that are not routinely included in drug development, 
and ADRs from excipients (3). For these reasons, RCTs alone are not enough to establish the 
full safety profile of a drug, therefore, post-licensing safety data must be collected to further 
understand the adverse reactions associated with a drug and build up a true profile of its safety.  
In 1961, serious adverse events, such as the development of limb defects called phocomelia, 
with thalidomide (4), and more recently, the abrupt worldwide withdrawal of rofecoxib due to 
its association with increased cardiovascular risk (5) have also widely highlighted the need for 
post-licensing studies or pharmacovigilance. Pharmacovigilance (PV) can be defined as the 





adverse effects or any other drug-related problems (6). The major aims of PV are early 
detection of unknown adverse reactions and interactions, detection of increases in frequency 
of known adverse reactions, identification of risk factors and possible mechanisms underlying 
adverse reactions, estimation of quantitative aspects of the benefit/risk analysis and 
dissemination of information needed to improve drug prescribing and regulation (6), thus,  
encouraging safer and more effective use of medicines. 
Despite the implementation of PV systems over the past 50 years, neither the prevalence of 
ADRs nor their consequences have decreased (7-14) probably because the complexity of drug 
therapy has increased. Regardless of all the advantages of pharmacotherapy, ADRs are 
commonly recognised hazards of drug therapy that cause hospital admissions, morbidity, 
mortality and extra costs to the healthcare systems (11, 12, 15-20). 
1.2 Definitions/terminologies 
ADRs have been subject to several definitions. In 1972, the World Health Organisation (WHO) 
defined an ADR as “a response to a drug that is noxious and unintended and occurs at doses 
normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modification 
of physiological function"(21). This definition is intended to include all doses used clinically 
but exclude deliberate overdose and has been used widely in ADR studies over the last 40 years 
(22, 23).  
Edwards and Aronson (24) suggest the following as an alternative: “An appreciably harmful 
or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, 
which predicts hazard from future administration and warrants prevention or specific treatment, 





doses used clinically, however, it disregards ADRs requiring no intervention, and has been 
used in ADR epidemiological research (10). 
Other definitions used in epidemiological studies which measure ADRs have a broader scope 
and examine adverse drug events (ADEs) as a whole. ADEs have been defined as "injury 
resulting from the medical intervention relating to the drug" (25). Therefore, all ADRs are 
ADEs but not all ADEs are ADRs. The terms are not used interchangeably as studies of ADEs 
can cover medication administration, prescription, and ordering errors. On the other hand, 
ADEs are not necessarily due to the drug itself. The term ADE is not particularly helpful to 
physicians, but it provides context for the more clinically useful term ADR. Additionally, 
ADRs occur despite appropriate prescribing and dosing, whereas ADEs may be associated with 
inappropriate use of the drug or other confounders that occur during drug therapy but are not 
necessarily caused by the pharmacology of the drug itself. Therefore, an ADR is an adverse 
event with a causal link to a drug. ADEs may also be caused by medication errors (MEs), which 
the National Coordinating Council for Medication Error Reporting and Prevention (NCC 
MERP) (26) defines as “any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of the health care 
professional, patient, or consumer.”  
According to Edwards and Aronson (24), “an adverse effect is defined as an adverse outcome 
that can be attributed to some action of a drug whereas an adverse event is an adverse outcome 
that occurs while a patient is taking a drug but is not or not necessarily attributable to it.” 
Therefore, the terms “adverse reaction” and “adverse effect” can be used interchangeably, 
except that an adverse effect is seen from the point of view of the drug, whereas an adverse 
reaction is seen from the point of view of the patient. However, the terms “adverse effect” and 





Based on the above definitions, Nebeker et al. (25) illustrated the relationship between ADEs, 
ME and ADRs in 2004 as shown in Figure 1.1.  
 
Figure 1. 1 Model to describe types and relationships of risk from drug treatment (25) 
Contrary to the above definitions, Morimoto et al. (27) defines an ADR as “a non-preventable 
ADE due to a medication where there is no error in the medication use process and includes an 
allergic reaction in a patient not previously known to be allergic to the medication or non-
preventable reactions due to side effects or allergic reactions.”  
This introductory chapter will firstly examine the prevalence of ADR-related hospitalisation 
and associated burden and outcomes, the classification of ADRs and causality assessment 
methods and will then focus on reviewing the literature on common ADR presentations, 
implicated drugs and risk factors associated with hospitalisation, and review current knowledge 
regarding ADR prevention strategies. At the end of this chapter, the Ethiopian heathcare and 
ADR reporting systems, definitions and methods used in this study, and the rationale and main 





1.3 Prevalence of ADR-related hospitalisation 
Globally, the rates of ADR-related hospitalisation vary from 0.2% (28) to 54.5% (29). For 
instance, studies from developed countries reported a prevalence of 8.8% (of which 57.3% 
were preventable) in Ireland (30), 5.8% (of which 76.5% were preventable) in Italy (31), 7.5% 
(of which 66.7%) were preventable) in the United Kingdom (32) and 36.2% (of which 62.3% 
were preventable) in the United States (33).The few studies from developing countries have 
revealed a prevalence of 6.9% (of which 59.6% were preventable) in India (34), 6.3% (of which 
53% were prevalent) in South Africa (23) and 10.7% (of which 85.7% were preventable) in 
Argentina (35). ADR-related mortality is also an important burden in medical care (36). The 
rates of fatal ADRs in patients presenting to hospital have been reported to range from 0.1% to 
10% (20, 37) with comparable proportions in developed and developing countries.  
1.4 Burden and outcomes of ADRs 
1.4.1 ADR-related morbidity and severity  
ADRs are an important healthcare problem, frequently associated with multiple detrimental 
outcomes. Some of these include hospital admissions, loss of confidence in treating doctors, 
increased costs of care, preclusion of the use of some drugs, unnecessary investigations, delay 
in treatment, and deaths (38). In addition, ADR-related morbidity decreases quality of life by 
causing worries and emotionally affecting the patient’s belief in the use of medication for 
treatment, as well as causing physical morbidity in some cases (e.g. permanent incapacity or 
organ damage)(38). Moreover, ADRs cause life-threatening reactions, such as Stevens-
Johnson Syndrome, prolongation of hospital stay, congenital anomaly or birth defects, 
significant disability or incapacity, and permanent organ damage (20, 39, 40). Although limited 
studies have focussed only on severe ADRs, the few available studies have reported that severe 





patients (41), and cause life-threatening effects and admission to intensive care unit in 1.8% to 
18.6% of the cases (40, 42, 43).  
ADR severity describes the extent to which the ADR influences the everyday life of the patients 
or it relates to the effect it has on the individual. Severity of ADR is distinct from seriousness. 
For instance, Edwards and Aronson (24) defined serious ADRs as “any untoward medical 
occurrence that at any dose results in death, requires hospital admission or prolongation of 
existing hospital stay, results in persistent or significant disability/incapacity, or is life 
threatening.” A severe reaction may not necessarily be serious. Severity of ADRs has been 
assessed using different scoring systems, such as the Karch et al. (44), Dormann et al. (45), and 
Hartwig et al. classifications (46). Karch et al. classify severity into minor, moderate, severe, 
and lethal. Dormann et al. devised an ADR severity score of mild, moderate or severe 
depending on the numerical score obtained when the algorithm is applied. It incorporates a 
quality of life assessment. A score of 1 to 4 indicates a mild, a score of 5 to 8 a moderate, and 
a score of >8 a severe ADR. The severity scale of Hartwig et al. has seven levels ranging from 
level 1 (where the ADR requires no change in the drug treatment), to level 7 (where the ADR 
is fatal). Levels 1 and 2 are less severe, levels 3 and 4 are moderate, and levels 5, 6 and 7 are 
classified as severe as indicated Table 1.1. The principles of ADR severity assessment by the 
Hartwig et al. method are based on length of stay, treatment required, and the patient’s 
prognosis. This ADR severity assessment method is simple, easy to use, has clear definitions, 
and it has been widely applied in prospective studies of ADR-related hospitalisations (47, 48).  
Different studies have revealed that 10.9% to 42.0% of the ADRs that led to admissions were 
classified as severe (9, 23, 47, 49-55) as indicated in Figure 1.2. For instance, out of 6.3% of 
ADR-related admissions, 14.1% were severe in a South African study (23). The majority of 





administration of specific antidotes. Therefore, the marked differences in the prevalence of 
severe ADRs in the studies discussed above were possibly due to the multiplicity of definitions 
of ADR severity and a lack of standardisation of the definitions across the studies.  





Description of the level 
Mild  Level 1 An ADR occurred but required no change in treatment with the 
suspected drug 
Level 2 The ADR required that treatment with the suspected drug be 
held, discontinued, or otherwise changed. No antidote or other 
treatment requirement was required. No increase in length of 
stay (LOS) 
Moderate  Level 3 The ADR required that treatment with the suspected drug be 
held, discontinued, or otherwise changed, and/or an antidote or 
other treatment was required. No increase in LOS 
Level 4 Any level 3 ADR which increases LOS by at least 1 day OR the 
ADR was the reason for the admission 
Severe  Level 5 Any level 4 ADR which required intensive medical care 
Level 6 The adverse reaction caused permanent harm to the patient 
Level 7 The adverse reaction either directly or indirectly led to the death 






Figure 1. 2 Proportion of overall and severe ADRs in relevant studies (9, 23, 47, 49-51, 53-
55). 
1.4.2 ADR-related length of hospital stay   
There is a relationship between the cost of care of a patient hospitalised for an ADR and the 
length of the hospital stay. A systematic review in the UK showed that ADRs led to 
prolongation of hospital stay and escalation of the hospital bed occupancy rate by 
approximately 15–20 in a 400-bed hospital (56). This systematic review of both prospective 
and retrospective studies was augmented by a prospective study by Pirmohamed et al. (10) 
illustrating an additional stay of 2.2 hospital days as a result of ADR. Another study in Australia 
(57) showed that there was an extraordinary escalation of age-related hospital stays due to 
ADRs; in 1981 it was 2.5 for every 1,000 person–years, increasing to almost 12.6 for every 



















































the average inpatient length of stay associated with ADR was 9.3 days, and the annual total 
health care cost was escalated due to ADRs. Mehta et al. (23) from South Africa reported that 
the median length of hospital stay in patients with ADRs was longer than in those without 
ADRs (8 (5-12) days vs. 6 (4-9) days) constituting 5.8% of bed occupancy.  
1.4.3 ADR-related mortality  
ADR-related mortality is a significant public health problem (59). According to a systematic 
review of 39 studies between 1970 and 2002 (60), ADR was recorded as the fourth leading 
cause of death in the US after heart disease, cancer and strokes. In this review, it was found 
that 106,000 people died because of ADRs and more than 2 million suffered serious side effects 
with a trend showing increasing death and injury from ADRs. In Australia, Hodgkinson 
reported that death occurred in 0.7% of ADR cases in 2004 (61). Pirmohamed et al. (10) from 
the UK revealed that over 2% of patients admitted with an ADR died between November 2001 
and August 2002, suggesting that ADRs may be responsible for the death of 0.15% of all 
patients admitted. A retrospective study conducted by Wester et al. (40) in a Swedish 
population found that fatal ADRs accounted for approximately 3% of all deaths in the general 
population between January 2001 to December 2001, where fatal ADRs were estimated to be 
the seventh most common cause of death. A 20-year survey that was concducted between 1974 
and 1993 in three Swiss teaching hospitals reported an ADR-related mortality rate of 0.054% 
of admissions (62). A study in a Finnish University Hospital in 2000 revealed that deaths in 
0.05% of hospital admissions (5% of in-hospital deaths) were attributed to ADRs (63).   
Although there are scanty data on the mortality rate of ADRs in low and middle-income 
countries, the few available studies reported a mortality rate that ranged from 0.24% (64) to 
10% (37) . ADR-related mortality rates of 0.24% of all admissions in a study conducted in a 6 





month period in 2005 (23) were reported from India and South Africa, respectively. Another 
study which was conducted in South Africa between April and Septmeber 2013 (65) reported 
that ADRs contributed to the death of 2.9% of medical admissions; the overall mortality rate 
in these study wards was 18 per 100 admissions. Prevalence of ADR-related deaths as a 
proportion of study setting admissions in some studies are presented in Figure 1.3. 
  
Figure 1. 3 Prevalence of ADR-related deaths in relevant studies (10, 23, 40, 61, 62, 64-66). 
1.4.4 ADR-related economic burden  
The increase in costs due to ADRs are related to the increased length of hospital stay and 
additional medical care provided to the patients. For instance, Classen et al. estimated that 
hospital admissions due to ADRs increased the cost of patient care by USD 2,262 per patient 
(67). According to Wu et al.’s (68) estimation in 2008, the cost of ADR-related visits to 
emergency departments was CAD 333 per visit and CAD 7,528 per hospitalisation for a total 
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Another burden of ADRs is attributable to prescribing new medication to treat the ADR, which 
increases the drug use in those patients (69). Litigation or malpractice-related costs are also 
burden of ADR that is frequently overlooked. For instance, Rothschild et al. (70) reported that 
ADRs represented 6.3% of malpractice claims by a New England malpractice insurance 
company, of which, 46% of the events were life-threatening or fatal and 73% of them were 
judged to be preventable. Those preventable drug events were estimated to cost USD 50.7 
million in 2001, which does not include additional costs such as plaintiffs’ legal expenses. 
Litigation against the healthcare provider can also be professionally and emotionally 
distressing, and long-term physician-patient relationships can also be affected due to loss of 
trust (71). In general, preventable ADRs should be the primary focus for implementing 
strategies that can help reduce the burden of ADRs. 
1.5 Classification of ADRs 
There are many ways of classifying ADRs. Although there is no consensus in the mechanisms 
of ADRs, it can be broadly classified on the basis of either the presence or absence of immune 
mediation (72). The terms “drug allergy”, “drug hypersensitivity”, and “drug reaction” are used 
interchangeably, however, drug reaction embraces all adverse events related to drug 
administration, regardless of aetiology. Drug hypersensitivity means an immune-mediated 
response to a drug agent in a sensitised patient whereas drug allergy is restricted specifically 
to a reaction mediated by IgE (73). The majority (75% to 80%) of ADRs are pharmacologically 
predictable and non-immunologic whereas the remaining 20% to 25% are unpredictable and 
immune-mediated (74). Specifically, IgE-mediated drug allergies account for 5% to 10% of all 
drug reactions and constitute true drug hypersensitivity (72, 73). 
Rawlins and Thompson (75) first formally classified the mechanisms of ADRs in 1977 as type 





of the drug. Type A ADRs commonly result from an exaggeration (augmentation) of a drug’s 
normal pharmacological action when given in the usual therapeutic dose. The severity of type 
A reactions ranges from minor to life-threatening effects. Because of their characteristics, the 
majority of type A ADRs are identified prior to product authorisation and are consequently 
listed in product labelling. Examples include hypoglycaemia with antidiabetic agents, bleeding 
with warfarin, and hypotension with beta-blockers. On the contrary, type B ADRs are not dose 
dependent, hence, are unpredictable. Perhaps partially because of their non-dose dependence 
and unpredictability, they are considered more serious than type A ADRs and appear to be 
associated with a higher rate of mortality (24). Due to unsubstantiated relationship to dose, type 
B ADRs can occur at any time after the drug has been started; emerging at any time during the 
course of therapy and sometimes after treatment has stopped (24). In addition, because of their 
tendency to be severe, re-challenge is dangerous. Therefore, the drug is usually discontinued if 
a patient experiences a type B ADR. Many type B ADRs are only revealed post-authorisation 
when a greater number of patients are exposed to the drug. One example includes anaphylactic 
reactions to antibiotics. According to previous studies (32, 47, 51, 55, 76, 77), 75% to 91% of 
ADRs have been classified as type A reactions based on Rawlins and Thompson’s 
classification method. This classification is simple; it helps drug regulatory bodies because pre-
licensing studies can reveal type A reactions (78), and it predicts that dose titration will increase 
the risk of some reactions. This classification system is the most widely accepted and 
recognised in the literature. 
According to the above ADR classification, it is sometimes impossible to assign a reaction to 
one type. Therefore, the above ADR classification has gradually been extended to 
alphabetically labelled types, including type C (dose and time dependent (chronic) reactions), 





This classification has mitigated some of the difficulties of the Rawlins and Thompson 
classification but has introduced others.  
Aronson  et al. (80) highlighted the limitations of the above classifications, and considered 
other parameters to classify the ADRs. These are time course, appearance and severity of the 
reaction, and the susceptibility of the individual, which are expressed as dose-relatedness, 
timing, and patient susceptibility (DoTS). Dose-related ADRs occur at supratherapeutic doses 
(toxic effects), standard therapeutic doses (collateral effects) and sub-therapeutic doses in 
susceptible patients (hyper-susceptibility reactions). With regard to timing, ADRs can be time 
dependent (the ADR depends on both the concentration of the drug at the site of action and the 
time course of its appearance there) and time independent (the ADR occurs at any time during 
treatment, independent of the duration of the course). According to this classification, the time 
dependent ADR can be sub classified into six subtypes - rapid, first dose, early, intermediate, 
late, and delayed reactions (80).  
1.6 ADR causality assessment 
Identifying the cause of a suspected ADR is a complex process because many patients take 
more than one drug that can often make detection of the causative agent problematic. 
Alternatively, the suspected ADR may in fact be a manifestation of other underlying disease 
states (81). Therefore, an important step in recognising an ADR and assessing causality is to 
obtain an accurate patient drug list through review of medical records and interview with 
patients or family members about medication usage. Then, it is crucial to establish a causal 






Many ADR causality assessment methods have been proposed to judge the relationship 
between a drug and an adverse reaction in a given patient, ranging from expert judgment to 
comprehensive algorithms. However, there is no universally accepted method for assessing 
causality of ADRs as a result of problems of reproducibility and validity (82). There are 
principally three types of method for causality assessment which are practical for regular use 
(82). These are: unstructured assessment by an assessor or a panel of assessors (global 
introspection), semi-structured assessment using pre-set guidelines, and standardised 
assessment using decision tables or algorithms. A fourth method, using the application of 
Bayesian statistics (the Bayesian Adverse Reaction Diagnostic Instrument: BARDI), has also 
been devised but its complexity has limited its use. 
The global introspection of ADR causality assessment is based on consensus 
agreement/personal judgement of each ADR report by the expert/investigator, following 
careful review of the case notes/medical records, laboratory parameters and application of 
clinical opinion. Because of its subjectivity, lower levels of certainty, and lack of transparency, 
it has been designated as an unsuitable method for assessing ADRs (83).  
Semi-structured ADR assessments, such as the World Health Organisation Uppsala Monitoring 
Centre (WHO-UMC) causality assessment method (84), provide guidelines for assigning a 
causality term, i.e. 'definite', 'probable', 'possible' and 'unlikely' ADR, without providing 
specific rules as to how the causality assessment should be carried out. The WHO-UMC 
causality assessment method (84) was developed in consultation with the National Centres 
participating in the Programme for International Drug Monitoring and is meant as a practical 
tool for the assessment of case reports. This causality assessment method has advantages over 
the unstructured method in that the guidelines for classifying the causality of an ADR are clear, 





causality categories and the assessment criteria of the WHO-UMC system are summarised in 
Table 1.2. 
Table 1. 2 WHO-UMC ADR causality categories 
Causality term  Assessment criteria* 
Certain  • Event or laboratory test abnormality, with plausible time 
relationship to drug intake 
• Cannot be explained by disease or other drugs 
• Response to withdrawal plausible (pharmacologically, 
pathologically) 
• Event definitive pharmacologically or phenomenologically (i.e. 
an objective and specific medical disorder or a recognised 
pharmacological phenomenon) 
• Rechallenge satisfactory, if necessary 
Probable/ 
Likely 
• Event or laboratory test abnormality, with reasonable time 
relationship to drug intake 
• Unlikely to be attributed to disease or other drugs 
• Response to withdrawal clinically reasonable 
• Rechallenge not required 
Possible • Event or laboratory test abnormality, with reasonable time 
relationship to drug intake 
• Could also be explained by disease or other drugs 
• Information on drug withdrawal may be lacking or unclear 
Unlikely • Event or laboratory test abnormality, with a time to drug intake 
• that makes a relationship improbable (but not impossible) 
• Disease or other drugs provide plausible explanations 
Conditional/ 
Unclassified 
• Event or laboratory test abnormality 
• More data for proper assessment needed, or 
• Additional data under examination 
Unassessable/ 
Unclassifiable 
• Report suggesting an adverse reaction 
• Cannot be judged because information is insufficient or 
contradictory 
• Data cannot be supplemented or verified 
Source: Adapted from WHO-UMC ADR causality assessment (84).        
*All points should be reasonably complied with 
 
Unstructured and sometimes semi-structured ADR causality assessment methods have a 





relationship between the suspected drug and the ADR. In order to solve these problems, many 
standardised algorithms, such as the Irey (85), Karch (86), Kramer (87) and Naranjo (88) 
algorithms, have been developed to assess the causality of ADRs. The first structured ADR 
causality algorithm that depends mainly on time-relationship and pathological evidences of the 
suspected drug and event was developed in 1976 by Irey (85).  Following this, Karch et al. (86) 
published a three-decision-table algorithm that requires evidence of a previously documented 
ADR having been associated with the suspected drug in question. This algorithm helps the user 
to assess potential drug reactions, the certainty of the link between the drug and event and the 
underlying cause of the detected adverse event. Then, Kramer (87) expanded the work of Karch 
et al. to a six-decision-table algorithm with a new scoring system through assessing previous 
general experience with the drug, alternative aetiologic candidates, timing of events, drug 
levels and evidence of overdose, dechallenge and rechallenge. 
Another algorithm, published in 1981, developed by Naranjo and co-workers (88) from the 
University of Toronto is often referred to as the Naranjo Probability Scale. Although it was not 
in use in routine clinical practice at that time, it helped standardise assessment of causality for 
all ADRs as it was initially designed for use in controlled trials and registration studies of new 
medications. Since then researchers have widely used it in observational studies because of its 
simplicity to apply and its objective measurement. It consists of 10 questions that are answered 
as either Yes, No, or “Do not know”.  Different point values (-1, 0, +1 or +2) are assigned to 
each answer for the 10 questions. The values assigned to each question answered are totalled, 
and the final score corresponds to causality categories of ‘definite’, ‘probable’, ‘possible’ or 
‘doubtful’. Total scores range from -4 to +13; the reaction is considered definite if the score is 
9 or higher, probable if 5 to 8, possible if 1 to 4, and doubtful if 0 or less as illustrated in Table 
1.3. The Naranjo ADR Probability Scale is quick to complete and has moderate reliability  (89, 





Table 1. 3 Naranjo ADR assessment algorithm/scale (88)  
Question Yes No Do Not 
Know 
1. Are there previous conclusive reports on this reaction?  +1  0  0  
2. Did the adverse event appear after the suspected drug was administered?  +2  -1  0  
3. Did the adverse event improve when the drug was discontinued or a 
specific antagonist was administered?  
+1  0  0  
*4. Did the adverse event reappear when the drug was readministered?  +2  -1  0  
5. Are there alternative causes that could on their own have caused the 
reaction?  
-1  +2  0  
6. Did the reaction reappear when a placebo was given?  -1  +1  0  
7. Was the drug detected in blood or other fluids in concentrations known 
to be toxic?  
+1  0  0  
8. Was the reaction more severe when the dose was increased or less severe 
when the dose was decreased?  
+1  0  0  
9. Did the patient have a similar reaction to the same or similar drugs in 
any previous exposure?  
+1  0  0  
10. Was the adverse event confirmed by any objective evidence?  +1  0  0  
* This question evaluates the response to rechallenge or re-exposure.  An answer of “Yes” (+2) 
indicates that the medication was stopped, the ADR resolved or improved, and there was an 
unequivocal reappearance or worsening of the reaction when the medicine was restarted in a 
similar dose and by the same route. The Naranjo scale also allows for a “Yes” if the causal 
association is well known and rechallenge cannot be done for clinical or ethical reasons. 
The last type of ADR causality assessment is the  BARDI method that calculates the  posterior  
probability,  a  ratio  between  two  probabilities both  of  which  are conditional  on  the  same 
background and  case  information, in  favour of  a  specific  drug  cause  based  on  background  
(e.g., epidemiologic)  and  case  information  (e.g. time of onset) (91). These approaches use 
specific findings in a case to transform the prior estimate of probability into a posterior estimate 





information and the posterior probability combines this background information with the 
evidence in the individual case to come up with an estimate of causation. The BARDI is 
advantageous in that it discriminates between drug and non-drug-induced ADRs while its 
complexity limits its use in routine practice. The risk of acquiring an ADR differs among an 
exposed population. In some cases, the risk of an ADR will be present in susceptible patients 
and absent in others.  
1.7 Drugs commonly implicated in ADR-related hospitalisations 
Based on the different ADR causality assessment methods, drugs commonly implicated in 
ADR-related hospitalisations have been identified and reported in different studies. Certain 
drugs are associated with an increased risk of adverse reactions or interactions due mainly to a 
low therapeutic ratio (i.e. the difference between a therapeutic and toxic dose is low) (92). 
These include oral anticoagulants, oral hypoglycaemic agents, some antihypertensives, many 
cytotoxic agents, anti-convulsants, corticosteroids, some antimicrobials, and nonsteroidal anti-
inflammatory drugs (NSAIDs). According to the reports of different studies, drug classes 
commonly implicated in ADR-related hospitalisations included antithrombotics (16, 35, 93-
97), cardiovascular agents (17, 20, 30, 94, 98, 99), NSAIDs (10, 16, 23, 35, 39, 93, 95, 98) and 
antimicrobials (33, 42, 66, 100) as summarised in Figure 1.4 below. In addition, drugs 
commonly implicated in causing severe ADRs are listed in Table 1.4. Antimicrobials, mainly 
anti-tuberculosis and antiretroviral therapies, were more commonly implicated in ADR-related 






Figure 1. 4 Drug classes commonly implicated in causing ADRs as per reports of relevant 
studies (9-11, 15, 16, 20, 23, 30, 32, 33, 35-37, 39, 42, 55, 59, 66, 76, 93, 94, 96-98, 100, 102-
108).  
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Angiotensin-converting enzyme inhibitors (enalapril, lisinopril) (109) 
Anticonvulsants ( phenobarbital, phenytoin/fosphenytoin) (110, 111) 
Antimicrobials (amoxicillin, ciprofloxacin,  efavirenz, gentamicin,  isoniazid, nevirapine,  
tenofovir, pyrazinamide) (23, 42, 65, 66, 96, 101, 112-114) 
Antipsychotics (haloperidol, quetiapine, zuclopenthixol) (115-117) 
Antithrombotics and coagulation inhibitors (acetylsalicylic acid, clopidogrel, enoxaparin, 
and warfarin) (110, 114, 116, 118) 
Benzodiazepines (midazolam, triazolam) (119-121) 
Beta-blockers (metoprolol) (10, 110, 122) 
Calcium channel blockers (nifedipine) (111, 123) 
Corticosteroids (prednisolone) (110, 111) 
Cytostatics (carboplatin, daunorubicin, etoposide, 5-fluoruracil, methotrexate) (110, 123) 
Diuretics (furosemide) (110, 117, 124) 
Insulin (125-128) 





1.8 ADRs commonly associated with hospitalisations 
ADRs are commonly reported in both developed and developing countries although there is 
considerable variation in disease distribution (9, 14, 23, 100), population characteristics (9, 14, 
23, 100), healthcare systems (104) and complexity of diseases and medications prescribed (9, 
14, 94). These included, but were not limited to, gastro-intestinal (GI) bleeding (20, 97, 99, 
100, 105), cardiovascular disorders (16, 23, 30, 32, 37, 93, 94),  electrolyte and metabolic 
disturbances (9, 16, 23, 58, 94), neuropsychiatric and central nervous system disorders (28, 
131) and  cytotoxicity (110, 123). In contrary to developed countries, studies from developing 
countries have revealed that drug-induced hepatotoxicity (DIH) (mainly due to anti-TB and 
ART agents) (23, 34) followed by drug-induced acute kidney injury (mainly due to ART 
agents) (101) were the major reasons for hospital admissions, reflecting the high burden of 
tuberculosis and HIV/AIDS in these settings.  
DIH is an important cause of hospitalisation (132), responsible for over 50% of acute liver 
failure (ALF) (133, 134) and remains a top reason for drug withdrawal from the market creating 
cost and medication availability ramifications (133, 135). DIH has a profound impact on 
healthcare by causing substantial morbidity and mortality, and healthcare expenditures (136). 
Drugs commonly implicated in DIH were antimicrobials, such as anti-tuberculosis drugs (137, 
138), and cytotoxic agents (139, 140). The patterns of DIH as hepatocellular, cholestatic, and 
a mixed-type, and may vary for the same drug. Studies have reported that the cholestatic pattern 
of DIH accounts for 20% to 40% of DIH, the hepatocellular pattern accounts for 40% to 78%, 
and the mixed pattern accounts for 12% to 20% (141, 142). 
Drug-induced acute kidney injury (AKI) is another common ADR characterised by elevations 
in blood urea nitrogen (BUN) and serum creatinine (SCr) levels. It results in electrolyte and 





creatinine (143). Patients with drug-induced AKI are often asymptomatic, but when they are 
symptomatic, they present with anorexia, fatigue, mental status changes, nausea, vomiting, 
pruritus, seizures if BUN levels are extremely high, and shortness of breath if volume overload 
is present (144). However, alterations in urine volume may be the only symptom that patients 
notice. Populations most at risk include the elderly, those with underlying renal insufficiency, 
cirrhosis, nephrotic syndrome, or congestive heart failure (145). Drug-induced AKI is a 
common medical problem requiring hospitalisation and the incidence of drug-induced AKI 
may be as high as 60% (146). Drugs frequently implicated in drug-induced AKI were diuretics 
(e.g. furosemide), ACE-inhibitors (e.g. enalapril), antiretroviral therapy (e.g. tenofovir) and 
NSAIDS (e.g. diclofenac) (23, 65, 101, 147-149).  
1.9 Risk factors for ADRs 
Despite the concerns that ADR-related hospitalisation, morbidity and mortality represent an 
important medical problem in the healthcare system, predictive factors for ADR are still poorly 
understood. One important strategy for preventing ADR-related hospitalisation and mortality 
is to identify the patients who are at risk of an ADR and to target additional resources toward 
these groups. Although multiple risk factors have been reported, there is no uniformity in 
reports due to the differences in the demographics of the study participants, healthcare systems, 
and disease distributions. Many studies have identified several risk factors contributing to 
ADR-related hospitalisations; these are discussed in more detail below. Figure 1.5 shows the 
relationship between different risk factors and ADR-related hospitalisation based on previously 







Figure 1. 5 The relationship between factors contributing to ADR-related hospitalisations  
1.9.1 Age  
Many studies (9, 30, 34, 55, 58, 96, 97, 137, 150-165) report that advanced age has been found 
to be a risk factor for ADR-related admission, irrespective of the socioeconomic status of the 
patients. This was mainly because of increased fragility, medical complexity, disease burden 
and physiological changes with increased age. In addition, as age advances, there is impairment 
of the kidneys and liver that lead to decreased excretion of drugs into the urine and 
biotransformation of many drugs, respectively (102). The amount of water in the body 
decreases and the amount of fat tissue relative to water increases, potentially leading to higher 
concentrations of drugs that dissolve in water and in fat. On the contrary, Mjorndal et al. (166) 
and Hellden et al. (167) reported that age itself had no effect on ADR-related hospitalisations 
that could alternatively be explained by appropriate adjustment of pharmacotherapy in 































Compared to males, females have lower body weight and organ size, more body fat, different 
gastric motility and a lower glomerular filtration rate (168), which results in variable drug 
pharmacokinetics and pharmacodynamics. Studies (14, 169, 170) have reported that being 
female was associated with increased risk of ADR-related hospitalisation in comparison to 
males taking similar medications. For instance, a study conducted by Rodenburg et al. (171) 
has reported that females showed most marked differences in incidence of ADR-related 
hospital admissions for different cardiovascular drug groups, such as cardiotonic glycosides, 
high-ceiling diuretics and coronary vasodilators. The possible reasons reported were 
multifactorial. Hepatic enzyme CYP3A4 is more active in females than males, which leads to 
different effects on drug metabolism (172, 173). Female specific concerns such as pregnancy, 
menopause and menstruation may have profound effects (174). Ensom et al. (175) reported 
that after the age of 45 years, when all sex-specific conditions were controlled, females had 
approximately 10–20% more physician visits and subsequently used more medications than 
males. 
1.9.3 Comorbidity and polypharmacy  
Multiple diseases make patients more vulnerable to ADRs due to the use of many drugs that 
increased opportunity for drug-drug interactions (9, 176). Increasing numbers of both co-
morbidities and medications lead to increased medical complexity, which has been associated 
with an increased risk of ADR-related hospitalisation, especially with advancing age (9, 176). 
Furthermore, irrespective of the age of the patients, the number of medications taken has been 
a consistently reported risk factor for ADR-related admissions (14, 17). The risk of ADR 
severity also increases as the number of medications increases . Moreover, multiple diseases 





Drugs that are helpful in one disease are harmful in another. For instance, some beta-blockers 
used for treatment of ischaemic heart diseases or high blood pressure can worsen respiratory 
symptoms and make it hard for people with diabetes by masking the signs and symptoms of 
low blood sugar (168).  
1.9.4 Hepatic and renal failure  
The pharmacokinetics of drugs can be affected in patients with impaired hepatic function since 
the liver is the main organ for metabolism and detoxification of endogenous and exogenous 
substances (177). In patients with abnormal intestinal permeability, the bioavailability of some 
drugs, such as drugs with a high hepatic extraction ratio is increased (178), as the absorption 
process may be altered due to porto-systemic shunting (179, 180). In patients with hepatic 
impairment, the free concentration of highly protein-bound drugs is increased due to 
hypoalbuminaemia (180). Hepatic impairment is also associated with a reduction or 
impairment of drug-metabolising enzymes that may cause reduced metabolism. These changes 
often result in an elevated drug exposure, and possibly ADRs (180, 181). For example, about 
30% of patients with cirrhosis suffer ADRs and it is estimated that nearly 80% of these ADRs 
could be prevented (182).  
Impaired renal function can have marked effects on the pharmacokinetics of many drugs 
because of changes in glomerular filtration, tubular secretion, reabsorption or metabolism (183). 
These may cause accumulation of the medicines or their metabolites, which may result in 
toxicity. The toxicity may be severe, especially if the medicine has a narrow therapeutic index 
(184). There is an increased risk of ADRs due to the use of contraindicated drugs and 
inappropriate doses (185). Studies have reported that patients with impaired renal function 





187). The risk of acute kidney injury and subsequent drug-related adverse effects was higher 
in patients with a lower body mass index (162). 
1.9.5 Alcohol consumption  
Alcohol affects the metabolism of many drugs and promotes the occurrence of ADRs through 
both pharmacokinetic and pharmacodynamic changes (188). Taking alcohol with some drugs 
can cause many ADRs like nausea, vomiting, headaches, drowsiness, fainting, loss of 
coordination, and hypotension (189), which sometimes lead to acute hospitalisations. If alcohol 
is concomitantly taken with NSAIDS, it may cause internal bleeding due to enhancing severe 
ulceration in patients with peptic ulcer or ex-peptic ulcer or gastritis (190). Onder et al. (9) 
reported that moderate alcohol consumption was associated with a 24% increased risk of ADR-
related hospital admission. This effect seemed more evident in women than men, while it was 
similar across different age groups. Considering the most common ADRs, moderate alcohol 
users presented a significantly higher risk of drug-related and metabolic/endocrine 
complications (191). Przybylski et al. (192) from Poland reported that alcohol abuse was 
independently associated with ADR-related hospitalisation among TB patients and lead to 
unsuccessful TB treatment of 10.5% of the patients.  
1.9.6 Malnutrition  
Malnutrition (based on BMI, protein-energy or micronutrient deficiencies) is one of the major 
public health problems world-wide, especially in most developing countries (193). There are 
multiple aggravating factors in developing countries, such as the high burden of TB and HIV 
infection, which adversely affect the nutritional status of patients (193-195). Malnutrition leads 
to adverse drug outcomes as the pathophysiological changes encountered in nutrient 
deficiencies interfere with pharmacokinetic and pharmacodynamic processes in the body (196). 





plasma protein binding capacity for commonly used drugs, such as anti-inflammatory and anti-
TB drugs can be decreased, resulting in an increased free fraction of the drug and hence ADRs. 
In addition, patients with hepatic and renal impairment are exceptionally vulnerable to 
developing malnutrition because of the key role played by the liver and kidney in regulating 
the nutritional state and energy balance. When these are adversely affected, the risk of ADR 
increases (198). 
1.9.7 HIV/AIDS and using antiretroviral therapy  
Immunosuppression with HIV and opportunistic infections are a known risk factor for ADR-
related hospitalisation (199). Mehta et al. (23) reported that patients’ HIV positive status tended 
to increase the risk of experiencing ADRs and mortality compared to those who were HIV 
negative or whose HIV status was unknown. HIV-infected patients taking antiretroviral therapy 
(ART) were also more likely to be admitted with an ADR than those not taking ART (23). 
Dimie et al. (199) reported that AIDS-defining illnesses due to direct ART-related 
complications in general and zidovudine-induced severe anaemia requiring blood transfusions 
in particular were the most common reasons for hospital admissions. Severe anaemia increased 
the risk of mortality six-fold. Similarly, Henry et al. (200) from Cameroon reported that 
zidovudine-related severe anaemia was one of the common reasons for hospital admissions. 
1.10 Preventing ADRs 
The logical approach for improving patient care and reducing the incidence of ADR-related 
hospitalisation is to focus on preventable or avoidable types of ADRs. Measuring 
preventability is important to classify ADRs as preventable or not preventable, but the ultimate 
aim remains to characterise those preventable ADRs, highlighting the clinical situations and 





preventability of ADRs, however, the majority of the studies conducted in this field have used 
the modified Schumock and Thornton (201) criteria followed by Hallas’ avoidability 
assessment criteria (202).  
Hallas et al. suggested a quick outline to aid in assessor rating of preventability of ADRs (202).  
Hallas defines three categories - unavoidable, possibly avoidable and definitely avoidable. 
Unavoidable means the ADR could not have been avoided by any reasonable means. Possibly 
avoidable means the ADR could have been avoided by an effort exceeding the obligatory 
demands of present day knowledge of good medical practice. Definitely avoidable means the 
ADR was due to drug treatment procedures inconsistent with present day knowledge of good 
medical practice. 
Studies show conflicting evidence on which instrument have the highest reliability for 
assessing ADR preventability (203, 204). Reliability was not reported in most studies and when 
reported, it varied markedly across studies. It was demonstrated that intra- and inter-rater 
reliabilities of the preventability judgements of ADRs were poorer when using implicit 
instruments compared to an explicit algorithm (205), perhaps due to the larger impact of the 
individual reviewers’ clinical judgement in implicit instruments. Therefore, studies 
summarised in Figure 1.6 show wide variations in the rates of preventable ADRs reported, 









Table 1. 5 Schumock and Thornton criteria for assessing ADR preventability  (201). 




1. Was there a history of allergy or previous reactions to the drug?              
 Yes       No 
2. Was the drug involved inappropriate for the patient’s clinical condition?      
 Yes       No 
3. Was the dose, route or frequency of administration inappropriate for the 
patient’s age, weight or disease state? 
    Yes       No 
4. Was a toxic serum drug concentration (or laboratory-monitoring test) 
documented?  
     Yes       No 
5. Was there a known treatment for the adverse drug reaction?  




1. Was required therapeutic drug monitoring or other necessary laboratory 
tests not performed?                       
  Yes       No 
2. Was a drug interaction involved in the ADR?  
 Yes       No 
3. Was poor compliance involved in the ADR?    
 Yes       No 
4. Were preventative measures not prescribed or administered to the 
patient?                                                        
 Yes       No 
c) Not preventable If all above criteria not fulfilled 
Answering “yes” to one or more of the questions in section “a” of the modified Schumock and 
Thornton criteria implies that an ADR is definitely preventable. If the answers are all negative 
to section “a”, then one proceeds to section “b”. Answering “yes” to one or more of the 
questions in section “b” implies that an ADR is probably preventable and if the answers are all 
negative to section “b”, then one proceeds to section “c”. In section “c”, the ADR is not 






Figure 1. 6 Proportion of overall and preventable ADRs of relevant studies (11, 30, 32, 34, 
41, 47, 50, 55, 58, 95, 152, 206). 
1.11 Strategies for preventing ADRs 
Strategies for preventing ADR-related hospitalisations focus on either the process of care or 
highlighting patients at risk of ADRs or both, so that appropriate interventions can be tailored 
to prevent the occurrence of an ADR (14, 207-209). For successful prevention of ADR-related 
admission, it is advisable to use a combination of both strategies as the healthcare environment 
and patients’ clinical characteristics are complex in nature. ADR preventative strategies 

























































interventions, strengthening pharmacovigilance and ADR reporting systems, use of clinical 
tools, monitoring ongoing drug therapy, and preventing drug interactions.  
The second ADR prevention strategy involves the identification of risks or developing risk 
prediction models to identify patients at risk of ADR. A primary effort to develop a risk 
prediction model was ensued by Elnicki and Schmitt in 1980 using ADE as an outcome (210). 
Approximately a decade later, Bates et al. (211) identified two independent variables, patients 
admitted to ICU and those with longer length of stay, predictive of ADE in a cohort of 4108 
admissions. Based on their finding, Bates et al. concluded that preventive strategy based on 
patient risk identification is less effective and recommended system-based approach as an 
alternative. In 2006, Johnston and colleagues (212) identified specific patients and clinical 
characteristics related to increased risk of experiencing adverse events (including ADRs), using 
a study population of 60,206. They found that age group (<1 year & ≥60 year), diagnosis, 
admission sources, types of insurance, and the use of specific medications or medication 
classes were associated with increased risk of adverse events (212). Another study by Zopf et 
al. (14) identified five independent predictors of ADRs. These were increased temperature, low 
thrombocyte levels, low erythrocyte levels, multiple drug use and female sex, with an AUROC 
of 80.0%, sensitivity of 64.0%, and specificity of 86.0%. More recently, Parameswaran et al. 
(213) identified five independent predictors of ADR-related hospitalisations in elderly patients 
with an AUROC of 70%. According to this study, independent variables predictive of ADR-
related admissions in the elderly were drug changes in the preceding 3 months, presence of 
renal failure and dementia, use of antihypertensives and anticholinergics. Many studies have 
identified several strategies for preventing ADR-related hospitalisations; these are discussed in 





1.11.1 Strengthening local pharmacovigilance centres and ADR reporting systems 
One of the foundations of identifying and managing ADRs is an effective ADR monitoring and 
reporting system. However, there is a lack of well-established national and local surveillance 
systems, especially in developing countries, with spontaneous ADR reporting remaining 
consistently poor, largely due to a lack of education and strong ADR reporting system (214). 
Hence, encouraging and improving levels of ADR monitoring and reporting represents a major 
component in a strategy for detecting and preventing ADRs through: 
• improving education and changing attitudes about ADR reporting;  
• greater involvement of pharmacists and multi-disciplinary teams;  
• strengthening drug and therapeutic committees; and  
• formation of more localised pharmacovigilance centres.  
On the other hand, implementing a mandatory ADR reporting system that encourages reporting 
and safeguards healthcare providers from repercussions creates an environment that is more 
insightful for reducing the prevalence of ADRs on the healthcare system. Interestingly, studies 
suggested that decentralised, interactive pharmacovigilance centres might improve levels of 
ADR reporting (215, 216). The risk of ADRs have been minimised through pharmacy-led 
effective drug information provision, along with continuing education regarding medication 
safety and quality use including herbal and OTC medications (217, 218). Through establishing 
and strengthening of the existing local pharmacovigilance centres, the perceived barriers and 
difficulties in early identification and reporting of ADRs can be overcome. 
1.11.2 Preventing drug interactions 
Most drug-drug interactions and subsequent ADRs involve commonly used medications. It has 





admissions (33). The risk of ADRs due to drug-drug interactions is substantially higher when 
more medications are being prescribed. For example, bleeding with warfarin therapy is 
increased with co-administration of NSAIDs, omeprazole and/or statins (219). Hospitalisation 
for hypoglycaemia was six times more likely with concomitant administration of glyburide and 
trimethoprim-sulfamethoxazole; digoxin toxicity was twelve times more likely with 
clarithromycin; and hyperkalaemia was twenty times more likely with concomitant 
administration of ACE inhibitors and potassium-sparing diuretics than individual drugs as 
reported by Juurlink et al. (220). Therefore, emphasis should be placed on individual drug 
pharmacokinetics/pharmacodynamics and patient conditions to identify drug interactions 
through clinical judgement and/or use of online drug interaction checkers, like Lexi-Interact 
Online, and Micromedex-2 software for subsequent prevention of ADR-related admissions 
(221, 222).  
1.11.3 Pharmacy/pharmacist-based interventions 
There are different forms of pharmacy/pharmacist-based interventions. These include ongoing 
drug therapy monitoring, which is a process in which pharmacists actively review patients’ 
records, identify and resolve drug therapy problems such as ADRs, and communicate with 
prescribers when problems occur (223). In contrast, therapeutic drug monitoring (TDM) is the 
clinical practice of measuring specific drugs at designated intervals to maintain a steady 
concentration in a patient's bloodstream, thereby optimising safe, effective therapy and 
individualising dosage regimens (224). TDM is employed mainly for drugs with narrow 
therapeutic ranges, marked pharmacokinetic variability, target concentrations that are difficult 
to monitor, and known to cause adverse effects. However, drug therapy monitoring using blood 
samples is not feasible for routine clinical practice due to economic, ethical and clinical points 





Alternatively, pharmacist-centred ongoing drug therapy monitoring processes (in some 
conditions it includes TDM) include three steps, which are reported to prevent drug-related 
problems such as ADRs (225). The first step is enhancing active participation of patients in 
their medication management and their own health decisions through education about their 
drug therapy, potential ADRs, and actions to take if problems occur. The second step is 
assessment of patients’ drug therapy regularly in order to ensure that patients take their 
medications as prescribed, proactively identify and resolve ADRs as they occur, and assess 
therapeutic effectiveness. The third step is ensuring that appropriate laboratory tests that can 
objectively rule-out or rule-in suspected ADRs are done, assessed, and adjustment of drug 
therapy is performed accordingly.  
Medication reconciliation involves the process of avoiding such unintentional medication 
discrepancies with subsequent reduction in medication errors and ADRs across transitions in 
the patient care process (226). This is achieved through reviewing their complete medication 
regimen at the time of admission, transfer, and discharge, and comparing it with the regimen 
being considered for the new setting of care. Patients often receive new drugs or have variations 
made to their existing drugs at the times of transitions in the care process - upon hospitalisation, 
transfer from one unit to another, or discharge from the hospital to home or referral to another 
facility. During the transition processes, unintentional changes occur frequently for a variety 
of reasons, such as hospital-based clinical practitioners not being able to easily identify patients' 
complete medication lists before admission or being uninformed of recent medication changes. 
As a result, the new medication regimen prescribed at the time of discharge may 
unintentionally omit needed medications, unreasonably duplicate existing therapies, or contain 
incorrect dosage regimens. More than 40% of medication errors are believed to result from 
inadequate medication reconciliation processes during admission, transfer, and discharge of 





majority of these errors would be averted if medication reconciliation processes in general, or 
pharmacy-led medication reconciliation interventions in particular, were in place (229). In 
addition, a 2016 systematic review by Mekonnen et al. (229) found that pharmacist-led 
medication reconciliation processes could prevent medication discrepancies and subsequently 
ADRs at hospital admissions.   
Proactive pharmacy-led interventions such as medication reviews and community pharmacist 
interventions also help in preventing ADRs, due to pharmacists’ expertise in pharmacotherapy, 
adverse effects and clinical use of medications. Recent meta-analyses (230, 231) revealed that 
pharmacist-led interventions, such as medication review, that involved a number of implicit 
structured methods to identify drug-related problems or a combination of explicit and implicit 
approaches including involvement in ward rounds, have reduced unplanned hospital 
admissions and ADRs. On the other hand, Home Medicines Reviews conducted by an 
accredited pharmacist in the patient's home have shown good evidence to support the role of 
pharmacists in addressing the drug burden index and the medication appropriateness index 
(232). Moreover, pharmacist-led nursing home medication reviews have reduced 
polypharmacy with a subsequent reduction in drug burden index and cost (233-235). Therefore, 
pharmacist-led interventions designed to optimise medication use have a key role to reduce the 
risk of ADRs. Effective communication among multi-disciplinary teams including physicians, 
clinical pharmacists and nurses with integral parts in providing clinical services have been 
shown to reduce medication errors and inappropriate medication use with subsequent 
improvements in the occurrence of ADRs (215, 236). 
1.11.4 Use of clinical tools  
The use of explicit clinical tools such as Beers, STOPP (screening tool of older persons’ 





treatment) criteria can help identify medications causing ADRs and result in significant 
reduction of the ADRs (237, 238). The Beers criteria are the most commonly used criteria to 
assist clinicians in preventing ADRs in older adults (239, 240). According to 2015 updated 
Beers criteria, medication classes are divided into three categories based on the updated criteria 
(239). These included potentially inappropriate medications and classes to avoid in older adults, 
potentially inappropriate medications and classes to avoid in older adults with certain diseases 
and syndromes that the drugs listed can exacerbate, and finally medications to be used with 
caution in older adults. Similarly, potentially inappropriate medications, as defined by 65 
clinically important STOPP criteria, are significantly associated with avoidable ADRs that 
contribute to urgent hospitalisation in older persons (241). Moreover, the STOPP and the 
START criteria represent the more common avoidable instances of inappropriate prescribing 
in older persons in day-to-day clinical practice. The START criteria consist of 22 evidence-
based prescribing indicators for commonly encountered diseases in older persons, which have 
been validated in the same fashion as the STOPP criteria and represent the more common 
instances of inappropriate omission of potentially beneficial medications (242). On the other 
hand, use of implicit criteria, such as the medication appropriateness index (MAI) is the most 
common approach that predicts adverse drug events in older adults (243-245).  
1.11.5 Effective use of informatics and computerised systems 
Effective use of health informatics and computerised systems such as electronic databases and 
the internet, enables healthcare facilities to utilise software programs and facility-wide systems 
that prompt warnings for potential ADRs when medical practitioners order medications for 
patients (246). These prompt warnings often include consideration of a patient’s age, weight, 
underlying clinical conditions and renal and liver function, providing a more holistic approach 





Rommers et al. (207) reported that Computerised Physician Order Entry (CPOE) and Clinical 
Decision Support Systems (CDSSs) are two types of computer-based intervention that have 
shown benefits beyond medication safety, although they have some limitations. CPOE is a 
computerised system where the prescriber accomplishes medication ordering online using 
computer programs whereas CDSS is a system used to provide computerised advice while 
prescribing and usually works in conjunction with CPOE. CDSS has the ability to execute 
automatic drug allergy and drug interaction checks, and advise on drug doses and routes. A 
study on the implementation of CPOE showed a significant decline in preventable, potential 
adverse drug events, including ADRs, from approximately 11 events per 1000 patients days to 
5 events (247) and the number of transcription errors reduced by 84%. However, there is still 
limited evidence available to show these interventions reduce the occurrence of ADRs (248). 
Therefore, improving access to various sources of information and hand-held devices with 
daily free database updates would aid improved prescribing and allow rapid checking of 
potentially hazardous drug interactions (249). In addition, adequate induction and staffing of 
medical practitioners regarding effective use of electronic databases coupled with 
strengthening of effective communication among multi-disciplinary teams help reduce the risk 
of occurrence of ADRs.  
1.11.6 Highlighting patients at risk using predictive parameters 
In addition to focusing on processes of care, highlighting patients at risk of ADRs can help in 
preventing ADR-related hospitalisations. More importantly, the central concept in developing 
a risk prediction model is the utilisation of predictors or risk factors in providing estimates of 
individual probabilities of risk and benefits. Identifying patients at high risk of ADR-related 
hospitalisation depends on several risk factors, including socio-demographics, genetic 





individualised intervention. For instance, ADR predictive factors might vary due to variations 
in therapeutic options used with regard to differences in disease distribution, population socio-
demographics (9, 14, 23, 100), healthcare systems (104) and ethnic origin (168, 250). Several 
risk factors have been identified by previous studies (14, 208); however, medical practitioners 
often lack awareness of predictors of ADR-related hospitalisations or factors contributing to 
ADR-related deaths (251, 252).  
A very recent study from Australia by Parameswaran et al. (213) identified five independent 
predictors of ADR-related hospitalisations in elderly patients. These include drug changes in 
the preceding 3 months, presence of renal failure and dementia, use of antihypertensives and 
anticholinergics; these variables were used to derive an ADR prediction score. According to 
this study, the predictive ability of the score, assessed from calculation of the area under the 
receiver operator characteristic (AUROC) curve, was 70% (95% confidence interval (CI) 65–
75%). Another study from Germany (14) that aimed to characterise risk factors associated with 
ADRs established five variables as independent predictors of ADRs: increased body 
temperature, low thrombocyte levels, low erythrocyte levels, multiple drug use, and female 
sex. According to this study, the risk prediction ability of the model based on the AUROC 
curve was 80% with a sensitivity of 64% and specificity of 86%. These risk factors were 
developed based on data from 907 patients with a mean age of 60 years old. Although there 
are few studies on prediction of ADR-related hospitalisations in adults, existing evidence 
suggests that ADR-related hospitalisation risk prediction models are a possible solution for 
early identification of and intervention for elderly patients who are at higher risk for ADRs.   
1.12.  Ethiopian healthcare system 
The Ethiopian healthcare system is a three-tier healthcare delivery system. The first level, the 





100,000 people), health centres (15,000-25,000 population) and their satellite health posts 
(3,000-5,000 population) that are connected to each other by a referral system. A primary 
hospital, health centre and health posts form a primary health care unit (PHCU) with each 
health centre having five satellite health posts (253).  
 
Figure 1. 7 Adapted from the Ethiopian Health Sector Development Plan 2010-2015 (253) 
 
The Health Extension Program in the primary healthcare system (at Health Post level)  is an 
innovative community-based health program that has enabled Ethiopia to increase primary 
health care coverage from 76.9% in 2005 to 90% in 2010 (254). Currently there are more than 





organised into a health development army (HDA) for participatory learning and action 
meetings to actively engage the community in the Health Extension Program (255).  
The HEWs are trained to implement a Health Extension Package (HEP) of 16 healthcare 
activities at the kebele (village) level. All HEWs are women, at least 18 years of age, with a 
minimum of 10th grade education and recruited from the communities in which they will work. 
HEWs must complete a one-year course of instruction and field training, provided by Technical 
and Vocational Education Training Schools (TVETs), operated by the Ministry of Education. 
Upon completion of training, HEWs are assigned, in pairs, to a kebele (village) where they 
staff health posts and work directly with individual families. Health posts, therefore, are the 
first level of healthcare for the community, emphasising preventive care. HEWs spend 75% of 
their time visiting families in their homes and performing outreach activities in the community. 
The remaining 25% is spent providing services at the health posts, including immunisations 
and injectable contraceptives, among others. The 16 components of HEPs, as a preventive 
health program, promote four areas of care: disease prevention and control, family health, 
hygiene and environmental sanitation, and health education and communication. These include 
HIV/AIDS and other STIs and TB prevention and control, malaria prevention and control, first 
aid emergency measures, maternal and child health, family planning, immunisation, nutrition, 
adolescent reproductive health, excreta disposal, solid and liquid waste disposal, water supply 
and safety measures, food hygiene and safety measures, healthy home environment, personal 
hygiene and health education and communication (256). 
The secondary level in the tier is a general hospital with population coverage of 1-1.5 million 
people; and the tertiary level is a specialised hospital that covers a population of 3.5-5 million. 
According to the Ethiopian healthcare system, referral can be vertical from the lower end of 
the health tier system to the higher ones. It can be horizontal between similar levels of facilities 





when a lower level health facility directly refers patients to a specialised facility without 
necessarily passing through the hierarchical system. Overall, referrals can be among public, 
private, community based and other traditional and alternative medicine practitioners and 
sometimes social services are also included (257). 
As a tertiary level hospital, Jimma University Specialised Hospital is the major public teaching 
and referral hospital with a capacity of 600 beds in Southwest Ethiopia. The hospital provides 
both general and specialised services for approximately 200,000 patients each year. The 
hospital delivers a range of services on an outpatient, inpatient and emergency basis in various 
clinical departments including internal medicine, surgery, obstetrics and gynaecology, 
paediatrics, anaesthesia, dentistry, ophthalmology, psychiatry, pharmacy, laboratory medicine 
and radiology (258).  
1.13. ADR reporting system in Ethiopia.  
Under the Ethiopian Federal Ministry of Health, the Food, Medicine, Healthcare 
Administration and Control Authority (FMHACA) carries out post-marketing surveillance of 
pharmaceuicals. The primary role and mandate of FMHACA is to ensure that marketed 
medicines are safe and of good quality for the public. The authority has the responsibility to 
investigate safety concerns and take action to prevent and minimise medicine-related harm. 
FMHACA consults the national drug advisory committee that is composed of mutidisciplanary 
health professionals team to evaluate drug safety concerns and recommends possible action to 
be taken by the authority. According to the FMHACA, all suspected ADRs, detected 
medication errors or product quality defects should be reported to the pharmacovigilance centre 
at FMHACA via the yellow prepaid report form available at each health facility (from primary 
to tertiary level), via telephone or via email. When the reports have been received by FMHACA, 
an acknowledgement letter is sent to the reporter and follow-up questions need to be answered. 





Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre (UMC) 
in Sweden (259).  
There are different stakeholders involved in ADR reporting from the healthcare facility level 
to the federal pharmacovigilence centre with different roles and responsibilities. These includes, 
but are not limited to patients and consumers, all healthcare professionals, drug and therapeutic 
committees (DTCs) and the marketing authorisation holders, such as pharmaceutical industry, 
drug and chemical importers, wholesalers and distributors. The DTC is a technical working 
group established at each health facility level with representative members from each 
department with the aim of managing medication use problems including assessment of ADEs, 
implementing programs to track ADEs, and designing interventions, methods and procedures 
that will prevent the occurecne of ADEs (259).  
Ethiopia established its own pharmacovigilance database management system under 
FMHACA in 2002 (260). Following this, Ethiopia became a full member of the WHO program 
for international drug monitoring (261), however, the ADR reports received from the centre 
are limited in numbers. For instance, a total of 249 ADR cases were reported between 2002 
and 2007 with an average of 0.5 ADR cases per million population per year. More than half 
(63%) of the cases were from health facilities in the capital city. Most (76.0%) of the ADRs 
were reported by physicians. More than two-thirds (70.0%) of the ADRs were associated with 
antiretroviral drugs (260). Spontaneous reporting of ADRs is a significant activity to improve 
the safety of medicines and health care professionals are pivotal players in spontaneous 
reporting of ADRs. However, surveys conducted at different times and places revealed that the 
majority of healthcare professionals have inadequate levels of knowledge and practice towards 





1.14. Definitions and methods used in this study  
The discrepancy in terms is a major source of error when comparing studies and their 
methodologies. A widely accepted, formal definition would allow for better comparison 
between ADR-related hospitalisation studies and their impact worldwide. For the purposes of 
this study, we adopted the WHO ADR definition because this definition is intended to include 
all doses used clinically but exclude deliberate overdose and has been used widely in ADR 
studies over the last 40 years (22, 23). Additionally, compared to other definitions described in 
Section 1.2, the WHO ADR definition comprehensively describes ADRs that encompasses all 
ADRs no matter their severity level.  
The Naranjo method was chosen to assess ADR causality in this study because it has been 
widely used in observational studies because of its simplicity to apply and its objective 
measurement (89). In addition, the Naranjo ADR Probability Scale is quick to complete when 
compared to other more comprehensive and detailed methods. The Naranjo algorithm has the 
advantage of a reduction in inter-rater disagreement and uncertainty in evaluation of potential 
ADRs and therefore it is commonly utilised by pharmacovigilance centres of several nations 
(265).  
The severity of ADRs in this study was assessed using the Hartwig et al. severity scale because 
it is simple, easy to use, has clear definitions, and it has been  applied in prospective study of 
ADR-related hospitalisations (47). Additionally, this scale uses the principles of ADR severity 
assessment based on length of stay, treatment requirement, and the patient’s prognosis that are 
important parameters to characterise the most common ADRs of public health relevance, 
particularly in resource-limited settings, such as Ethiopia.  
Although some ADRs are unavoidable and occur even with the most extraordinary precautions 





criteria was chosen for assessing ADR preventability in this study because it is widely used in 
observational studies and clinically focussed to assess avoidability of an ADR. According to 
Schumock and Thornton criteria, preventable ADRs include but are not limited to: allergic 
reactions where the allergy is previously known and/or documented; avoidable dose-related 
reactions; idiosyncratic reactions that have occurred previously; ADRs secondary to drug 
interactions; and ADRs associated with inappropriate compliance, prescribing, or 
administrations.  
1.15. Rationale of the study 
ADRs are a major health problem for the public (267) and are associated with morbidity, 
hospitalisation, mortality and additional costs (10). Studies have reported that the prevalence 
of ADR-related hospitalisation varies from 0.2% (28) to 54.5% (29). Severe ADRs were an 
important reason for extensions of the hospital stay in approximately 20.0% of patients (41), 
and can cause life-threatening effects and admission to intensive care unit in up to 19.0% of 
the ADR cases (40, 42, 43). Studies focusing on predictors of ADR-related hospitalisations are 
from developed countries and have focussed on the older population (9-11, 14). However, there 
are significant variations between the populations of developed and developing countries with 
regard to disease distribution (9, 14, 23, 100), population demographics (9, 14, 23, 100), 
healthcare systems (104), complexity of diseases, medications prescribed (9, 14, 94), and 
ethnic origin (168, 250).  
Despite reporting of the burden of diseases, all-cause mortality, medication use patterns and 
associated adverse events, to our knowledge, there are no studies focusing on ADR-related 
hospital admissions and mortality in Ethiopia. However, there are number of factors 
suspected to increase the risk of ADR-related hospital admissions. These include, but are not 





traditional remedies (269), and concomitant anti-TB and antiretroviral therapies with 
overlapping adverse effects (270) than in developed countries. In addition, there is a higher 
proportion of the slow acetylator phenotype among patients on ART and anti-TB drugs that 
increases susceptibility to ADRs (271). Moreover, there are higher frequencies of genetic 
variants conferring increased risk for ADRs for commonly used drugs treating cancer, 
HIV/AIDS and tuberculosis (271, 272) in people of African descent. Furthermore, there are 
higher proportions of patients with concomitant infectious and non-communicable diseases 
taking multiple medications for long-term or life-long therapy than in developed countries 
(23, 199, 200, 273, 274). Unlike developed countries, there is substantial all-cause mortality 
rate among patients presenting to emergency departments (275), a high rate of mortality 
among HIV/TB co-infected patients on drug therapy (276), a less health-literate population 
(277), a lesser ability to provide healthcare (278), and a higher prevalence of malnutrition 
(279, 280).  
Given ADRs are associated with substantial clinical, economic, and humanistic problems in 
the healthcare system, our research aimed to address a gap in knowledge to allow developing 
(and developed) countries to better understand and address the level of problem. Considering 
the overall burden of ADR-related hospitalisation and mortality, the application of prevention 
strategies to prevent ADRs is of great importance, thus, this research intended to identify key 
areas for intervention to help reduce the ADR-related hospitalisation and mortality. To address 
the gaps in knowledge, the level of the problem and intervention areas, especially in developing 
countries, we conducted a review of the current literature followed by a prospective 
observational study. The review compared the prevalence and contributing factors of ADR-
related hospitalisations in developed and developing countries. Despites the differences in the 
healthcare system, patient demographics, disease distribution and drug therapy used, the review 





developed and developing countries. Following this, prospective observational studies 
determined the prevalence of ADR-related hospitalisation and mortality in adults; identified 
drugs commonly implicated in hospitalisation and mortality; characterised the severity and 
patterns of ADRs; highlighted the patients at higher risk for ADR-related hospitalisation using 
an ADR risk prediction model and determined preventability of ADRs. 
1.16. Aims 
The overall aim of this thesis was to investigate ADR-related hospitalisation and mortality in 
Ethiopian adult patients.  
Specific objectives were to: 
• Summarise and compare existing literature on the prevalence and contributing factors 
of ADR-related hospitalisation between developing and developed countries.  
• Characterise the ADR types, severity, preventability and the drugs implicated in 
hospitalisation and identify predictors of ADR-related hospitalisation. 
• Determine the mortality rate attributable to ADRs in patients presenting to hospital, 
identify drugs implicated in the ADR-related deaths and identify factors contributing 
to ADR-related mortality.   
• Determine the prevalence, severity and clinical patterns of DIH and identify commonly 







2. Adverse drug reaction related-hospitalisations in developed 
and developing countries: A review of prevalence and 
contributing factors  
2.1 Abstract 
Adverse drug reactions (ADRs) are one of the leading causes of hospital admissions and 
morbidity in developed countries and represent a substantial burden on health care delivery 
systems. However, there is little data available from low and middle-income countries. This 
review compares the prevalence and characteristics of ADR-related hospitalisations in adults 
in developed and developing countries; including the mortality, severity, and preventability 
associated with these events, commonly implicated drugs and contributing factors. A literature 
search was conducted via PubMed, Scopus, Web of Science, Embase, ProQuest, and Google 
Scholar to find articles published in English from 2000 to 2015. Relevant observational studies 
were included. The median (with interquartile range (IQR)) prevalence of ADR-related 
hospitalisation in developed and developing countries were 6.3% (3.3%-11.0%) and 5.5% 
(1.1%-16.9%), respectively. The median proportion of preventable ADRs in developed and 
developing countries were 71.7% (62.3%-80.0%) and 59.6% (51.5%-79.6%), respectively. 
Similarly, the median proportion of ADRs resulting in mortality in developed and developing 
countries were 1.7% (0.7%-4.8%) and 1.8% (0.8%-8.0%), respectively. Commonly implicated 
drugs in both settings were antithrombotic, non-steroidal anti-inflammatory, and 
cardiovascular drugs. Older age, female gender, number of medications, renal impairment, and 
heart failure were reported to be associated with an increased risk for ADR-related 





The majority of ADRs were preventable in both settings, highlighting the importance of 
improving medication use, particularly in vulnerable patient groups such as the elderly, patients 
with multiple comorbidities, and those in developing countries with HIV/AIDS. 
2.2. Key points 
Reviews comparing the prevalence of ADR-related hospitalisations and contributing factors 
among adults in developed and developing countries were uncommon. 
ADR-related hospitalisations from the influence of HIV/AIDS and other infectious diseases 
and their associated medications are the main difference in developing countries.  
 There was wide variation in the prevalence of ADR-related hospitalisations among studies due 
to lack of golden standard tools for causality assessment, severity scaling and preventability 
classification.  
The use of a standardised approach for assessment of ADR causality, severity, and 
preventability would greatly contribute towards an improved understanding of the global 







The World Health Organisation (WHO) defines an adverse drug reaction (ADR) as: “any 
response to a drug which is noxious and unintended, and which occurs at doses normally used 
in man for prophylaxis, diagnosis, or therapy of disease, or for the modification of 
physiological function” (21). ADRs are a major health problem for individuals and the public 
in general (267); studies from different parts of the world have reported that the overall 
prevalence of ADR-related hospitalisation varies from 0.2% (28) to 54.5% (29).  
The wide variation in the prevalence of ADR-related hospitalisations among studies is due to 
differences in disease distribution and population characteristics (9, 14, 23, 100), healthcare 
systems (104) and ethnic origin (168, 250). In addition, complicated case management with 
multiple medications, mainly in studies from developed countries (9, 14, 94, 281), and 
differences in study designs (retrospective vs prospective) (282) have contributed to the 
variations in reported prevalence. Moreover, differences in the definition of ADR used (24, 
283) and ADR causality assessment methods (84, 88) have contributed to these variations. 
Between 1998 and 2015, six reviews reported a prevalence of ADR-related hospitalisation in 
adult populations of 0.16% to 41.3% (56, 106, 117, 284-286).  There were, however, a number 
of limitations to these reviews. Some reviews applied a search strategy using a limited number 
of key words and search engines. As a consequence, relevant studies may have been excluded. 
In addition, some reviews provide limited information about the method used for ADR 
detection, causality assessment, proportion of severe and preventable ADRs, ADR-related 
mortality, and specific risk factors contributing to the occurrence of ADRs. The reviews 
commonly included studies from developed countries, focusing on mainly the elderly and 





In developing countries, the risk of ADR-related hospitalisation is becoming a major health 
concern as a result of increasing numbers of patients presenting with common morbidities such 
as human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and 
tuberculosis comorbid with other chronic illnesses (23, 199, 200, 273). The specific concerns 
of the developing world (where majority of the population are young adults (287)) have not 
been considered in previous reviews. The use of complex and relatively new therapies in these 
settings may make detection and reporting of ADR-related burden more crucial than before 
(199, 200). Similarly, a growing attention to chronic diseases and their complicated 
management with multiple medications presents an important clinical burden for developing 
healthcare settings (273). In addition, most developed countries with effective regulatory 
systems and market control (e.g. United States of America, European Union, Australia, 
Canada, Japan, New Zealand) currently have a very low proportion, i.e. less than 1% of market 
value of counterfeit medicine, however, in many developing countries of Africa, parts of Asia, 
and parts of Latin America have areas where between 10% and 30% of the medicines on sale 
can be counterfeit (288). We therefore undertook a review with a focus on comparing the 
prevalence of ADR-related hospitalisation, mortality, severe reactions and commonly 
implicated drugs among adults in developed and developing countries. In addition, we 
reviewed information on contributing risk factors, and the prevalence of preventable ADR-
related hospitalisations which represent an important target for intervention. 
2.4 Methods 
A literature search focusing on ADR-related hospitalisations was conducted via PubMed, 
Scopus, Web of Science, Embase, Proquest, and Google Scholar to find articles published in 
English from 2000 to 2015 using key terms: “adverse drug reactions”, “drug related side 





related problems”, “drug toxicity”, “drug therapy problems”, ”adult patients”, “elderly 
patients”, “older patients”, “geriatric patients” combined with “hospitalization”, “emergency 
admission”,  “hospital admission”, “acute care admission”, and “hospitalisation”. The search  
was conducted between December 2014 and December 2015. 
Observational studies that estimated the prevalence of ADRs prospectively and/or 
retrospectively were included. We excluded studies which focused on ADRs and adverse drug 
events (ADEs) in relation to a specific drug or drug group (e.g. anticoagulants); a specific 
clinical condition (e.g. renal failure); those investigating ADR-related hospital readmissions; 
those carried out in intensive care unit; and studies reporting medication errors, therapeutic 
failures, non-compliance, accidental and intentional poisoning, and drug abuse. Study 
participants included were patients (age ≥ 15 years) admitted due to ADRs. For studies that 
included all ages in the study population, only data for patients aged 15 years and over were 
included in this review. For inclusion in this review, studies had to include an explicit definition 
of what was considered as an ADR (e.g. WHO (283) or Edwards and Aronson(24) definition), 
an explicit assessment of causality (e.g. Naranjo (88) or WHO(283)), a clear description of the 
method used for ADR identification, and exploration of factors associated with the risk of 
ADR. Duplicate studies were removed by screening on title, abstract, and full text. 
For data analysis, we categorised ADRs as either severe or non-severe based on the information 
obtained in the selected studies, according to the classifications of Hartwig et al. (46) and 
Morimoto et al. (27). Severe ADRs were those leading to hospital admissions and prolonged 
existing hospitalisation, leading to permanent defects or life threatening complications, 
demanding a dosage reduction and therapy cessation, or requiring additional therapeutic 
measures or specific treatment (27, 46), whereas others were non-severe. Similarly, we 
categorised ADRs as preventable and non-preventable according to the details provided, using 





was recorded from ADRs leading to death (fatal ADRs). ADRs were classified as type A (dose 
dependent, augmented pharmacological and predictable reactions) and type B (bizarre, dose 
independent and non-predictable reactions) according to the Rawlins and Thompson 
classification method (75). We categorised countries into developing or developed on the basis 
of socio-economics, per capita income, industrialisation, literacy rate, and living standards 
published by the World Bank (289). ADR-related admission was defined as ADRs which were 
assessed as being implicated directly as a reason for admission and the ADRs identified at the 
time of medical admission that have contributed directly or indirectly to the hospital admission.  
The following data was extracted: 
1. Study characteristics: country; year conducted; study design (prospective or retrospective); 
number of study participants. 
2. Identification of ADR-related burden: prevalence of ADR-related admission; associated 
mortality; proportion of severe and preventable ADRs; ADR identification techniques. 
3. Information relating to the ADR: implicated drug(s); commonly reported ADRs; associated 













 Figure 2. 1 Flow chart showing inclusion and exclusion of articles used in this review  
2,948 articles (using the above 
key terms) 
200 articles screened for relevance  
101 articles reviewed for 
inclusion  
43 articles included in this 
review   
Criteria for exclusion of 2748 articles: 
• Study design (not comparative/ 
observational) = 1,328 
• Full text not available = 432 
• Publication year before 2000 = 415 
• Non-human study = 121 
• Not published in English = 113 
• Duplicate articles = 339 
Criteria for exclusion of 99 articles: 
• Specific to single drug-related effect = 38 
• Specific to single clinical condition = 27 
• Reporting of non-compliance, therapeutic 
failure and drug abuse as outcomes = 22 
• Conducted in an intensive care units = 12 
58 studies excluded: 
• ADR-related admission was not main aim = 11 
• Systematic review, review article = 6 
• Described medication errors and  adverse 
events as outcome = 21 
• Described in-hospital ADRs as an outcome        
= 12 
• ADR definition* and identification technique 
not clear = 8 
 
*Indicates ADR definitions used in this review: WHO definition: “any response to a drug which is noxious 
and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of 
disease, or for the modification of physiological function” [21].Edwards and Aronson definition: “an 
appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal 
product, which predicts hazard from future administration and warrants prevention or specific treatment, 






Based on the inclusion and exclusion criteria, 43 articles exploring ADR-related 
hospitalisations in more than 2.1 million adult patients (2,009,751 patients in developed 
countries and 131,649 patients in developing countries) were identified (Table 2.1). The study 
designs varied from a large retrospective hospital database review of 668,714 patients(12) to a 
small prospective cross-sectional clinical study of 106 patients. Thirty-one studies were 
conducted solely in an adult population with the remainder in all age groups. The majority of 
the ADRs (68.2%) were type A and therefore most were potentially avoidable. Out of 43 
studies included in this review, 30 were conducted in developed countries (out of which 28 
were in Europe) and 13 studies were conducted in developing countries.  
2.5.1 Prevalence of ADR-related hospitalisations and deaths  
There was wide variation in the reported prevalence of ADR-related hospitalisations in the 43 
selected studies, from 0.2% to 54.5%. The median prevalence of ADR-related hospitalisation 
of overall studies was 6% (interquartile range (IQR), 2.7%-11.0%). The prevalence in 
developed countries ranged from 0.5% to 37.5% with the median of 6.3 % (IQR, 3.3%-11.0%), 
while in developing countries it ranged from 0.2% to 54.5% with the median of 5.5% (IQR, 
1.1%-16.9%) (Figure 2.2 and Table 2.3).  
The prevalence of ADR-related hospitalisations were relatively more consistent among studies 
in developed countries than developing countries (Figure 2). Irrespective of the socio-economic 
background of the countries, prospective studies were associated with a higher ADR 
prevalence than retrospective studies (median of 6.5% (IQR, 3.8%-11.5%) versus 4.2 % (IQR, 
1.4%-11%)).  
Out of 43 studies included in this review, only 19 reported on the severity level of the ADRs 





leading to hospitalisation was 20% (IQR, 9.8%-24.0%) in developed countries and 10.0 % 
(IQR, 5.7%-24.0%) in developing countries The minimum and maximum proportions of severe 
ADRs with regard to the countries were 3.6% in 4,403 Spanish patients (retrospective study) 
(98) and 62.0% in 3,190 German patients (prospective study) (94). Irrespective of socio-
economic background, severe ADRs were reported to be common in older patients with greater 
comorbidity (9) and who were taking more medications (9, 281).  Across all studies, the 
majority of ADR-related admissions were preventable. The proportion of preventable ADR-
related admissions ranged from 20.1% of 57,000 German patients (58) to 92% of 4,403 Spanish 
patients (98) with a median proportion of 71.7 % (IQR, 62.3%-80.0%) in developed countries 
and 59.6 % (IQR, 51.5%-79.6%) in developing countries. In the majority of cases, prospective 
observational studies were associated with a higher median proportion of severe ADR-related 
admissions than retrospective studies (17.2% (IQR, 5.5%-32.2%) versus 5.7 % (IQR, 9.8%-
24.0%)) (Table 2.3). Similarly, preventable ADR-related admissions were higher in 






Table 2. 1 Characteristics of selected studies examining ADR-related admissions in study population of this review 
Reference   Study design  Study population 
& sample size  
Country & year 




admission   
Proportion of  
severe ADR 
Proporti







Drug classes reported to cause 
ADR-related admissions 
Ahern F et al. (30) Prospective observational  Adults (n=856) Ireland, 2010 8.8% NR 57.3% NR Cardiovascular and CNS drugs  
Alexopoulou A et al. 
(16) 
Prospective observational  Adults (n=548)  Greece, 2008 12.8% 18.6%  NR NR NSAIDs, diuretics, 
antithrombotics, hypoglycaemic 
agents  
Alvarez PA et al. (35) Pharmacovigilance approach Adults (n=1045) Argentina, 
2010 to 2012 
10.7% 4.0% 85.7% 8.0% NSAIDs and antiplatelets  
Budnitz DS et al. (290) Retrospective record review Adults (n=12,666) USA, 2007 to 
2009 
37.5% NR NR NR Antithrombotic and anti-diabetic 
agents 
Brvar M et al. (39) Retrospective review of 
medical records  
Adults (n=520) Slovenia, 
2006 
5.8% NR 90.0% 0.0% NSAIDs, aspirin, warfarin 




All age groups (n= 
350,835) 
Spain, 2001 to 
2006 
1.6%  NR NR 5.6%  Antineoplastics and 
immunosuppressives  
Chen YC et al. (37) Prospective observational 
study 
Adults (n=58,569) Taiwan, 2009 to 
2010 
0.8% 24.0% 73.4% 10.0% Cardiovascular agents  
Chen YC et al. (291) Case-control study  Adults (n=20,628) Taiwan, 2009 to 
2010 
1.4% NR NR NR Anti-diabetics, analgesics, 
cardiovascular drugs and 
anticoagulants 




Adults (n=1756) Italy, 2004 to 
2005 
5.8% NR 76.5% NR NSAIDs, oral anticoagulants, low-






Table 2.1 Characteristics of selected studies continued…… 
Reference   Study design  Study population 
& sample size  
Country & year 




admission   
Proportion of  
severe ADR 
Proporti







Drug classes reported to cause 
ADR-related admissions 
Green CF et al. (32) Review of patient medical 
records  
Adults (n=200) UK, 2000 7.5% NR 66.7% 1.0% NSAIDs and cardiovascular agents   
Hartholt KA et al. 
(103) 




17.6%  NR 40.0% NR Agents affecting blood constituents, 
cardiovascular drugs and analgesics  
Hofer-Dueckelmann C 







7.5%  62.0%  NR NR Diuretics and anticoagulants 




Scotland, 2006 2.7% NR 83.3% 6.7%  Antiplatelets and NSAIDs 





Mannese CK et al. 
(52) 
Prospective cross sectional  Adults (n=106) Netherlands, 
1994 
12.0% 24.0%  NR NR Oral anticoagulant  
Matanovic SM et al. 
(293) 
Prospective and observational 
study 
Adults  (n=454) Croatia, 2009 to 
2010  
11.0% NR NR NR NSAIDs and benzodiazepines  
McDonnell PJ et al. 
(33) 
Retrospective chart review All ages (n=437)   USA, 1998 to 
1999 
36.2% 24.0% 62.3% NR Chemotherapy, anticoagulants and 
antidiabetics 






6.3% 14.1%  53.0% 1.5% Antiretroviral drugs, ACE-
inhibitors, diuretics, warfarin and 
NSAIDs 
Mjörndal T et al. (166) Patient interview and record 
review 
Adults (n=681) Sweden, 2002 12.0% NR 91.0% 
 
NR NR 
aNoblat AC et al. (66) Prospective observational 
study 
All age groups (n= 
37,658) 
Brazil, 2007 0.4% 5.7% NR 0.5% Antineoplastic and antibiotics 
Olivier P et al. (96) Prospective survey  Elderly (n=789) France, 2002 to 
2003 






Table 2.1 Characteristics of selected studies continued…… 
Reference   Study design  Study population 
& sample size  
Country & year 




admission   
Proportion of  
severe ADR 
Proporti







Drug classes reported to cause 
ADR-related admissions 
Onder G et al. (9) Multicentre pharmaco-
epidemiology survey 
Adults (n=28,411) Italy, 1988 to 
1997 
3.4%  20.0%  75.0%  4.0%  Cardiovascular agents and NSAIDs 
aPatel H et al. (17) Retrospective review  of 
hospital database   
All age group 
(n= 447, 071) 
UK,  1998 to 
2005 
0.5 %  NR NR NR Cancer chemotherapy, analgesics 
and cardiovascular drugs  
Patel KJ et al. (34) Prospective observational Adults (n=6899) India, 2005 6.9%  6.8% 59.6% 0.8%  Anti-tuberculosis drugs, warfarin 
and chloroquine 
Pedrós C et al. (98) Cross sectional study  
 




3.6% 92.0% 3.2% RAS inhibitors,  
oral anticoagulants,  
antiplatelets and NSAIDs 
Pérez Menéndez-
Conde C et al. (104) 
Cross-sectional, prospective 
and observational study 
Adults (n=252) Spain, 2011 19.4% 20.4% 65.0% NR Antineoplastic therapy and 
immunosuppressants 




Adults (n=18,820) UK, 2001 to 
2002 
6.5% NR 72.0%  2.3%  Low dose aspirin, diuretics, 
warfarin, and NSAIDs 
Pourseyed S et al. (55) Prospective observational 
study  
Adults (n=400) Iran, 2004 1.8 %  
 
14.3% 50.0% 4.3%  Antineoplastics, 
and immunosuppressives  
Pouyanne P et al. (20) Cross sectional study  Adults  
(n=3137) 
France,1998 3.2% NR NR 0.1% Cardiovascular agents  
Ramesh M et al. (42) Prospective observational 
study 
All age groups 
(n=3717) 
India, 2003 5.5% 10.0% NR 1.8% Cardiovascular agents, anti-
infectives and NSAIDs  
Rottenkolber D et al. 
(58) 
Medical record review  Adults (n=57,000) Germany, 2006 
to 2007 
3.3%  9.8%  20.1% 1.0% Antithrombotics, anti-diabetics and 
diuretics  
Ruiter R et al. (97) 
 
Review of registry of hospital 





1.3%  NR NR NR Anticoagulants, anti-diabetics, 





Table 2.1 Characteristics of selected studies continued…… 
 
Notes: a In some articles where the prevalence of ADR was not directly reported in the original publication for the study population, it was calculated as the number of patients identified with an ADR out of all 
included patients. Abbreviations: ADR, adverse drug reaction; WHO, World Health Organization; GI, gastrointestinal; NSAIDs, non-steroidal anti-inflammatory drugs; CCB, calcium channel blockers; CNS, central 
nervous system; NR, Not reported; RAS, renin angiotensin system. 
Reference   Study design  Study population 
& sample size  
Country & year 




admission   
Proportion of  
severe ADR 
Proporti







Drug classes reported to cause 
ADR-related admissions 
Sánchez Muñoz-
Torrero JF et al. (100) 
Prospective observational 
study 
Adults (n=405) Spain, 2009 6.0%  17.0% NR  1.6% Antibiotics, enoxaparin, phenytoin 
and atorvastatin  








2.4%  44.0%  79.0%  1.7%  Cardiovascular, antithrombotics, 
analgesics and anti-rheumatics  
Sonal Sekhar M et al. 
(28) 
Retrospective record review  Adults (n=575) India, 2002 to 
2009 
0.2% NR NR NR CNS drugs, NSAIDs, antibiotics and 
anticoagulants 
Tipping B et al. (109) Prospective cross sectional 
study 
Adults (n=517) South Africa, 
2005 
23.0% NR NR NR Cardiovascular drugs, 
anticoagulants and antidiabetics 




Adults (n=728) Uganda, 2005 4.5% No severe 
ADR 
NR No death  Quinine  
van der Hooft CS et al. 
(12) 
Retrospective review of 
hospital discharge record 




1.8%  NR NR 6.0%  Anticoagulants, cytostatics, 
immunosuppressives and diuretics  
avan Der Hooft CS et 
al. (99) 




4.1% 5.7% 30.0% 0.3% Antithrombotics, cardiovascular and 
cytostatics 
Varallo FR et al. (107) Prospective cross sectional 
study 
Adults (n=248) Brazil, 2008 46.4% NR 
 
NR NR Cardiovascular drugs and 
omeprazole  
Varallo FR et al. (29) Prospective cross sectional 
study 
Adults Brazil, 2006 54.5% NR NR NR Cardiovascular, CNS and 
respiratory drugs  
von Euler M et al. (76) Retrospective review of 
computerised medical records  
Adults (n=168) Sweden, 2002 11.0% NR 70.0%  NR Warfarin, beta-blockers and insulin  
Walsh D et al. (294) Prospective observational 
study 
Adults (n=137) Ireland, 
2012 





















































































































































































































































































































2.5.2 ADR identification methods/causality assessment techniques  
The majority of studies (N=21) used the WHO causality assessment criteria (283) for detection 
of ADRs, followed by the Naranjo et al. (88) criteria. In 7 studies, ADRs were detected by a 
team of physicians, clinical pharmacologists, and pharmacists reviewing medical records, 
discharge summaries or hospital registries (10, 14, 30, 35, 76, 93, 166).  
2.5.3 Medications associated with ADR-related hospitalisation  
There was considerable variation in medications involved in ADR-related admissions between 
developed and developing countries, possibly as a result of difference in disease distribution 
(9, 14, 23, 100), population characteristics (9, 14, 23, 100), healthcare systems (104), and 
complexity of diseases and medications (9, 14, 94). The majority of the studies found that 
antithrombotics (oral anticoagulants and antiplatelet agents) (16, 34, 35, 93-97), non-steroidal 
anti-inflammatory drugs (NSAIDs) (10, 16, 23, 35, 39, 93, 95, 98), and cardiovascular 
medications (20, 30, 34, 94, 98, 99) were commonly associated with ADR-related hospital 
admissions, irrespective of the socioeconomic status of the countries. Other implicated 
medications included anti-infectives (34, 96, 100), antineoplastics, immunosuppressants (12, 
15, 104), and antidiabetic agents (16, 76, 97). However, anti-infectives were more commonly 
reported to be associated with ADR-related admissions in developing countries (23, 28, 42, 66, 
156) than developed countries. Top three ADRs commonly reported to cause hospital 
admissions were gastrointestinal (GI) bleeding (12, 20, 34, 97, 100, 105), electrolyte and 





2.5.4 Risk factors associated with ADR-related admissions  
Thirty studies included in this review have reported risk factors associated with ADR-related 
hospitalisation of adults, detailed in Table 2.2. These risk factors for hospital admissions have 
been categorised as patient-related, disease-related, medication-related, and healthcare-related. 
Eight studies found older age to be an independent predictor for ADR-related admissions 
(Table 2.2). Five studies reported that female gender was an independent risk factor for ADR-
related admissions (9, 20, 94, 97, 169). Increasing medical complexity, both in terms of number 
of co-morbidities (9, 95) and number of medications (9, 14, 16, 17, 94, 96-98), were reported 
to be associated with an increased risk for ADR-related hospitalisations. In addition, specific 
medical conditions such as HIV (23), renal failure (100) and heart failure (9) were also reported 
to be associated with ADR-related hospital admissions, with HIV identified as a risk factor for 













Table 2. 2 Identified predictors for ADR-related admissions  
Category of predictive risk 
factors  
Identified specific predictors [referenced studies]  
Patient-related Age (15, 20, 39, 55, 98, 99, 103) 
Female gender (9, 20, 94, 97, 169) 
Disease-related  Number of comorbidities (9, 95) 
Higher Charlson Comorbidity Index (37) 
Severe ADRs (37) 
Renal failure (100) 
Heart failure (9) 
HIV/AIDS (23) 
Gastrointestinal bleeding (52) 
Hormonal therapy (104) 
History of falls (52) 
Medication-related Number of drugs (9, 14, 16, 34, 94, 96, 97, 107) 
Anticoagulant use (96, 99, 109) 
NSAIDs (109) 
Angiotensin-converting enzyme inhibitors (109) 
Digitalis use (105) 
Antibacterial use (96) 
Antiretroviral drug use (23, 199, 200) 
Self-medication (96) 
Drug interactions (100)  
Alcohol use (9) 
Health system-related  Ward type (104) 







Table 2. 3 Comparison of prevalence and proportion of ADR-related hospital admission, severe ADR, preventable ADR and ADR-related 
mortality in developed and developing countries. 
Statistical 
tests  
Prevalence of ADR-related 
admission (%) 
Proportion of severe ADRs (%) Proportion of preventable ADRs 
(%) 

















country   
Minimum 0.5 0.2  3.6 4.0 20.0 50.0 0.0 0.5 
Maximum 37.5 54.5 62.0 74.5 92.0 85.7 6.7 10.0 
Median 6.3 5.5 20.0 10.0 71.7 59.6 1.7 1.8 
IQR(Q1,Q3) 7.7(3.3-11.0) 15.8(1.1-16.9) 14.2(9.8-24.0) 18.3(5.7-24.0) 17.7(62.3-80.0) 28.1(51.5-79.6) 4.1(0.7-4.8) 7.2(0.8-8.0) 
 









Detection of ADR-related hospitalisation provides an important measure of the burden of drug-
related morbidity on patients and on the healthcare system and also recognition of drug safety 
as a major public health priority (56). The findings from this review indicate that ADR-related 
hospitalisations constitute a substantial healthcare issue for the adult population, regardless of 
the socioeconomic context of developed or developing countries,.  
The overall prevalence of ADR-related hospitalisation ranged from 0.2% to 54.5%, which is 
comparable with the previous review findings of 0.2% to 41.3% by Beijer et al. (285). The 
median prevalence of this review was also comparable with three other reviews (282, 284, 
285). However, there were marked differences in the prevalence of ADR-related 
hospitalisations between studies selected for this review, possibly reflecting a lack of 
standardisation across the studies, especially with regard to the definitions of ADR used (24, 
283); and causality assessment and detection methods (84, 88).  
There is large difference in the prevalence of ADR-related admissions between studies even 
within the same countries. For instance, in Brazil Noblat et al. reported a prevalence of 0.4% 
ADR-related admissions (66) whereas Varallo et al. reported 54.5% (107). Similarly, in the 
United Kingdom Patel et al. reported a prevalence of 0.5% ADR-related admissions (17) 
whereas Green et al. reported 7.5%. The reasons for such large differences in ADR prevalence 
are likely due to the difference in study designs (higher proportions of prevalence were reported 
in prospective than retrospective studies in most cases), the population (higher prevalence of 
ADRs were reported in elderly age groups compared to broader age groups; differences in 
prescribing of higher or lower risk medications)(295), method of ADR identification (chart 
review versus patient/staff interview). Moreover, there is no gold standard method of ADR 





WHO (283) causality assessment methods, which influence the prevalence estimates. 
Additionally, various research groups may have had differing interpretations of the causality 
assessment criteria.  A large prevalence of ADR-related admissions were reported by Budnitz 
et al (290)and McDonnell et al (33) from United States despite being retrospectively designed 
studies; this might be due to high proportions of chronic disease, elderly patients and the high 
prevalence of medication use in the USA.   
Although there was a comparable prevalence of ADR-related hospitalisations between 
developing and developed countries, there was a wide variation and inconsistent prevalence 
between studies, especially in developing countries. The reasons for this could be variation in 
therapeutic options used with regard to differences in disease distribution and population 
characteristics (9, 14, 23, 100), healthcare systems (104), and ethnic origin (168, 250). In 
addition, complicated case management with multiple medications mainly in developed 
countries (9, 14, 94) and difference in study designs, primarily retrospective versus prospective 
design, (282) may have contributed to the variation in reported prevalence. Moreover, the wide 
variation could be as a result of differences in the populations being studied (for example, 
elderly populations had a higher rate than adult patients)(285).  
Even though there was variation in the medications associated with ADR-related 
hospitalisations between developed and developing countries, there were medications common 
to both settings. These included antithrombotics (16, 35, 93-95, 97), NSAIDs (10, 16, 23, 35, 
39, 93, 95, 98), and cardiovascular agents (17, 20, 30, 94, 98, 99). These medications have been 
associated with number of complications such as GI bleeding (20, 97, 99, 100, 105) and 
electrolyte and metabolic disturbances (9, 16, 23, 58, 94), which were similar to those reported 





In contrast to the developed countries, anti-infectives were commonly reported to be associated 
with ADR-related hospitalisations in developing countries (23, 28, 42, 66, 156).  This was 
probably because of the difference in the population at risk of ADRs in developing countries, 
particularly in sub-Saharan Africa, where HIV/AIDS co-infections and cross-fertilisation 
between other chronic illnesses (273) and infectious diseases are common. In addition, lack of 
proper legislation and policies for anti-infective use, including for ADR reporting, a large 
number of substandard and counterfeit products circulating in the markets, a lack of 
independent drug information centres and the irrational use of drugs (283) could have also 
contributed to the additional burden of ADR-related hospitalisation compared to the developed 
countries.   
Despite the differences in socioeconomic status of the study participants and study designs, 
there was significant consistency in some risk factors associated with ADR-related 
hospitalisations. For instance, female gender was associated with increased risk of ADR-related 
hospitalisation despite women taking similar medications to men (9, 20, 94, 97, 169). 
Moreover, a recent study by Rodenburg et al (171) showed that there was a pronounced risk 
among females taking diuretics, cardiotonic glycosides and coronary vasodilators. Possible 
reasons for the higher susceptibility of women to ADRs could be due to lower body weight and 
organ size, more body fat and a lower glomerular filtration rate. In addition, poorer educational 
opportunities, poorer empowerment and status for women (296) compared to men might have 
led to poorer management and handling of medications, particularly in the developing world, 
which might expose women to higher risk than men.   
Irrespective of the age and socioeconomics of the patients, the number of medications taken 
was also a consistently reported risk factor for ADR-related admissions (14, 17). The risk of 





this could be a greater risk of patient error due to more complicated regimens and also a greater 
chance of drug-drug and drug-disease interactions.    
Advanced age was found to be a risk factor in many studies irrespective of the socioeconomic 
status of the patients; this is hypothesised to be mainly as a result of increased fragility, medical 
complexity, disease burden and physiological changes. This is in agreement with a previous 
review (285). In contrast, Mjorndal et al. (166) and Hellden et al. (167) reported that advancing 
age itself had no effect on ADR-related hospitalisations, which could alternatively be explained 
by poor monitoring of renal function and adjustment of pharmacotherapy (drug selection and 
dose), particularly in very elderly women which can contribute to the occurrence of ADRs.  
There was great diversity in the role of specific medical conditions as independent risk factors 
for ADR-related hospitalisation. This makes it challenging to make firm conclusions on the 
contribution of specific medical conditions to the risk. Heart failure, renal failure and liver 
failure were clear risk factors for ADR-related admission (10, 32, 297). Immunosuppression 
with HIV and highly active antiretroviral therapy (HAART) were revealed as risk factors for 
ADR-related hospitalisation mainly in developing countries, as reported by Mehta et al. (23). 
Dimie  et al. (199) from Nigeria similarly reported that direct HAART-related complications 
in general and zidovudine-induced severe anaemia requiring blood transfusions in particular, 
were the most common reason for hospitalisation, and resulted in a six-fold risk of mortality in 
those with severe anaemia. Moreover, Henry et al. from Cameroon (200) reported that 
zidovudine-related severe anaemia was one of the main reasons for hospitalisations. Thus, 
patients’ HIV positive status tended to increase the risk of experiencing ADRs and mortality 
when compared with those who were HIV negative or whose HIV status was unknown (23). 





Severity and preventability of ADRs were under-reported in these studies. The highest 
proportion of severe cases reported was 62.0% by Hofer-Dueckelmann et al. in Germany  (94). 
The reason for this might be due to frequent use of drugs with narrow therapeutics index, such 
as anticoagulant and higher medication regimen complexixity. The majority of preventable 
ADRs were known to have occurred in the elderly. Thus, identifying preventable ADRs along 
with an understanding of the causes such as poor therapeutic monitoring and 
pharmacotherapeutic adjustments (167), is crucial in constructing interventions to minimise 
ADR-related admissions. In addition, patient empowerment through health education and 
literacy may reduce the burden of ADR-related hospital admissions such that complications 
arising from therapy can be addressed promptly or prevented altogether. 
There is large differences in the proportion of preventable ADR-related admissions irrespective 
of the socioeconomic status of the countries. The reason for huge difference in the proportion 
of preventable ADR could be lack of gold standard method for assessing preventability of 
ADR, as there is conflicting evidence on which instruments have the highest reliability for 
assessing preventability (298). In the articles reviewed we found that reliability was not 
reported in most of them and when reported, it varied markedly across studies. It was also 
revealed that intra- and inter-rater reliabilities of the preventability judgments of ADR was 
poorer when using implicit instruments compared to an explicit instruments (205), perhaps due 
to the larger impact of the individual reviewers’ clinical judgment in implicit instruments. In 
addition, there is difference in the risk factors and capacity of the health professionals in 
addressing these risk indicators of ADR.  There is also substantial difference between 






In the majority of cases, prospective observational studies were associated with a higher 
median prevalence of ADR-related admissions than retrospective studies. The reason could be, 
in prospective studies in addition to reviewing the medical records; patients are interviewed, 
observed and evaluated exhaustively for the presence of ADR. Therefore, there is more chance 
of identifying any hidden ADRs on top of reviewing physicians’ records only as there is more 
data available at the time of admission compared to retrospective data. 
The main strength of this study was the strict inclusion criteria applied regarding ADR-related 
hospitalisations in the adult population and the focus on comparison of studies from developed 
and developing countries. In addition, the majority of the studies included a clear description 
of the method applied in the identification of ADRs, prevalence of ADR-related 
hospitalisations, severe and preventable ADRs, frequency of drugs causing ADR and risk 
factors for ADR-related admissions. Risk factors for ADR-related admissions were discussed 
in a more comprehensive manner than in previous reviews. Moreover, the review was limited 
to mainly observational studies focussing on ADR-related hospitalisations in adults, in an 
attempt to minimise the heterogeneity among included studies. 
Despite the above strengths, there was a limited number of articles and inconsistent prevalence 
reporting from developing countries. ADR causality, severity and preventability described in 
this review were obtained from different studies that used different measurement criteria or 
scales that might have created discrepancies in the rates reported. In addition, the proportions 
of ADR-related mortality, severe and preventable reactions were reported in only about half of 
the studies, and findings are therefore not necessarily generalizable. Moreover, studies 
conducted in intensive care unit were excluded as our focus was on admissions to general 






ADRs are an important cause of hospital admission and contribute to substantial morbidity in 
patients and pressure on the healthcare system. The prevalence of ADR-related hospitalisation 
and mortality was similar in both the developed and developing worlds and many of the same 
medication classes were often implicated. The main difference between developed and 
developing worlds was the influence of HIV/AIDS and other infectious diseases and their 
associated medications. The prevalence of ADR-related hospitalisation was higher in 
prospective studies than retrospective studies irrespective of a country’s sociodemographic 
status, suggesting the need for a focus on prospective methodologies for identification and 
documentation of ADRs during post-marketing surveillance and pharmacovigilance studies. 
The majority of ADRs were preventable, highlighting the importance of improving medication 
use, particularly in vulnerable patient groups, such as the elderly, patients with comorbidities 
and multiple drugs, and in the developing world, patients with HIV/AIDS.  
The proportion of severe ADRs in developed countries were twice that of developing countries 
indicating that there were a large number of older patients with greater comorbidity and who 
were likely taking more medications due to both greater age and greater opportunity to obtain 
a wider variety of medications.  
The use of a standardised, simple methodology for assessment of causality, severity, and 
preventability should be considered which would greatly contribute towards an improved 
understanding of the global nature and extent of this public health problem and the measures 






3. Predictors of adverse drug reaction-related hospitalisation in 
Southwest Ethiopia: A prospective cross-sectional study  
3.1 Abstract 
Background: Adverse drug reactions (ADRs) are an important causes of morbidity and 
mortality in the healthcare system; however, there are no studies reporting on the magnitude 
and risk factors associated with ADR-related hospitalisation in Ethiopia.  
Objectives: To characterise the reaction types and the drugs implicated in admission to Jimma 
University Specialized Hospital, Southwest Ethiopia, and to identify risk factors associated 
with ADR-related hospitalisation. 
Methods: A prospective cross-sectional study was conducted from May 2015 to August 2016 
among consenting patients aged ≥18 years consecutively admitted to medical wards taking at 
least one medication prior to admission. ADR-related hospitalisations were determined through 
expert review of medical records, laboratory tests, patient interviews and physical observation. 
ADR causality was assessed by the Naranjo algorithm followed by consensus review with 
internal medicine specialist. ADR preventability was assessed using Schumock and Thornton’s 
criteria. Only definite and probable ADRs that provoked hospitalisation were considered. 
Binary logistic regression was used to identify independent predictors of ADR-related 
hospitalisation.  
Results: Of 1,001 patients, 103 (10.3%) had ADR-related admissions. Common ADRs 
responsible for hospitalisation were hepatotoxicity (35, 29.4%) and acute kidney injury (27, 
22.7%). The drug classes most frequently implicated were anti-tubercular agents (45, 25.0%) 





related hospitalisation were body mass index (BMI) <18.5 kg/m2 (adjusted odd ratio 
[AOR]=1.69; 95% confidence interval [CI]=1.10-2.62; p=0.047), pre-existing renal disease 
(AOR=2.84; 95%CI=1.38-5.85, p=0.004), pre-existing liver disease (AOR=2.61; 
95%CI=1.38-4.96; p=0.003), number of comorbidities ≥4 (AOR=2.09; 95%CI=1.27-3.44; 
p=0.004), number of drugs ≥6 (AOR=2.02; 95%CI=1.26-3.25; p=0.004), and history of 
previous ADRs (AOR=24.27; 95%CI=11.29-52.17; p<0.001). Most ADRs (106, 89.1%) were 
preventable.   
 Conclusions: ADRs were a common cause of hospitalisation. The majority of ADRs were 
preventable, highlighting the need for monitoring and review of patients with lower BMI, ADR 
history, renal and liver diseases, multiple comorbidities and medications. ADR predictors 
should be integrated into clinical pathways and pharmacovigilance systems.  
Key words: Adverse drug reaction, hospital admission, hospitalisation, Jimma University 
Specialised Hospital, Southwest Ethiopia  
3.2 Introduction 
Adverse drug reactions (ADRs) are one of the leading causes of morbidity and mortality in the 
healthcare system (22). Globally, studies have reported that the overall prevalence of ADR-
related hospitalisation varies from 0.2% (28) to 54.5% (29). A recent review of 43 
observational studies identified a comparable prevalence of ADR-related hospitalisation in 
developed and developing countries (22). However, most of the studies included in this review 
were conducted in developed countries, where the disease characteristics and prevalence, 
access to medicines, drug use patterns, and management systems differ markedly from those 
in developing countries (299). With respect to potential risk factors for ADRs, developing 
countries differ from developed countries in several important areas. These include greater 





(268), a high prevalence of anaemia and malnutrition (270), widespread use of traditional 
remedies (269), a higher incidence of concomitant anti-TB drugs and ART with overlapping 
adverse effects (270), and increasing rates of concomitant infectious and non-communicable 
diseases demanding multiple medications with potential interactions (23, 199, 200, 273, 274). 
There are also higher frequencies of genetic variants conferring increased risk for ADRs for 
commonly used drugs treating cancer, human immunodeficiency virus (HIV)/acquired 
immunodeficiency syndrome (AIDS) and tuberculosis (TB) in persons of African descent (272).  
In Ethiopia, a developing country, the risk of ADR-related hospitalisation is a health concern 
due to an increasing number of patients eligible for anti-TB and ART, due to decentralisation 
and scale-up of the HIV/AIDS care programme (277), and concomitant drug management of 
HIV/TB co-infected patients (277). According to a 2014 World Health Organization (WHO) 
report, the prevalence of all forms of TB was 211 per 100,000 of the population, of whom 13% 
of patients were HIV co-infected (300). The prevalence of HIV among the adult population in 
2015 was estimated to be 1.0% with national ART coverage of 52.0% (301). There is growing 
attention to chronic disease management with multiple medications (273, 302). The use of new 
and complex therapies for chronic diseases has increased due to the establishment of 
community care programs (303) and strengthening of health systems for chronic care at the 
level of local health centres, primary, general, and specialised hospitals (303). The provision 
of primary health care services by health extension workers (health professionals working at 
the lowest health care level targeting preventive and curative health services at the household 
level) (278) and the expansion of community pharmacies and drug stores at the community 
level has remarkably increased medication access and use in the community, although 
medication regulation is poor (304).  There are also higher rates of drug-related problems (305) 
and irrational use of medicines (306) among patients with chronic illnesses in ambulatory care 





Studies have identified several factors contributing to ADR-related hospitalisations including 
older age (98, 99), female gender (97, 169), increased number of co-morbidities (9, 95), 
increased number of medications (17), renal diseases (100, 307), liver diseases (308), heart 
failure (9), higher Charlson Comorbidity Index (CCI) (37), presence of chronic illnesses (16, 
176), and history of previous ADRs (14, 33). HIV/AIDS patients taking ART have been 
identified as a risk factor for ADR-related hospitalisations only in developing countries (23, 
101). Drugs commonly reported as contributing to ADRs include anticoagulants (96, 99), non-
steroidal anti-inflammatory drugs (NSAIDs) (109), and angiotensin-converting enzyme 
inhibitors (109). However, studies focussing on risk factors for ADR-related hospitalisation in 
developing countries are very limited in number (22). Therefore, identification and reporting 
of factors contributing to ADR-related hospitalisation for community-based patients is crucial 
to develop preventive strategies to decrease the burden in the developing world (199, 200).   
To our knowledge, there are no studies reporting on the prevalence and risk factors associated 
with ADR-related hospitalisation in Ethiopian patients. Thus, the main aim of this study was 
to characterise the reaction types and the drugs implicated in admission to Jimma University 
Specialized Hospital (JUSH), Southwest Ethiopia, and to identify risk factors associated with 
ADR-related hospitalisation.  
3.3 Methods 
3.3.1 Study setting, design and population  
This study was conducted at the JUSH, which is the major public hospital in southwest Ethiopia 
with a catchment population of about 15 million people (258).  
A prospective cross-sectional study was conducted from May 2015 to August 2016. Consenting 





to admission to medical wards were included in the study. Patients were excluded if they were 
unwilling to participate, unable to be interviewed due to health or other reasons, not taking at 
least one medication prior to admission and had incomplete medical and medication records. 
3.3.2 Data collection  
One of the authors (MTA) interviewed consecutively admitted patients as soon as practical for 
socio-demographic information, social drug use, medical history, drug allergies, use of over-
the-counter and herbal medicines (S1 Table). Patients’ medical records were reviewed for 
admission diagnosis, ADR history, and clinical data within 48 hours of admission. Medication 
exposure in the month preceding hospitalisation was obtained through review of patients’ 
medical records and /or interview with the patient or family members. Common laboratory 
tests were evaluated within 48 hours of admission for each patient case including: renal 
function (serum creatinine mg/dL, blood urea nitrogen mg/dL and estimated glomerular 
filtration rate (eGFR) mL/min/1.73m2), liver function (alanine transaminase IU/L, aspartate 
transaminase IU/L, alkaline phosphatase IU/L and total bilirubin mg/dL), and complete blood 
count (white blood cell count cells/mm3, red blood cell count cells/mm3, haemoglobin g/dL, 
haematocrit %, and platelet count cells/mm3). Parameters describing nutritional and metabolic 
status (serum albumin g/dL, total triglyceride mg/dL, low-density lipoprotein mg/dL, high-
density lipoprotein mg/dL, glucose mg/dL), serum electrolytes (serum calcium mmol/L, 
potassium mmol/L, and sodium mmol/L), and coagulation status (prothrombin time) were 
recorded. Vital statistics such as body temperature, blood pressure, respiratory rate, and pulse 
rate were recorded at admission. Other diagnostic data, such as echocardiography, ultrasound, 





3.3.3 Definitions of terms and variables used 
The WHO definition of an ADR was used in this study: “any response to a drug which is 
noxious and unintended, and which occurs at doses normally used in man for prophylaxis, 
diagnosis, or therapy of disease, or for the modification of physiological function” (21). This 
definition excludes treatment failure, drug abuse, intentional drug overdose, and accidental or 
self-poisoning. Alcohol consumption was recorded as number of standard drinks per day. Khat 
chewing, which was of interest as it contributes to elevated blood pressure (309), was defined 
as regular chewer if a patient chewed khat at least four times per week. Drugs were classified 
using the WHO Anatomical Therapeutic Chemical Classification (ATC) System (310) and 
diagnoses were coded according to International Classification of Primary Care 2nd edition 
(311). Calculation of the number of medications was based on the number of active ingredients 
in single and combination products (312). A cut off point for polypharmacy was ≥6 medications 
(313). A cut off point for comorbidities was ≥4 diseases based on a similar study (101). Adult 
nutritional status was assessed using the body mass index (BMI) (314) and classified as <18.5 
kg/m2 and ≥ 18.5 kg/m2 for analysis purposes. Patients were considered to have pre-existing 
chronic kidney disease if the eGFR was <60 mL/minute/1.73m2 and they had a documented 
abnormal renal ultrasound (abnormal renal echogenicity or kidney size or presence of cysts) 
for at least 3 months prior to admission (315). Drug-induced acute kidney injury was suspected 
among patients with baseline renal insufficiency (eGFR < 60 mL/minute/1.73m2), volume 
depletion, and multiple exposures to nephrotoxic agents prior to admission, as long as other 
potential causes were excluded. Chronic liver disease was considered pre-existing if liver 
diseases (such as cirrhosis, chronic viral hepatitis) or liver dysfunction or liver injury were 
documented by the treating physician prior to admission (308). Drug-induced hepatotoxicity 
was suspected when aspartate aminotransferase (AST) or alanine aminotransferase (ALT) 





UNL (316), as long as other potential causes were excluded. The response to rechallenge or re-
exposure to some drugs, such as anti-TB drugs, were implemented based on the WHO 
guidelines for the treatment of TB (317). HIV/AIDS and TB patients were those patients 
diagnosed with HIV/AIDS and TB, respectively, and taking ART and anti-TB drugs prior to 
the current admission.  All comorbidities were defined as present if documented in the medical 
records. A patient who had studied at least to a primary school level and was able to read and 
write in the local language(s) was considered as educated, whereas other patients were 
considered uneducated. According to the Ethiopian context, cities and small towns were 
considered as urban areas while rural villages or other similar clusters were considered as rural 
areas. The readmitted cases were treated as separate cases as far as the reasons for readmissions 
were different from the previous cause of admissions. 
3.3.4 Identifying ADR-related hospitalisation  
The primary researcher (MTA) evaluated all patients admitted to medical wards during the 
study period to assess if the admission had been caused by an ADR. The identification of 
whether one or more drugs led to the hospitalisation was based on a review of medical records, 
evaluation of laboratory tests, interview with patients or family members about medication 
usage and physical observation. An ADR was suspected if there was a relationship between 
the time of drug administration and the onset and course of the adverse reaction, while 
excluding other potential causes. The known adverse reaction profile of each drug was 
evaluated based on Ethiopian National Drug Formulary (2014), British National Formulary 
(318), and Up-To-Date 19.3 (319). Confirmation of the causal relationship of an ADR to the 
suspected medication was performed using the Naranjo ADR assessment scale (88). Applying 
the Naranjo algorithm, ADRs were classified as definite (9-12 points), probable (5-8 points), 





(DY) independently and blindly reviewed all cases of suspected ADRs and cases without 
suspected ADRs for the presence of ADRs and to confirm the Naranjo rating using a similar 
approach to other studies (116, 213). The primary researcher (MTA) and the senior supervising 
internal medicine specialist met to reach a consensus decision on the presence of an ADR-
related admission and excluded possible and doubtful cases. When consensus was not reached 
on the causality assessment, an additional clinical pharmacy specialist’s opinion was sought 
for majority decision. Only definite and probable ADRs that provoked hospitalisation were 
considered. ADRs were assessed for preventability using Schumock and Thornton criteria (201) 
through the same approach. ADRs were classified as type A (dose dependent, augmented 
pharmacological and predictable reactions) and type B (bizarre, dose independent and non-
predictable reactions) according to the Rawlins and Thompson classification method (75). 
ADRs observed during the hospital stay were excluded.  
3.3.5 Data analysis and interpretation 
Data was recorded into an Access database (2016, Microsoft, Redmond, Washington) and 
analysed using the IBM Statistical Package for the Social Science (IBM SPSS version 23.0 
Inc., Chicago, Illinois). Frequency of adverse reaction types and drugs implicated were 
determined. The chi-square test or Fisher’s exact test were used to compare categorical data 
between ADR- and non-ADR patients. For non-normally distributed variables, comparisons 
were undertaken with Mann-Whitney tests and the results were presented as medians and 
interquartile ranges (IQR). For normally distributed continuous variables, comparisons were 
performed using Student’s t-tests with results presented as means and standard deviations (SD).  
Independent variables were assessed for multicollinearity and association to rule out correlation 
between two or more independent variables using variance inflation factor. Independent 
variables with p<0.25 in univariate analyses were entered into a multivariable binary logistic 





performance of the ADR-related admission risk prediction model was assessed using the area 
under the receiver operator curve (AUROC), which assesses the ability of independent risk 
score to predict ADR-related admissions. The ROC curve was prepared using R (2015, R 
Foundation for Statistical Computing, Vienna) (320). A p value of <0.05 was considered 
statistically significant in all analyses. 
3.3.6 Ethics 
The study was approved by the Tasmanian Health and Medical Human Research Ethics 
Committee (reference number H0014718) and the Jimma University Institutional Review 
Board (reference number RPGC/58/2015). We received permission from Jimma University 
Specialised Hospital management to conduct the research. Written informed consent was 
obtained from all individual participants included in the study.  
3.4 Results 
3.4.1 General information   
A total of 3,224 patients were screened; 2,223 patients were excluded due to age <18 years 
(255), not taking at least one medication prior to admission (576), incomplete medical and 
medication records (70), unwillingness to participate (463) and inability to be interviewed as a 
result of health or other reasons (859). One thousand one patients fulfilled the inclusion criteria. 
Therefore, ADR-related admissions were estimated to be 3.4% (103/3,224) of all medical 
admissions and 10.3% (103/1,001) of the patients who met the inclusion criteria during the 
study period (Fig 3.1).  
One hundred and nineteen ADRs were identified among the 103 patients, equating to 1.2 ADRs 
per patient. Of these, 26.1% were definite and 73.9% were probable. Most ADRs (106, 89.1%) 
were considered preventable. Ninety-nine (83.2%) of the ADRs were considered 
















Patients fulfilled inclusion criteria 
= 1,001 
Patients suspected of ADR and 
causality assessment using Naranjo 
algorithm = 103 
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internist, author (DY) = 100 
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Third clinical pharmacist opinion 
sought = 3 patients  
Overall patients screened = 3,224 
Patients excluded = 
2,223 
Confirmed non-ADR-
related admission = 898 
patients  
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Table 3. 1 Causality, type and preventability of ADRs causing hospitalisation (N=119) 
ADR classifications   n (%) 
Causality of ADRs  
Definite  31(26.1) 
Probable  88 (73.9) 
Preventability scale  
Not preventable  13 (10.9) 
Definitely preventable  19 (16.0) 
Probably preventable  87 (73.1) 
Rawlins classification of reaction  
Type A (pharmacologically predictable) 99 (83.2) 
Type B (pharmacologically non-predictable) 20 (16.8) 
 
3.4.2 ADR characteristics and drugs implicated in ADRs 
The most common ADRs responsible for hospital admissions were hepatotoxicity (35, 29.4%) 
followed by acute kidney injury (due to drug-induced pre-renal azotaemia and nephrotoxicity)  
(27, 22.7%), skin reactions (8, 6.7%), hypokalaemia (7, 5.9%), and gastrointestinal bleeding or 
gastritis (7, 5.9%). Commonly implicated drugs in hepatotoxicity were isoniazid (21, 11.7%) 
followed by pyrazinamide (18, 10.0%), efavirenz (5, 2.8%), and atorvastatin (5, 2.8%). 
Commonly implicated drugs in acute kidney injury were tenofovir (9, 5.0%), furosemide (7, 
3.9%), and enalapril (7, 3.9%). The drugs most commonly suspected of causing skin reactions 
were sulfamethoxazole (2, 1.1%), trimethoprim (2, 1.1%) and rifampicin (2, 1.1%). The drug 
most commonly suspected of causing hypokalaemia was furosemide (6, 3.3%). The drugs most 





1.7%), and diclofenac (3, 1.7%). In general, anti-TB agents constituted the major source of 
ADRs (45, 25.0%) followed by antivirals (22, 12.2%) and diuretics (19, 10.6%). Table 3.2 























Table 3. 2 ADRs (N=119) and implicated drugs (N=180)  
ADR types  n (%) Drugs implicated in causing ADRs (n) n (% ) 
Hepatotoxicity  (cholestatic (22), 
hepatocellular (8), and mixed (5))  
35 (29.4) Isoniazid (21), pyrazinamide (18), atorvastatin 
(5), efavirenz (5), acetyl salicylic acid (ASA)# 
(2), clopidogrel (2), propylthiouracil (2), 
paracetamol (2), phenytoin (2), rifampicin (1), 
omeprazole (1), ritonavir (1), atazanavir (1) 
63 (35.0) 
Acute kidney injury (27) 27 (22.9) 
 
Tenofovir (9), furosemide (7), enalapril (7), 
diclofenac (4), acetyl salicylic acid# (4),  
cimetidine (1), heparin (1), clopidogrel (1) 
34 (18.9) 
Skin reactions involving mucous 
membrane (pruritic skin rash (6), 
gingival hyperplasia (1) and 
Steven Johnson Syndrome(1)) 
8 (6.7) Sulfamethoxazole (2), rifampicin (2), 
trimethoprim (2), ciprofloxacin* (1), ampicillin 
(1),  isoniazid (1), nevirapine (1), methotrexate 
(1), cloxacillin (1), phenytoin (1),  
phenobarbital (1), warfarin (1) 
15 (8.3) 
Gastrointestinal bleeding (6) and 
gastritis (1) 
7 (5.9) Warfarin (3), heparin (3), diclofenac (3), 
clopidogrel (2), acetylsalicylic acid# (2), 
propylthiouracil (1), glibenclamide  (1) 
15 (8.3) 
Hypokalaemia 7 (5.9) Furosemide (6), insulin (3), digoxin (1) 10 (5.6) 
Hypocalcaemia 6 (5.0) Furosemide (6)  6 (3.3) 
Diarrhoea 5 (4.2) Lamivudine (3), rifampicin (2), amitriptyline  
(1) 
6 (3.3) 
Hypoglycaemia  4 (3.4) Insulin (4), glibenclamide (1), acetyl salicylic 
acid (1) 
6 (3.3) 
Anaemia 4 (3.4) Sulfamethoxazole (2), trimethoprim (2), 
methotrexate (1), phenytoin (1) 
6 (3.3) 
Swelling of tongue (angioedema) 
(2) and severe dry cough (1)  
3 (2.5) Enalapril (3) 3 (1.7) 
Delirium  2 (1.7) Efavirenz (2) 2 (1.1) 
Thrombocytopenia 2 (1.7) Isoniazid (1), heparin (2) 3 (1.7) 
Falls 1 (0.8) Diazepam (1), thioridazine  (1)   2 (1.1) 
Osteomalacia  1 (0.8) Phenobarbital (1), phenytoin (1) 2 (1.1) 
Hypotension (orthostatic)  1 (0.8) Atenolol (1) 1 (0.6) 
Syncope  1 (0.8) Metoprolol (1) 1 (0.6) 
Dizziness  1 (0.8) Quinine (1) 1 (0.6) 
Blurred vision 1 (0.8) Amlodipine (1)  1 (0.6) 
Vertigo  1 (0.8) Metoprolol (1) 1 (0.6) 
Lactic acidosis  1 (0.8) Metformin (1) 1 (0.6) 
Vaginal bleeding   1 (0.8) Medroxyprogesterone acetate (1) 1 (0.6) 
 
^suspected to have caused lactic acidosis, * suspected to have caused Steven Johnson Syndrome, #high dose (≥300mg) acetyl salicylic acid 
3.4.3 Drugs used  
Out of the 4,018 drugs used by the 1,001 patients, 562 (14.0%) were used by patients who 





implicated in the 119 ADRs. Anti-infectives constituted the major proportion (52.1% versus 
40.5%, p=0.001) followed by cardiovascular system agents (18.9% versus 24.9%, p=0.013) in 
both the ADR and non-ADR groups, respectively (Table 3.3).  
Table 3. 3 Comparison of drugs used between non-ADR and ADR patient groups 
ATC class name Non-ADR 
group n (%) 
ADR group  
n (%) 
p-value  
Alimentary tract and metabolism 348 (10.1) 57 (10.1) 0.962 
Blood and blood forming organs 374 (10.8) 46 (8.1) 0.085 
Cardiovascular system 862 (24.9) 106 (18.9) 0.013 
Dermatologicals 4 (0.1) 2 (0.4) 0.173 
Genitourinary system and sex hormones 19 (0.5) 2 (0.4) 0.556 
Systemic hormonal preparations 96 (2.8) 9 (1.6) 0.113 
Anti-infective for systemic use 1398 (40.5) 293 (52.1) 0.001 
Antineoplastic and immunomodulating 
agents 
0 (0.0) 1 (0.2) NAa 
Musculoskeletal system 78 (2.3) 9 (1.6) 0.331 
Nervous system 188 (5.4) 24 (4.3) 0.273 
Anti-parasitic products 37 (1.1) 6 (1.1) 0.995 
Respiratory system 52 (1.5) 7 (1.2) 0.640 
Total  3456 (100.0) 562 (100.0)  
aNA = Not applicable, ATC = Anatomical Therapeutic Chemical Classification 
3.4.4 Patient characteristics in univariate analysis  
The main socio-demographic difference between the ADR-and non-ADR groups was a 
difference in urban versus rural residence (P=0.004), where urban residents were more likely 
to be admitted with ADRs than rural residents. The mean body mass index (kg/m2) was lower 
in the ADR group, 19.1±2.8 versus 20.1±2.9, p=0.004. There was no difference between the 
ADR and non-ADR groups for age, gender, educational status, smoking, alcohol use, khat 
chewing, and herbal use. Patients with a previous ADR history (p<0.001), pre-existing renal 





and HIV/AIDS taking ART (p<0.001) were more likely to be admitted with ADRs than those 
without these risk factors.  Similarly, ADR admission was more likely in patients who had been 
hospitalised in the preceding 3 months (p=0.030). Patients in the ADR group had a more 
comorbidities (4.0±1.4 versus 3.2±1.2, p<0.001) and used more drugs than the non-ADR group 





















Table 3. 4 Characteristics of patients experiencing ADR-related admissions and non-ADR-
related admissions at Jimma Universality Specialised Hospital 





Total patients  N=898 N=103  
Age, median (IQR) 40 (28-55) 40 (28-60) 0.490 
Gender, female n (%) 404 (45.0) 51 (49.5) 0.382 
Body mass index (kg/m2), mean ± SD 20.1±2.9 19.1±2.8 0.004 
BMI (kg/m2), n (%)    
<18.5kg/m2 260 (29.0) 44 (42.7)  
>/=18.5 kg/m2 638 (71.0) 59 (57.3) 0.004 
Education, n (%)    
Educated   613 (68.3) 68(66.0)  
Uneducated  285 (31.7) 35(34.0) 0.644 
Residence, n (%)    
Urban resident  421 (46.9) 64 (62.1)  
Rural resident  477 (53.1) 39 (37.9) 0.003 
Alcohol users, n (%) 218 (24.3) 17 (16.5) 0.080 
Khat chewers, n (%)  121 (13.5) 5 (5.9) 0.141 
Herbal users, n (%) 73 (8.1) 6 (5.8) 0.710 
Previous ADR history, n (%) 12 (1.3) 29 (28.2) <0.001 
eGFR, n (%)    
<60 mL/minute/1.73m2 307 (34.2) 27 (26.2)  
≥60 mL/minute/1.73m2 376 (41.9) 61 (59.2)  
Unknown  215 (23.9) 15 (14.6) 0.003 
Pre-existing renal diseases, n (%) 48 (5.3) 13 (12.6) 0.003 
Pre-existing liver diseases, n (%)     70 (7.8) 20 (19.4) <0.001 
Pre-existing heart failure, n (%)  232 (25.8) 27 (26.2) 0.934 
HIV/AIDS patients taking ART, n (%)    86 (9.6) 22 (21.2) <0.001 
TB patients taking anti-TB drugs, n (%)  171 (19.0) 36 (35.0) <0.001 
Malignancy of any type, n (%)  40 (4.5) 5 (4.9) 0.853 
Cerebrovascular diseases, n (%)   84 (9.4) 4 (3.9) 0.063 
Diabetes with complications, n (%)   69 (7.7) 9 (8.7) 0.705 
Chronic obstructive pulmonary diseases, n (%) 54 (6.0) 3 (2.9) 0.198 
Peptic Ulcer Diseases, n (%) 20 (2.2) 3 (2.9) 0.660 
Pre-existing hypertension, n (%)   109 (12.1) 11 (10.7) 0.666 
Number of comorbidities, mean ± SD          3.2±1.2 4.1±1.4 <0.001 
Number of comorbidities, n (%)    
1-3 comorbidities 563 (62.7) 36 (35.0)  
≥ 4 comorbidities 335 (37.3) 67 (65.0) <0.001 
Number of total medications, mean ± SD          3.9±2.1 5.6±2.7 <0.001 
Number of medications, n (%)    
1-5 medications  721 (80.3) 59 (57.3)  
≥ 6 medications  177 (19.7) 44 (42.7) <0.001 
Admission in the preceding 3 months (≥1 
admission(s)), n (%) 






3.4.5 Factors associated with ADR-related admissions 
Variables included in the multivariable binary logistic regression model were those with 
p<0.25 in the univariate analyses. There was no multicollinearity identified in the included 
variables. Six risk factors associated with ADR-related hospitalisation were identified in the 
multivariable binary logistic regression model: BMI < 18.5kg/m2, pre-existing renal diseases, 
pre-existing liver diseases, number of diagnoses ≥4, number of medications ≥6, and previous 
ADR history (Table 3.5). The ADR-related admission risk prediction model was found to have 
an AUROC of 79.0% (95% CI 73.9%-84.1%). The model had a sensitivity of 59.2% and 
specificity of 86.6%, suggesting that the ADR risk predictors are strong in identifying patients 
who are not at risk of ADRs and moderate in strength in identifying patients at risk of ADRs 
(Fig 3.2).  
 
Figure 3. 2 The area under the receiver operator curve showing risk prediction capacity of 






Table 3. 5 Regression model of ADR-related hospitalisation (N=1,001)  
Predictors                 Crude        Adjusted  
OR (95%CI) p-value OR (95%CI) p-value 
BMI < 18.5kg/m2 1.83 (1.21-2.78) 0.004 1.69 (1.10-2.62) 0.047 
Pre-existing renal diseases         2.56 (1.34-4.90) 0.005 2.84 (1.38-5.85) 0.004 
Pre-existing liver diseases 2.85 (1.65-4.92) <0.001 2.61 (1.38-4.96)  0.003 
Number of comorbidities ≥ 4 3.13 (2.04-4.79) <0.001 2.09 (1.27-3.44) 0.004 
Number of medications ≥ 6  3.04 (1.99-4.64) <0.001 2.02 (1.26-3.25) 0.004 
History of previous ADR         28.94 (14.18-59.05) <0.001 24.27 (11.29-52.17) <0.001 
Alcohol users  1.62 (0.94-2.79)  0.080 2.45 (1.29-4.65) 0.060 
Urban residence  1.86 (1.22-2.83) 0.004 1.50 (0.89-2.52) 0.123 
Khat chewers  1.46 (0.88-2.41) 0.141 1.03 (0.58-1.82)  0.932 
TB patients taking anti-TB drugs 2.28 (1.47-3.54) <0.001 1.41 (0.79-2.50) 0.241 
HIV/AIDS patients taking ART 4.06 (2.49-6.62) <0.001 1.33 (0.67-2.65) 0.416 
Admission in the preceding 3 
months 














Identification and reporting of predictors of ADR-related hospitalisation for community-based 
patients is crucial to develop preventive strategies and responsible care of patients. Medical 
practitioners may lack awareness of factors predicting ADRs leading to hospitalisation (251, 
252). To overcome this, studies, mainly from developed countries (9, 14), have identified 
several predictors of ADRs causing hospitalisation. However, Ethiopia is a developing country 
with different healthcare issues. These issues include a lesser ability to provide healthcare (278), 
a rising proportion of colliding epidemics of infectious and non-communicable diseases 
demanding multiple medications with potential of interactions (273, 321), a greater prevalence 
of HIV/AIDS and TB co-infection (322) with overlapping adverse effects of their medications 
(270), and a less health-literate population (277). Additionally, malnutrition and anaemia are 
more common than in developed countries (279, 280). Our study, the first in Ethiopia, 
identified risk factors associated with ADRs, and characterised the reaction types and drugs 
implicated in admission to the JUSH in Southwest Ethiopia.  
We found that 10.3% of admissions were related to ADRs, a prevalence comparable to other 
studies from South Africa (101) and Argentina (35). Similarly, a review of studies with a 
similar design to ours found comparable rates of ADRs in both developed and developing 
countries (22). More than half of the ADR-related admissions were due to hepatotoxicity 
(mainly due to isoniazid and pyrazinamide) and acute kidney injury (mainly due to tenofovir, 
enalapril and furosemide). Very few studies, only Patel et al. (34) from India and Mouton et 
al. (101) from South Africa, have reported comparable proportions of anti-TB-induced 
hepatotoxicity and tenofovir-induced renal impairment. The higher prevalence of 
hepatotoxicity in the current study could be due to concomitant anti-TB, ART and other 
medications with overlapping hepatotoxic effects. In addition, there was a substantial number 





some Ethiopian patients with isoniazid (271) could have exacerbated the hepatotoxic reactions. 
ADRs commonly responsible for hospitalisation in previous studies included gastrointestinal 
bleeding (97, 100), electrolyte and metabolic disturbances (9, 16, 23), and cardiovascular 
disorders (9, 17). Similar ADRs were reported in the current study, but at lower rates probably 
due to differences in population, diseases characteristics, and drug therapy used.   
Most of the predictors of ADRs, such as number of comorbidities (9, 95), number of drugs (9, 
16), pre-existing renal failure (100, 323), pre-existing liver  diseases (14) and history of 
previous ADRs (14, 33), were in line with reported findings from both developed and 
developing countries. HIV/AIDS patients taking ART was identified as an independent 
predictor that raised the risk of experiencing ADRs in South African studies (23, 101) in 2005 
and 2013, respectively. However, this variable was not included in the predictive model in the 
current study. This is possibly due to the intrinsic relationships between HIV/AIDS and 
malnutrition, multiple comorbidities, and polypharmacy; although, multicollinearity was not 
detected. In addition, the strength of the effect of HIV/AIDS patients taking ART as an 
independent variable is likely less than that of the other variables possibly because HIV/AIDS 
patients taking ART would have shown crossover-interaction with ADR-related hospitalisation. 
Additionally, compared to earlier South African studies, the burden of HIV/AIDS is now 
markedly reduced due to improvements in health care and greater availability of more tolerable 
ART. The two South African studies were conducted in communities with a high prevalence 
of HIV/AIDS, when more toxic antiretroviral drugs were in use. Finally, pharmacogenomic 
variations and other clinical characteristics of patients may have contributed to this difference 
(271).  
Patients with pre-existing renal diseases were more likely to be hospitalised with ADRs than 
patients with normal renal function, as has been identified in other studies (186, 187). About 





whom, 18.5% had pre-existing renal diseases. Nearly one-third of patients were underweight 
(Table 3.4) and patients with lower BMI were at increased risk of developing ADRs in the 
current study (Table 3.5), which is in line with another study (162). The combined effect of 
reduced muscle mass (malnutrition) with chronic illnesses may have contributed to a depressed 
eGFR despite normal serum creatinine levels, and concealed renal insufficiency may impact 
on the clearance of hydrophilic drugs (324). In addition, patients in the current study might 
unintentionally be overdosed based on their weight and/or renal function (using eGFR) that 
may have led them to develop ADRs. It is therefore important to evaluate renal function to 
assess the potential therapeutic benefit against the risk of ADRs before initiating renally cleared 
drugs. 
Similar to previous studies (308, 325), patients with pre-existing liver diseases were more likely 
to develop ADRs. Patients with liver diseases may have multiple comorbidities that require 
complex medical regimens (326). Pharmacokinetic and pharmacodynamic changes such as a 
decreased drug elimination or increased toxic metabolites, alteration in drug distribution or 
protein binding provide opportunity for adverse reactions (308). In addition, some drugs (such 
as anti-TB and ART) commonly used in the sample population are more likely to be associated 
with hepatotoxicity, in contrast to drugs used in developed countries.  
We found that ADR patients were prescribed a higher number of medications compared to non-
ADR patients. That means, increasing medical complexity, both the number of co-morbidities 
and number of medications, were associated with an increased risk for ADR-related 
hospitalisations. This is clearly described in the literature (9, 14, 17).  
Patients with a previous ADR history were more likely to be admitted with ADRs which is 
consistent with other studies (14, 33). This might be explained by immunological reactions 
tending to become worse on repeated exposure due to immunologic memory or cross-reaction 





be used. Most of the ADRs observed were preventable. Most of the ADRs in the current study 
occurred due to lack of close review of patients’ previous clinical and medication-related 
progress. ADR prevention could have been improved with better knowledge of patients’ 
medical and medication history and associated risk factors. 
The ADR-related hospitalisation risk prediction model demonstrated a capacity of 79.0% to 
discriminate patients who are at risk of ADR-related hospitalisation and those patients who are 
not. The sensitivity and specificity of the ADR-risk prediction model was 59.2% and 86.6%, 
respectively, which suggests that it can moderately rule-in patients at risk of ADRs and strongly 
rule-out those patients not at risk of ADRs. To our knowledge, there is no previously developed 
similar ADR-risk prediction model in similar study populations aged ≥18 years, especially in 
low and middle-income countries. Previous models developed by Zopf et al. (14) and 
Parameswaran et al. (213) showed comparable results (predictive abilities of 80.0% and 70.0%, 
respectively), but these models were developed in different populations with different clinical 
characteristics and drug therapy. Our model was further augmented by an ADR preventability 
assessment using Schumock and Thornton’s preventability assessment criteria, in which the 
majority of the ADRs were preventable provided these risk factors were reviewed and 
monitored closely. Although our ADR risk prediction model was not validated in other 
populations, the majority of the variables identified as independent predictors of ADRs have 
been described in previous studies (14, 213), suggesting that it is a useful model to assist 
healthcare practitioners to moderately identify patients at risk for ADRs for implementation of 
intervention strategies.  
Limitations and strengths  
Due to the cross-sectional nature of this study, we were only able to consider the incidence of 
ADRs at a time, so there is a need for future longitudinal studies to consider the incidence of 





related burdens. The self-reported responses for previous ADR history, for instance, may be 
limited by recall bias and could have influenced the identified predictors of ADRs, especially 
in patients taking multiple medications for chronic illnesses. Some questions in the Naranjo 
causality assessment tool were designed for controlled clinical trials; they were not feasible nor 
ethical for clinical practice, such as observing effects on giving placebo. Commonly used over-
the-counter medicines, contraceptives, topical agents, and herbal remedies were not typically 
recorded in drug histories, which may have resulted in underestimation of the rate of ADR-
related admissions. Some patients who were too ill to be interviewed due to health or other 
reasons were excluded from the study. This may have resulted in underrepresentation of certain 
ADRs. The results of this study should be extrapolated to other countries with caution, as the 
study findings depend on the patient characteristics, disease distribution, healthcare 
infrastructure, detection methods and definitions of ADRs adopted.  
The strength of our study is the prospective identification of ADRs immediately upon 
admission, allowing for accurate evaluation of the clinical presentation and laboratory 
parameters. We used a three-step process in ADR assessment, evaluating individual patient’s 
clinical and laboratory parameters, causality assessment using the Naranjo algorithm followed 
by consensus review with a senior supervising internist, to help mitigate the subjectivity 
associated with interpretation of some ADRs. Our study is the first to identify independent 
predictors of ADR-related hospitalisation in Ethiopian patients. Our yearlong sampling 
avoided the bias associated with anti-infective use pattern due to seasonal variation. Our study 
was conducted in a teaching and referral hospital serving a population of 15 million; therefore, 
our results allow extrapolation to other settings in the southwest of Ethiopia.  
3.6 Conclusions 
ADRs were a common cause of hospitalisation in adults admitted to medical wards of the JUSH. 





of patients with lower BMI, previous ADR history, pre-existing renal and liver diseases, 
multiple comorbidities and medications. The ADR-related hospitalisation risk prediction 
model demonstrated some ability to identify patients at higher risk for ADRs, and clearly 
identify patients at lower risk of ADRs. ADR predictors should be integrated into clinical 
pathways and pharmacovigilance systems. However, validation and refinement of the model is 
necessary prior to its implementation in routine clinical practice. The prevention of incident 
ADR may be of paramount importance, as previous ADR was a strong predictor of subsequent 
events in this patient population. Assessment of ADR causality and effective use of a 
pharmacovigilance system to monitor drug response in patients should be considered at 
ambulatory care units of all health care levels to minimise the burden of admissions related to 














4. Mortality from adverse drug reaction-related hospitalisations 
in southwest Ethiopia: A cross-sectional study 
4.1 Summary 
What is known and objective: Adverse drug reactions (ADRs) are an important cause of 
mortality during medical care. To our knowledge, there are no studies in Ethiopia regarding 
the mortality rate from ADRs, characteristics of the reactions and the drugs implicated 
among patients presenting to hospital with community-acquired ADRs. Therefore, the aim 
of this study was to determine the mortality rate attributable to ADRs in patients presenting 
to hospital and identify drugs implicated in the ADR-related deaths at the Jimma University 
Specialised Hospital (JUSH), Southwest Ethiopia.  
Methods: This cross-sectional study included 1,001 patients aged ≥18 years consecutively 
admitted to medical wards from May 2015 to August 2016. ADR-related mortality was 
determined through detailed review of medical records, laboratory tests, and patient 
interviews followed by causality assessment by the Naranjo algorithm and expert consensus.  
Results: Of 1,001 patients, 15, 1.5% (95% confidence interval [CI]: 0.80-2.30%) died with 
an ADR. The primary suspected causes of death were drug-induced hepatotoxicity (7, 43.8%) 
followed by acute kidney injury (4, 25.0%). Isoniazid (6, 33.3%), pyrazinamide (3, 16.7%), 
efavirenz (2, 11.1%) and tenofovir (2, 11.1%) were commonly implicated drugs. The 
majority of ADRs (14, 93.8%) were preventable. Unadjusted bivariate comparisons 
suggested patients who died with ADRs were more likely to have pre-existing liver disease 
(40.0% vs. 7.0%; 95% confidence interval [CI]: 8.1-57.8%), a history of ADRs (40% vs. 





± 2.9 kg/m2; 95% CI=0.9-3.9), exposure to anti-tubercular (46.7% vs. 18.9%; 95% CI: 2.3-
53.1%) and antiretroviral (40.0 % vs. 7.7%; 95% CI: 7.5-57.2%) therapies, and a higher 
mean number of medications (7.1 ± 3.3 vs. 3.8 ± 2.1; 95% CI: 2.2-4.4) and Charlson 
Comorbidity Index (3.9 ± 2.9 vs. 1.6 ± 1.8; 95% CI: 1.4-3.2) than surviving patients without 
ADRs.  
What is new and conclusion: Fatal ADRs were common in patients presenting to hospital. 
The drugs implicated were mostly anti-tubercular and antiretroviral therapies, reflecting the 
high burden of HIV and tuberculosis in the study population. ADR-related deaths were 
significantly associated with poor nutritional status. The majority of ADR-related deaths 
were preventable, highlighting the need to develop a multidisciplinary approach to closely 
monitor patients who are prescribed anti-tubercular and antiretroviral therapies, particularly 
in patients with hepatic disease, a history of ADRs, who are malnourished, and who are 
exposed to multiple medications. 
Key words: Adverse drug reaction; hepatic disease; malnutrition; mortality; Southwest 
Ethiopia 
4.2 What is known and objective 
Adverse drug reactions (ADRs) are an important cause of mortality during medical care (36). 
Globally, the rate of fatal ADRs in patients presenting to hospital has been reported to range 
from 0.1% to 10% (20, 37). Studies in developed countries reported that the rate of fatal 
ADRs ranged from 0.05% to 3% of all patients admitted due to an ADR (40, 61-63, 327). A 
recent review of 43 observational studies (where few studies were from developing countries) 
found that the median proportion of ADRs resulting in mortality in developing countries was 
1.8% (interquartile range (IQR) 0.8-8.0%) which was similar to 1.7% (IQR 0.7-4.8%) in 





developing countries in population demographics, disease distribution, drug therapy used 
and healthcare systems. 
Treatment of epidemics and other infectious diseases are of particular concern in developing 
countries, where anti-tuberculosis (anti-TB) (34), antiretroviral (23), and antibacterial drugs 
(42, 64) are commonly associated with ADR-related hospitalisation. There is a ‘double 
burden’ in developing countries where there are rising rates of concomitant infectious and 
non-communicable diseases that require therapy with multiple medications with increased 
potential for interactions (273, 321). Unlike developed countries, there is: a high rate of 
mortality among HIV/tuberculosis infected patients on drug therapy (276), a less health-
literate population (277),  a lesser ability to provide healthcare (278), and a higher prevalence 
of malnutrition (279, 280). 
There is substantial all-cause mortality rate among patients presenting to emergency 
departments in Ethiopia (275). There is increasing access to complex treatment of 
concomitant infectious and non-communicable diseases (268, 328), and a higher prevalence 
of concomitant anti-TB and antiretroviral therapy (ART) with overlapping adverse effects 
(270). Recent studies report a higher prevalence of drug-related problems (305) and irrational 
use of medicines among patients on chronic follow up in ambulatory care clinics (306).  
Despite reporting of the burden of diseases, all-cause mortality, medication use patterns and 
associated adverse events, to our knowledge, there are no studies in Ethiopia regarding ADR-
related mortality, characteristics of the reactions, and the drugs implicated among patients 
presenting to hospital with community-acquired ADRs. Therefore, the aim of this study was 
to determine the mortality rate attributable to ADRs in patients presenting to hospital, 
identify drugs implicated in the ADR-related deaths and identify factors contributing to 







4.3.1 Study design, setting and procedure 
A cross-sectional study was conducted in patients consecutively admitted to general medical 
wards of JUSH from May 2015 to August 2016. JUSH is the major public teaching and referral 
hospital with a capacity of 600 beds in Southwest Ethiopia. The hospital provides general 
medical and specialised services for approximately 200,000 patients each year. The catchment 
population is 15 million (258).  
Patients hospitalised due to ADRs and other causes were identified through detailed review of 
medical records, laboratory tests and patient interviews followed by Naranjo causality 
assessment and expert consensus meeting. ADRs were defined according to the definition of 
the World Health Organisation (WHO) (21), where treatment failure, drug abuse, intentional 
drug overdose, and accidental or self-poisoning were excluded. The first author (MTA), who 
was fully dedicated to this project, interviewed patients as soon as practical for socio-
demographic information, social drug use, medical history, drug allergies, and use of over-the-
counter and herbal medicines. MTA also reviewed each patient’s medical records and 
medication exposure in the month preceding hospitalisation. Common laboratory tests were 
evaluated within 48 hours of admission for each patient case including renal function, serum 
electrolytes, liver function, and complete blood count. An ADR was suspected if there was a 
relationship between the time of drug administration and the onset and course of the adverse 
reaction, while excluding other potential causes. The Naranjo ADR causality assessment scale 
(88) was administered by the author (MTA) followed by ADR severity scaling using the 
modified Hartwig et al. method (46). A consensus review was performed between the first 
author and an internal medicine specialist to confirm the causal relationship of an ADR to the 
suspected medication using a similar approach to a previous study  (65). Applying the Naranjo 





ADR-related or non-ADR-related. Subsequently, all deaths in the ADR-related group were 
considered to be definitely or probably associated with the ADR. ADRs observed during the 
hospital stay were excluded.   
4.3.2 Definitions Used 
ADRs that were suspected of causing death were classified as preventable and non-preventable 
using the principles of Schumock et al..  ADRs were classified as preventable if they met at 
least one of the following criteria: there was a previous reaction to the drug; if the drug, dose, 
route or frequency of administration involved was inappropriate for the patient; if there was a 
known treatment for the ADR; if the required therapeutic/laboratory monitoring test was not 
performed; if a drug interaction was involved; if poor medication compliance was involved; or 
if preventative measures were not prescribed.  
For each patient, we determined the Charlson Comorbidity Index (CCI) (329), drug count, 
drugs implicated, HIV status, tuberculosis status, and other characteristics that could have been 
related to the patient’s death. All-cause mortality refers to death from any cause (drugs and 
other medical illnesses). Adult nutritional status was assessed using the body mass index (BMI) 
(314) as underweight (<18.5 kg/m2), normal (18.5-25 kg/m2) and overweight (>25 kg/m2). 
Drugs were classified using the WHO Anatomical Therapeutic Chemical Classification (ATC) 
System (310). Calculation of the number of medications was based on the number of active 
ingredients in single and combination products (312). Drug interactions were checked using 
the Micromedex-2 software followed by clinical judgment, and the severity levels were 
classified as contraindicated (avoid combination), major (consider therapy modification), 
moderate (monitor therapy) and minor interactions (no action needed) (330). All comorbidities 





Patients were considered to have pre-existing chronic kidney disease if the eGFR was <60 
mL/minute/1.73m2, or they had documented abnormal renal ultrasounds (abnormal renal 
echogenicity or kidney size or presence of cysts) for at least 3 months prior to admission (315). 
Drug induced acute kidney injury was suspected among patients with baseline renal 
insufficiency (e.g., eGFR < 60 mL/minute/1.73m2), volume depletion, and multiple exposures 
to nephrotoxic agents at admission, provided other potential causes of the admission were 
excluded. Chronic liver disease was considered pre-existing if liver diseases (such as cirrhosis, 
chronic viral hepatitis) or liver dysfunction or liver injuries were documented by the treating 
physician at/prior to admission (308). Drug-induced hepatotoxicity was considered when 
aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels were ≥3 times 
upper normal limit (UNL) or total bilirubin was ≥2 times UNL (316). The response to 
rechallenge or re-exposure to some drugs, such as anti-TB drugs, was applied by the treating 
physician using the WHO guideline for the treatment of tuberculosis (317).  
4.3.3 Data entry, analysis and interpretation 
Data were entered into a Microsoft Access 2016 database (Redmond, Washington) and 
analysed using SPSS version 23.0 Inc. (Chicago, Illinois). Independent variables were 
compared between patients who died with ADRs and patients who survived without ADRs 
using unadjusted bivariate analysis, unadjusted for effect modification or confounding. The 
chi-square test or Fisher’s exact test were used to compare categorical data between patients 
who died with ADR and patients who survived without ADRs. Comparisons were performed 
for continuous variables using Student’s t-tests with results presented as means and standard 
deviations (SD). Comparisons between patients who died with ADR (15 patients) and 
patients who survived without ADRs (797 patients) were presented using differences in 
proportions and means and 95% confidence intervals. Patients who died with other illnesses 





the heterogeneity, and subsequent confounding, in the comparator group. A p value of <0.05 
was considered statistically significant in all analyses. 
4.3.4 Ethics  
The study was approved by the Tasmanian Health and Medical Human Research Ethics 
Committee (reference number H0014718) and Jimma University Institutional Review Board 
(reference number RPGC/58/2015). Written informed consent was obtained from all 
individual participants included in the study before collection of any information. 
4.4 Results and discussion 
Of the 1,001 patients, 103 patients were hospitalised due to ADRs. ADRs contributed to the 
death of 15 patients, which represented a mortality rate of 1.5% (95% confidence interval 
[CI]: 0.80-2.30%) in patients included in the study and 12.9% of all deaths (Fig 4.1). Studies 
conducted in South Africa (23), Iran (331), and India (64) reported comparable rates of 
ADR-related mortalities. However, the rate of ADR-related mortality in the current study 
was higher than the rates reported from Sweden (40),  Finland (63) and the United Kingdom 
(47). This higher rate may be due to the growing use of polypharmacy in concomitant 
infectious and non-communicable diseases, a larger proportion of underweight patients with 
deranged pharmacokinetics and overlapping adverse effects of anti-TB and ART (162, 271). 
Alternatively, the variations in rates of fatal ADRs between studies and countries might be 
explained by differences in study design (prospective vs. retrospective), disease distribution, 










Figure 4. 1 Screening process for ADRs and ADR-related mortality  
 
Malnutrition is one of the major public health problems in most developing countries, 
including Ethiopia (196). Unadjusted bivariate analysis suggested that patients died with 
ADRs had lower mean (± SD) BMI than patients alive without ADRs with a mean difference 
of 2.4 kg/m2 (17.6 ± 2.1 vs. 20.0 ± 2.9; 95% CI: 0.9-3.9) (Table 4.1). Probable reasons 
include the pathophysiological changes encountered in nutrient deficiencies that interfere 
with pharmacokinetic and pharmacodynamic processes in the body, resulting in altered drug 
response (196). Malnutrition can also alter plasma and tissue protein quantitatively (197). 
Therefore, the plasma protein binding capacity for commonly used drugs, such as anti-
inflammatory (diclofenac) and anti-TB drugs (pyrazinamide and isoniazid), might have been 
decreased resulting in an increased free fraction of the drug and hence ADRs. Forty percent 
of the patients who died with ADRs had liver diseases in the current study (Table 4.1). 
Patients with liver diseases are exceptionally vulnerable to developing malnutrition because 
of the key role played by the liver in regulating the nutritional state and the energy balance 
(198), which increases the risk of developing adverse clinical outcomes. There could have 
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been unintentional over dosage in patients with lower body weight or BMI that resulted in 
severe toxicity and subsequently death. Early and evidence-based nutritional interventions, 
especially in HIV/AIDS and tuberculosis patients, are strongly needed to minimise ADRs 
and ultimately improve the prognosis of such patients.  
Table 4. 1 Unadjusted bivariate comparisons of clinical and demographic characteristics of 
patients discharged alive without ADRs and patients who died with ADRs 
 



















Total patients  1,001 797 15   
Age, mean ± SD 42.4 ± 17.0 42.1 ± 16.9 44.5 ± 17.9 2.4 -6.3-11.1 
Female, n (%) 455 (45.5) 360 (45.2) 7 (46.7) 1.5 -23.9-26.9 
Previous ADR 
history, n (%) 
41 (4.1) 11 (1.4) 6 (40.0) 38.6 13.8-63.4 
Weight, mean ± SD 54.7 ±9.0 54.7 ± 8.9 53.2 ± 11.0 1.5 -3.1-6.1 




4.0 ± 2.3 3.8 ± 2.1 7.1 ± 3.3 3.3 2.2-4.4 
Charlson 
Comorbidity Index, 
mean ± SD 
1.9 ± 2.0 1.6 ± 1.8 3.9 ± 2.9 2.3 1.4-3.2 
HIV/AIDS patients 
taking ART, n (%) 
108 (10.8) 61 (7.7) 6 (40.0) 32.3 7.5-57.2 
TB patients taking 
anti-TB drugs, n 
(%) 
207 (20.7) 151 (18.9) 7 (46.7) 27.7 2.3-53.1 
Pre-existing renal 
diseases, n (%) 
61 (6.1) 38 (4.8) 2 (13.3) 8.6 -8.7-25.8 
Pre-existing liver 
diseases, n (%) 
90 (9.0) 56 (7.0) 6 (40.0) 33.0 8.1-57.8 
Admissions (≥1) in 
the preceding 3 
months#, n (%) 
135 (13.5) 100 (12.5) 2 (13.3) 0.9 -16.6-18.1 
 
#patients hospitalised before recruitment in the current study, * relates to the differences between patients alive without ADRs and patients 







The main suspected causes of death in the current study were hepatotoxicity (7, 43.8%) 
followed by acute kidney injury (4, 25.0%) and electrolyte disorders (2 [hypokalaemia, 
hypocalcaemia], 12.5%). Drugs frequently implicated in hepatotoxicity-related death 
included isoniazid (6, 33.3%) followed by pyrazinamide (3, 16.7 %) and efavirenz (2, 11.1%). 
Out of seven hepatotoxicity-related deaths, prophylactic isoniazid therapy was implicated in 
two of them (Table 4.2). Anti-TB drugs (isoniazid and pyrazinamide) and antiretroviral 
therapies (tenofovir and efavirenz) were frequently implicated in the ADR-related deaths, 
reflecting the high burden of HIV and tuberculosis and their associated drug-related 
problems in the study region. Isoniazid, the major hepatotoxic agent in the current study, 
was associated with the deaths of six patients in combination with pyrazinamide, rifampicin, 
efavirenz, nevirapine and ritonavir. Tenofovir, which is now being used in the majority of 
first-line highly active antiretroviral therapy regimens, was the single drug implicated in two 
ADR-related deaths due to acute kidney injury. Studies have shown that the decline in eGFR 
attributable to tenofovir was approximately 3-10 fold greater than the normal age-related 
decline (332, 333). Tenofovir-associated kidney injury and mortality is common, especially 
in patients with pre-existing renal disease, TB/HIV co-infection and concomitant anti-
TB/HIV therapy (333, 334). This is in line with the results of this study. Tenofovir use in 
acutely ill patients with pre-existing renal diseases is of concern, particularly when tenofovir 
is co-prescribed with other potentially nephrotoxic drugs, as there are limited facilities for 
renal replacement therapy. Anti-infectives were also identified as the major causes of death 
in similar studies (335). In contrast, studies conducted in some high-income countries (10, 
40, 63) reported that the most frequent fatal ADRs were gastrointestinal and intracranial 
haemorrhages attributed to antithrombotic agents, non-steroidal anti-inflammatory drugs 
(NSAIDs) and corticosteroids. This is probably due to substantial differences in the burden 





to developed countries, we identified ADR-related deaths associated with enalapril, 
diclofenac and metformin, at lower rates. This highlights the increasing double burden of 
ADRs associated with multiple drugs used in infectious and non-infectious diseases in 
Ethiopia.  
A higher proportion of patients who died with ADRs had pre-existing liver diseases than 
those who did not as suggested in unadjusted bivariate analysis with a difference between 
the proportions of 33% (40% vs. 7%, 95% CI: 8.1-57.8%) (Table 4.1). Five of the seven 
patients who died from hepatotoxicity had overwhelmingly elevated AST and ALT levels 
that ranged from 6 to 50 times the UNL; medians (IQR) were 317.6 (228.8-991.2) U/L and 
583.2 (227.3-789.2) U/L, respectively (Table 4.1). Slow acetylators of isoniazid are more 
susceptible to hepatotoxicity than rapid acetylators. (336, 337) The slow acetylation status 
has been shown to be the predominant phenotype in Ethiopian TB/HIV co-infected patients 
(271). Patients with prior liver diseases (338, 339) and lower BMI (malnutrition) (162) are 
also at higher risk of hepatotoxicity. Therefore, the combined effects of malnutrition, pre-
existing liver diseases and slow isoniazid acetylation status in some Ethiopian patients may 
have contributed to the severe drug-induced hepatotoxicity that was a major cause of 
mortality in our study.   
Nine of the 15 deaths occurred in patients with various combinations of HIV/AIDS, TB, low 
BMI (<18.5 kg/m2) and pre-existing liver diseases (Table 4.2). Twenty-seven percent of 
ADR-related deaths were in patients with TB plus HIV/AIDS; this combination of 
comorbidities was seen in 4.1% of surviving patients. Similarly, TB plus pre-existing liver 
disease was seen in 27% of ADR-related deaths but only 1.4% of surviving patients. Low 
BMI with HIV/AIDS was seen in 27% of the ADR-related deaths and 2.8% of surviving 
patients; and low BMI with TB was present in 40% of ADR-related deaths compared to 8.2% 





than surviving patients without ADRs (3.9 ± 2.9 vs. 1.6 ± 1.8, 95% CI: 1.4-3.2) (Table 4.1). 
These findings highlight the high rates of interrelated comorbidities among the patients who 
suffered ADR-related deaths, potentially leading to increased medication regimen 
complexity. This, along with being immunocompromised, could have increased the risk of 
drug-drug and drug-disease interactions, deranged pharmacokinetics, serious ADRs and 
finally death.  
According to the Schumock and Thornton preventability assessment criteria, two reactions 
(12.5%) were definitely preventable, 13 (81.3%) were probably preventable and one (6.2%) 
was not preventable (Table 4.2). Major underlying factors were poor therapeutic monitoring 
and the presence of clinically significant drug interactions that required therapy modification. 
The proportion of preventable ADRs in this study is comparable to previously described figures 
of 85.7% to 92% (35, 39). However, studies conducted in South Africa reported that only 45% 
(65) and 53% (23) of ADRs were preventable. The reason for this could be the difference in 
study design (prospective vs. retrospective identification of ADRs) and the nature of drugs used 
by the patients. In addition, there were more idiosyncratic reactions in the South African 
studies, possibly due to the larger number of patients with HIV-related immunodeficiency, 
where these type of reactions were mediated through a combination of immunologic (by 










Table 4. 2 Case details of ADR-related deaths 
aall ADRs were classified as level 7 according to modified Hartwig et al. method,  b possible causality in Naranjo scale, c acetylsalicylic acid (ASA) dose ≥300mg
Drugs used by the patients prior to admission Drug interaction 
severity level in 
drugs used by the 
patients  prior to 
admission 
Laboratory test results supportive of 
ADRs at admission  
Significant comorbidities ADR(s)a  suspected 





Preventability of  
the ADR(s)  
using Schumock  
and  Thornton 
criteria  
Isoniazid, tenofovir, lamivudine, efavirenz, 
sulfamethoxazole, trimethoprim 
Major AST=317.6 U/L, ALT=583.2 U/L, 
ALP=1416.0 U/L, total 
bilirubin=3.5mg/dL 




Metronidazole, paracetamol, bisacodyl, tenofovir, 
lamivudine, efavirenz 
None Serum creatinine (SCr)=8.3 mg/dL, 
Blood Urea Nitrogen (BUN)=474mg/dL 
HIV/AIDS/ liver diseases  Kidney injury Tenofovir Not preventable  
Isoniazid, rifampicin, pyrazinamide, ethambutol  Major AST=421.2 U/L, ALT=620.7 U/L, 
ALP=2223.8 U/L, total bilirubin=8.3 




Glibenclamide,  metformin, enalapril Moderate Scr=2.7 mg/dL, BUN=167.8 mg/dL Type-2 diabetes, 
hypertension, stroke 
Kidney injury and 





Dexamethasone, trimethoprim, sulfamethoxazole,  
isoniazid, rifampicin, pyrazinamide, ethambutol,   
tenofovir, lamivudine, efavirenz 
Major AST=1750 U/L, ALT=789.2 U/L, 







Tenofovir, lamivudine, nevirapine, omeprazole, 
metoclopramide, isoniazid, sulfamethoxazole, 
trimethoprim 
Major AST=284.5 U/L, ALT=227.3 U/L, 
ALP=388.0 U/L, total bilirubin=5.1 




Tenofovir, lamivudine, efavirenz 
sulfamethoxazole, trimethoprim, rifampicin, 
ethambutol 
Major AST=991.2 U/L, ALT=11450.0 U/L, 
ALP=2045.0 U/L, total bilirubin=3.2 
mg/dL 
TB/HIV/AIDS/low 
BMI/liver diseases  
Hepatotoxicity Efavirenz Definitely 
preventable  
Isoniazid, rifampicin, pyrazinamide, ethambutol,   
tenofovir, lamivudine, efavirenz, pyridoxine, 
sulfamethoxazole, trimethoprim 
Major Scr=3.2 mg/dL, BUN=72.4 mg/dL TB/HIV/AIDS/low BMI Kidney injury Tenofovir Probably 
preventable  
Isoniazid, rifampicin, pyrazinamide, ethambutol,  
pyridoxine, heparin, azithromycin, cimetidine, 
metoclopramide, diclofenac, paracetamol, 
dexamethasone  
Major AST=228.8 U/L, ALT=223.4 U/L, 
ALP=321.0 U/L, total bilirubin=3.0 
mg/dL 




Diazepam, heparin, phenytoin, digoxin, 
cimetidine,  thioridazine 
Major - Epilepsy, stroke, rheumatic 
heart diseases  




Furosemide, prednisolone, isoniazid, rifampicin, 
pyrazinamide, ethambutol  




Furosemide,  acetylsalicylic acid, metoprolol, 
atorvastatin, enalapril, hydrochlorothiazide, 
diclofenac 
Major Scr=4.7mg/dL, BUN=125mg/dL Ischaemic heart disease, 
congestive heart failure 




Tenofovir, lamivudine, ritonavir, lopinavir, 
isoniazid, rifampicin, cimetidine, ferrous sulphate 
Major AST=210 U/L, ALT=246.4 U/L, 
ALP=415.0 U/L, total bilirubin=3.7 
mg/dL 





Acetylsalicylic acid, digoxin, furosemide Moderate Serum potassium=2.1 mEq/L Rheumatic heart disease, 
congestive heart failure  




Furosemide, tramadol, enalapril, acetylsalicylic 
acid, clopidogrel, heparin 
Major - Acute myocardial infarction 
and ascites  
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Limitations of this study were that some questions in the Naranjo causality assessment tool 
were not feasible nor ethical for clinical practice, such as observing effects on giving placebo. 
Inter-rater reliability agreement was not measured for ADR causality, although consensus 
was reached in all cases. The study only identified death due to ADR-related admissions to 
hospital, not in-hospital ADRs, nor patients who died before presenting to hospital, so our 
results may have underestimated the full burden of ADR-related mortality. Severely 
obtunded and critically ill patients who were not able to be interviewed were excluded from 
the study. This might have underestimated the proportion of death in both the ADR and non-
ADR groups. Commonly used over-the-counter medicines, contraceptives, topical agents, 
and herbal remedies were not commonly recorded in drug histories, which may have 
influenced the findings of this study. Multivariable regression analysis was not conducted 
due to overfitting because of the low number of deaths, therefore, the results may be 
impacted by confounding. The results of this study should be extrapolated to other countries 
with caution, as the study findings depend on the patient characteristics, disease distribution, 
healthcare infrastructure, ADR detection methods and definitions of ADRs adopted.  
However, despite its limitations, this study is relevant to healthcare authorities, programme 
leaders and policy makers, as it describes one of the major drug-related problems that is little 
known in the region. We used a three-step process in ADR assessment, evaluating individual 
patients’ clinical and laboratory parameters; causality and preventability assessment; followed 
by consensus review, to help mitigate the subjectivity associated with interpretation of some 
ADRs. A yearlong sampling period avoided the bias associated with anti-infective use patterns 
due to seasonal variation.  
4.5 What is new and conclusion 
Fatal ADRs were common in patients presenting to medical wards of the JUSH. Unlike in 
high-income countries, isoniazid and pyrazinamide-induced hepatotoxicity followed by 
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tenofovir-induced kidney injury were the major suspected causes of mortality, reflecting the 
high burden of HIV and tuberculosis in the study setting. ADR-related deaths were 
significantly associated with poor nutritional status. The majority of ADR-related deaths 
were preventable, highlighting the need to develop a multidisciplinary approach to closely 
monitor patients who are prescribed anti-tubercular and antiretroviral therapies, particularly 
in patients with hepatic disease, a history of ADRs, who are malnourished, and who are 
exposed to multiple medications. Drug-drug interactions were the major challenges in ADR 
causality assessment especially in patients taking fixed dose combination of anti-TB drugs 
and ART. On-the-job training and follow-up of medical practitioners, especially physicians 
and clinically trained pharmacists, focusing on preventable ADRs and effective use of a 
pharmacovigilance system should be considered at emergency and ambulatory care units of 
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Chapter Five 
5. Drug-induced hepatotoxicity-related hospitalisation: Patterns, 
severity and implicated drugs 
5.1 Abstract 
Background: Drug-induced-hepatotoxicity (DIH) is responsible for over 50% of cases of acute 
liver failure and 0.1-5% of all hospital admissions. However, little is known about DIH-related 
hospitalisation in Ethiopia.  
Objective: The aim was to determine the prevalence, severity and clinical patterns of DIH-
related hospitalisation and identify commonly implicated drugs. 
Methods: Ethiopian patients aged ≥18 years, taking at least one regular medication prior to 
hospital admission and who had at least one set of liver function tests were included. DIH-
related hospitalisation was identified through evaluation of patient history, clinical and 
biochemical characteristics and causality assessment of likely precipitating drug(s) followed 
by expert consensus. DIH severity was classified using the Drug-Induced Liver Injury Expert 
Working Group criteria. The R-value was used to define patterns of liver injury. 
Results: Of 674 patients, 35 (5.2%) were hospitalised due to DIH. Twenty-two patients (62.9%) 
exhibited a cholestatic pattern, followed by eight (22.9%) with a hepatocellular pattern. 
Commonly implicated drugs were isoniazid (21, 60.0%), pyrazinamide (16, 45.7%), efavirenz 
(5, 14.3%), nevirapine (5, 14.3%) and atorvastatin (5, 14.3%). More than two-thirds of cases 
(24, 68.6%) were severe or fatal; these were mainly caused by anti-tuberculosis (anti-TB) drugs 
(15, 42.9%), antiretroviral therapy (ART) (4, 11.4%) or concomitant anti-TB/ART (6, 17.1%).  
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Conclusion: DIH is an important cause of hospitalisation and mortality in Ethiopia. Most cases 
were cholestatic and caused by anti-TB agents and ART. Special consideration should be given 
to patients taking anti-TB drugs and ART, particularly those with malnutrition, pre-existing 
liver disease and previous ADR history.  
5.2 Introduction 
Drug-induced hepatotoxicity (DIH) is a frequent cause of liver injury (341). The true incidence 
of DIH for community-based patients is largely unknown due to a scarcity of population-based 
studies, under-reporting of adverse reactions and multiple confounding factors in the diagnosis 
(342). However, the incidence of DIH is likely to rise in the general population because of the 
increasing number of drugs used in medical care (342, 343). According to a 2017 Council for 
International Organizations of Medical Sciences working group report on drug-induced liver 
injury (DILI), the hepatotoxic potential of a drug can only be recognised through post-
marketing surveillance (344). For most medications, the risk of DIH is higher than reported in 
initial clinical trials (342, 345-347). Antimicrobials have been reported to be the major cause 
of DIH worldwide (138, 348), with amoxicillin and flucloxacillin commonly implicated in 
developed countries (349) and anti-tuberculosis (anti-TB) drugs in developing countries (350). 
DIH is responsible for over 50% of acute liver failure (133, 134) and between 0.1% and 5% of 
hospital admissions (351, 352). DIH has profound implications for morbidity, mortality and 
healthcare expenditure (136).  
Studies have revealed that hospital admissions for DIH have increased steadily over the last 
three decades due to an aging population, access to multiple medications and dietary 
supplements with potential for hepatotoxicity, chronic illness, and infectious diseases (57, 132, 
133, 353). Risk factors for DIH include genetics, younger and older age, female gender, 
pregnancy, malnutrition, obesity, diabetes mellitus, pre-existing liver disease, human 
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immunodeficiency virus (HIV), smoking, alcohol consumption, and infections or inflammatory 
episodes (354-356). Many of these factors are common in the Ethiopian population. The 
ongoing epidemics of HIV/AIDS and TB, plus the emergence of chronic non-infectious 
diseases due to increasing life expectancy, mean that the exposure to hepatotoxic drugs in this 
population is likely to increase. We previously identified DIH as the most common cause of 
adverse drug reaction (ADR)-related admission in a hospital in Southwest Ethiopia (147), 
highlighting its importance in this clinical setting. To our knowledge, there are no studies 
investigating the prevalence, severity and patterns of DIH-related hospitalisation for 
community-based patients in Ethiopia. Therefore, the aim of this study was to determine the 
prevalence, severity and clinical patterns of DIH and identify drugs commonly implicated in 
DIH-related admission to Jimma University Specialised Hospital (JUSH), Southwest Ethiopia.  
5.3 Methods 
This is a sub-study of a prospective observational study investigating ADR-related admissions 
at JUSH from May 2015 to August 2016 (147). JUSH is the major public teaching and referral 
hospital with a capacity of 600 beds in Southwest Ethiopia. The hospital provides general 
medical and specialised services for approximately 200,000 patients each year. The catchment 
population is 15 million. 
Criteria for this sub-study were: age ≥18 years, taking at least one regular medication prior to 
hospital admission, documentation of at least one set of liver function tests including AST 
(aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase) and 
total bilirubin at admission, and presence of complete records of past medical and medication 
history at admission. Suspected DIH-related hospitalisation was based on the relationship 
between the time of drug administration and the onset and course of the adverse reaction, the 
patient’s history and clinical and biochemical characteristics, combined with a drug known to 
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cause liver injury, and exclusion of other forms of liver disease. Patients admitted with a 
confirmed diagnosis of acute viral hepatitis (patients with positive serological tests for hepatitis 
virus), and autoimmune or metabolic liver disease (haemochromatosis, biliary obstruction, 
alcohol-induced) were excluded from analysis. Patients were classified as having pre-existing 
liver disease if liver diseases (such as cirrhosis, chronic viral hepatitis) or liver dysfunction or 
liver injury were documented by the treating physician at, or prior to admission (308).  
Patients with a principal admission diagnosis of DIH were identified. Additionally, patients 
with DIH were identified using biochemical diagnostic criteria from any of the following:  
• ALT/AST ≥5 times upper limit of normal (ULN); 
• ALP ≥2 times ULN;  
• ≥3-fold elevation in ALT with simultaneous elevation of bilirubin exceeding twice 
ULN, and  
• Any increase in AST and/or ALT levels together with anorexia, nausea, vomiting, and 
jaundice provided other causes were excluded (141, 357).  
Confirmation of the causal relationship between DIH-related hospitalisation and the suspected 
medication was performed using the Naranjo ADR assessment scale (88), followed by clinical 
consensus between the authors (clinical pharmacist MTA and internal medicine specialist DY). 
We considered DIH with definite, probable and possible causality.  
According to the DILI Expert Working Group (358), the ULN of AST, and ALP was 41 U/L, 
and 128 U/L, respectively. The ULN of ALT for men and women were 33 U/L and 29 U/L, 
respectively.  Hyperbilirubinemia was considered when the serum total bilirubin level was >1.0 
mg/dL. Hypoalbuminemia was considered when the serum albumin level was <3.5 g/dL. Adult 
nutritional status was assessed using the body mass index (BMI) (314) and classified as <18.5 
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kg/m2 and ≥ 18.5 kg/m2 for analysis. The patterns of DIH were defined based on the R-value 
or ALT and ALP levels (348, 358). The R-value is calculated as ALT/ULN divided by 
ALP/ULN (Table 1). However, patterns of DIH may vary for the same drug. 
Table 5. 1. Definition and classification of the patterns of DIH 
DIH pattern  R-value  Predominant liver enzyme  
Hepatocellular  ≥5 ALT ≥3 ULN 
Cholestatic  ≤2 ALP ≥2 ULN 
Mixed  2<R<5 ALT >3 ULN and ALP >2 ULN 
The severity of DIH was classified as defined by the DILI Expert Working Group (358) based 
on the liver function test values at admission as:  
• Grade 1: 1.25–2.5 x ULN, or mildly elevated ALT or ALP reaching criteria for DIH 
but bilirubin <2 x ULN;  
• Grade 2: 2.6–5.0 x ULN, or moderately elevated ALT or ALP reaching criteria for DIH 
and total bilirubin ≥2 x ULN;  
• Grade 3: 5.1–10 x ULN, or severely elevated ALT or ALP reaching criteria for DIH 
and total bilirubin ≥2 x ULN and one of the following: INR ≥1.5, ascites, 
encephalopathy, disease duration <26 weeks, absence of underlying cirrhosis, and/or 
other organ failure considered due to DIH; and  
• Grade 4: >10 x ULN, or death or required transplantation of liver.  
Based on the clinical signs, symptoms and liver function tests at discharge, DIH was classified 
as recovered (the signs and symptoms were resolved and liver enzyme levels returned to normal 
range), did not recover (patients discharged or referred to other settings with the presence of 
signs and symptoms and/or abnormal liver enzyme levels) and fatal.  
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Data was recorded into an Access database (Microsoft 2016, Redmond, Washington) and 
analysed using the IBM Statistical Package for the Social Sciences (IBM SPSS version 23.0 
Inc., Chicago, Illinois). Categorical variables were presented as frequencies and percentages 
whereas continuous variables were presented as mean ± standard deviations or median 
(interquartile range).  
The study was approved by the Tasmanian Health and Medical Human Research Ethics 
Committee and the Jimma University Institutional Review Board. Written informed consent 
was obtained from all patients included in the study. 
5.4 Results 
5.4.1 Socio-demographic and clinical characteristics of DIH patients   
Of the 1,001 patients included in the original prospective observational study, 674 (369 males 
and 305 females) fulfilled the inclusion criteria for this sub-study. Of these, 35 (5.2%) were 
hospitalised due to DIH (Fig 5.1). Over half of the DIH patients were underweight (18, 51.4%) 
and had pre-existing liver disease (19, 54.3%). Their mean number of medications was 7.0 ± 
2.8. Sixty percent of the patients with DIH had been using anti-TB drugs, and 12 (34.3%) were 
on ART. Eleven (31.4%) had a previous ADR history. Their mean length of stay (LOS) was 
15.6 ± 9.9 days (Table 5.2).  
The median AST and ALT serum levels were at least six times above the ULN and median 
bilirubin was three times above the ULN. Ten patients (28.6%) recovered, 18 (51.4%) did not 
recover prior to discharge and seven (20.0%) died. The majority (70.0%) of the patients who 
recovered from DIH exhibited a cholestatic pattern. Of seven DIH-related deaths (two males 
and five females), four were cholestatic, two were hepatocellular, and one was mixed. The 
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median time for the onset of DIH after the initiation of the suspected drug was 22 (IQR 15-34) 
days (Table 3).  
 
Figure 5. 1 Flow diagram of DIH-related hospital admission assessment procedure 
5.4.2 Drugs implicated in DIH 
Overall, 239 drugs were being taken by the 35 DIH patients; of these, 64 drugs were suspected 
to be implicated in DIH-related hospital admissions. The most frequent drug classes implicated 
were anti-TB drugs (21 patients, 60.0%) followed by ART (12 patients, 34.3%). Specific drugs 
most commonly implicated were isoniazid (21, 60.0%), pyrazinamide (16, 45.7%), efavirenz 
(5, 14.3%), nevirapine (5, 14.3%) and atorvastatin (5, 14.3%). Patients taking anti-TB drugs 
Patients included in main prospective 
observational study = 1,001(chapter 3) 
Patients who fulfilled inclusion 
criteria for DIH sub-study = 674 
Overall patients screened = 3,224 
Patients excluded = 
2,223* 
Confirmed non-DIH-
related hospital admission 
= 639 patients  
Confirmed DIH-related 
hospital admission = 35 
patients  
Patients who donot have liver function 
tests = 327 
*2,223 patients were excluded due to age <18 years (255), not taking at least one medication 
prior to admission (576), incomplete medical and medication records (70), unwillingness 
to participate (463) and inability to be interviewed because of health or other reasons (859). 
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were unintentionally overdosed according to their respective body weight in 11 cases (31.4%) 
(Table 5.3). 
5.4.3 DIH biochemical patterns, severity and associated drugs  
The majority of DIH biochemical patterns were cholestatic (22, 62.9%) followed by 
hepatocellular (8, 22.9%) and mixed (5, 14.3%). Over two-thirds (68.6%) of cases of DIH were 
severe (grade 3) and fatal/required liver transplantation (grade 4). All cases of hepatocellular 
and mixed DIH, and half of the cases of cholestatic DIH, were classified as grade 3 and 4. 
Fifteen (43%) of the DIH cases were suspected to be caused by anti-TB drugs alone, followed 
by anti-TB/ART combinations (6, 17.1%) and ART only (4, 11.4%). Most (83%) of the severe 
and fatal (grade 3 and grade 4) DIH was suspected to be caused by anti-TB drugs alone (11/24, 
45.8%), followed by anti-TB/ART combinations (5/24, 20.8%) and ART alone (4/24, 16.7%) 
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Table 5. 2. Socio-demographic and clinical characteristics of patients with and without DIH at 
admission   
Variables at admission  Patients without 
DIH, N=639 
Patients with DIH, 
N=35 
Age, mean ± SD 42.0 ± 16.9 43.7 ± 19.4 
Male, n (%)  352 (55.1) 17 (48.6) 
BMI*<18.5 kg/m2, n (%) 196 (30.7) 18 (51.4) 
Number of medications*, mean ± SD 4.0 ± 2.2 7.0 ± 2.8 
Alcohol consumers, n (%)    143 (22.4) 5 (14.3) 
Herbal remedies users, n (%) 53 (8.3) 3 (8.6) 
Smokers, n (%)   45 (7.0) 3 (8.6) 
Anti-TB drugs*, n (%)   141 (22.1) 21 (60.0) 
ART*, n (%)  66 (10.3) 12 (34.3) 
Patients with pre-existing liver diseases*, n (%)    60 (9.4) 19 (54.3) 
Patients with previous ADR history*, n (%)    21 (3.3) 11 (31.4) 
Had at least one chronic illness*, n (%)    234 (36.6) 27 (77.1) 
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Table 5 3. Case details of patients with DIH  


































F/24 18.3 Isoniazid, 
pyrazinamide, 
rifampicin  
Easy fatigability, vomiting, high-grade fever and epigastric pain  229.0 219.0 461.0 NA 2.4 Cholestatic No  Not recovered  
F/35 19.8 Isoniazid, 
pyrazinamide 
Vomiting, yellow discoloration of eyes, anorexia and ascites 277.8 301.0 1262.8 4.1 2.9 Cholestatic No  Not recovered  
F/58 16.9 Propylthiouracil  Epigastric pain, nausea and vomiting 186.7 173.1 393.0 0.9 NA Cholestatic No  Recovered 
F/47 15.5 Phenytoin  Abdominal pain, vomiting, wasting syndrome and negative hepatitis B 
surface antigen  
317.6 583.2 1416.0 3.5 1.5 Cholestatic No  Not recovered 
M/30 16.5 Isoniazid, 
pyrazinamide 
Tiredness, fatigue and negative hepatitis B surface antigen 337.4 179.3 1192.4 NA 2.4 Cholestatic No Not recovered  
M/38 22.3 Isoniazid, 
rifampicin, ritonavir 
Yellow discoloration of eyes and skin, itchy skin, ascites and negative 
hepatitis B surface antigen 
210.0 246.4 415.0 3.7 NA Mixed Yes  Died 
M/75 22.4 Atorvastatin  Abdominal pain and negative hepatitis B surface antigen 627.0 2226.6 1271.6 1.5 4.7 Hepatocellular No Not recovered  
M/29 18.3 Efavirenz  Right upper quadrant abdominal pain, yellow discoloration of eyes, 
vomiting, and negative hepatitis B surface antigen 
1500.0 789.2 570.0 14.5 NA Hepatocellular No Not recovered 
M/21 13.7 Isoniazid, 
pyrazinamide 
Vomiting, mucoid diarrhoea, yellow discoloration of eyes, wasting 
syndrome and negative hepatitis B surface antigen and hepatitis C virus 
263.2 2103.0 387.3 10.6 1.2 Hepatocellular No Recovered 
M/60 17.2 Nevirapine Abdominal pain, vomiting and negative hepatitis B surface antigen 246.2 320.9 790.0 NA NA Cholestatic No Recovered  
F/55 22.6 Isoniazid, 
pyrazinamide, 
efavirenz 
Vomiting, abdominal pain, swallowing difficulty and negative hepatitis 
B surface antigen 
196.2 159.7 326.6 4.2 4.0 Cholestatic Yes Recovered  
F/40 19.2 Isoniazid, 
pyrazinamide 
Yellow discoloration of eyes, watery diarrhoea and vomiting.  421.2 620.7 2223.8 8.3 1.7 Cholestatic No Died 
F/28 19.7 Isoniazid, 
pyrazinamide 
Yellow discoloration of eyes, nausea, vomiting and diarrhoea 183.3 140.0 277.2 3.1 1.6 Cholestatic No Recovered 
M/40 15.1 Isoniazid, 
rifampicin, 
atazanavir  
Wasting syndrome, loss of appetite, fever, ascites and negative hepatitis 
B surface antigen 
991.2 1269.9 845.0 3.2 2.4 Hepatocellular Yes Not recovered  
M/33 15.9 Nevirapine Generalised body rash, fatigue, wasting syndrome, yellow discoloration 
of eyes mucosa, difficulty of swallowing  
169.0 141.9 311.3 3.0 1.7 Cholestatic No Not  
recovered 
M/24 17.3 Isoniazid, 
pyrazinamide 
Weight loss, fatigue, diarrhoea, high grade fever, and global headache  496.8 302.1 1234.7 1.1 NA Cholestatic No Not recovered 
F/40 13.3 Isoniazid, efavirenz   Wasting syndrome, abdominal pain and vomiting  317.6 583.2 1416.0 3.5 2.2 Cholestatic Yes Died 
F/28 22.3 Isoniazid, 
pyrazinamide 




976.1 NA 3.5 Hepatocellular No Not recovered 
F/55 19.8 Isoniazid, 
pyrazinamide, 
efavirenz 
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F/65 14.2 Isoniazid Yellow discoloration of skin, wasting, abdominal pain, vomiting 238.8 221.2 474.9 NA 1.6 Cholestatic  No Died  
F/28 15.6 Isoniazid, 
pyrazinamide 
Wasting, difficulty of eyes opening, and abdominal discomfort and 
weakness 
228.8 223.4 481.0 3.0 NA Cholestatic No Recovered  
M/33 20.2 Nevirapine, 
clopidogrel,  
atorvastatin  
Abdominal pain, vomiting, negative hepatitis B surface antigen   115.7 325.8 727.6 
 
NA 2.2 Cholestatic  No  Recovered 
M/65 17.9 Phenytoin Abdominal pain, nausea, vomiting and mental confusion 979.6 862.1 1689.0 NA 3.6 Cholestatic   No Not recovered  
M/33 16.9 Nevirapine, 
clopidogrel,  
atorvastatin 
Poor appetite, yellow discoloration of eyes, high grade fever, 
encephalopathy and negative  hepatitis B surface antigen 
185.4 146.4 415.5 3.7 1.6 Cholestatic  No Not 
recovered 
M/65 20.1 Isoniazid, 
pyrazinamide 
Malaise, abdominal pain and vomiting 1286.0 1270.0 513.0 NA 2.6 Hepatocellular  No Not recovered 
M/95 21.8 Omeprazole  Abdominal pain, yellow discoloration of eyes and urine, nausea, 
vomiting, and fatigue 
745.1 1296.3 1456.0 NA NA Mixed  No Not recovered 
M/80 19.6 Atorvastatin   Yellow discoloration of skin and abdominal pain  136.6 160.3 360.0 3.2 NA Cholestatic  No Not recovered 
F/24 20.8 Isoniazid, 
pyrazinamide 
Loss of appetite, nausea, vomiting, ascites and fatigue 184.6 194.9 256.1 NA 1.9 Mixed  No Not recovered 
M/68 23.9 Efavirenz  Abdominal pain, yellow discoloration of eyes and dark urine, nausea, 
vomiting and weakness 
177.0 122.2 667.0 4.7 NA Cholestatic No Died  
M/48 18.4 Isoniazid, 
pyrazinamide 
Abdominal pain, yellow skin, nausea, vomiting, encephalopathy and 
tiredness 
991.2 1145.0 2045.0 3.2 NA Mixed   No Recovered  
F/26 18.0 Propylthiouracil Weight loss, poor appetite, vomiting and malaise  200.0 132.0 321.0 NA NA Cholestatic  No Not recovered 
F/25 20.6 Isoniazid, 
pyrazinamide 
Abdominal distension, yellow discoloration of eyes, and chronic viral 
hepatitis B 
1750.0 789.2 570.0 14.5 1.6 Hepatocellular No Died 
F/21 16.6 Isoniazid, 
nevirapine  
Abdominal discomfort, yellow discoloration of eyes, vomiting and 
mental confusion 
740.5 980.5 457.6 NA NA Hepatocellular Yes  Died   
F/28 19.8 Atorvastatin Abdominal pain, yellow discoloration of eyes, vomiting and coma 284.5 227.3 570.0 5.1 2.6 Mixed   No Recovered  
F/65 22.3 Isoniazid, 
pyrazinamide  
Abdominal pain, yellow discoloration of skin and urine, nausea, 
vomiting and fatigue 
156.0 217.6 1678.0 NA NA Cholestatic  No Not recovered 


















Annotations: a grade 1 and 2 that represents patients who present with elevated level of liver enzymes/bilirubin and/or serum albumin 
without signs/symptoms, b grade 3 and 4 that represent patients who present with both elevated liver enzymes/bilirubin and typical clinical 


















Patterns of DIH using R-value Severity level, n (%) 
Non-severea Severe/fatalb 
Cholestatic  11 (50.0) 11 (50.0) 
Hepatocellular  0 (0.0) 8 (100.0) 
Mixed  0 (0.0) 5 (100.0) 
Total Patients 11 (31.4) 24  (68.6) 
Major drug groups implicated  Non-severea Severe/fatalb 
Anti-TB drugs only, n (%)  4 (26.7) 11 (73.3) 
ART only, n (%)   0 (0.0) 4 (100.0) 






The prevalence of DIH-related hospital admission in this study was 5.2%, which highlights the 
substantial impact of the problem in community-based Ethiopian patients. Studies conducted 
in the United States (351) and Sweden (359) reported comparable results for the prevalence of 
DIH-related hospitalisation, while studies from South Korea (360) and Thailand (361) have 
reported that 1.1% and 1.2% of hospital admissions were due to DIH, respectively. These 
differences might be due to variations in population characteristics, drug therapies and DIH 
detection methods employed. In addition, there might be differences in the nature of DIH due 
to wide spectrum patterns of manifestations, ranging from asymptomatic elevation of liver 
enzymes to fulminant hepatic failure. Moreover, the DIH analysis in this study was performed 
in a selected group of admissions - only in 674 of more than 3,000 screened. While there are 
no directly comparable studies from Ethiopia, three studies have reported on the prevalence of 
DIH in patients with TB and HIV in follow-up clinics (162, 362, 363), where DIH-related 
hospitalisation was not described. These studies showed a higher prevalence of DIH (8.0-
15.0%), most likely due to a higher use of hepatotoxic anti-TB/ART compared to the general 
population admitted to hospital in the current study.  
The cholestatic pattern was more common than hepatocellular or mixed patterns, which is in 
line with another Ethiopian study (363). Also in agreement with other studies (363, 364), anti-
TB drugs (e.g. isoniazid, pyrazinamide) followed by ART (e.g. efavirenz) and statins (e.g. 
atorvastatin) were frequently suspected to cause cholestatic DIH. In addition, the presence of a 
significant proportion of patients with malnutrition and pre-existing liver diseases could have 
heightened the risk of developing cholestatic DIH (136, 364). Moreover, in patients taking 
multiple drugs, some drugs causing enzyme inhibition might have increased the plasma 
concentration of concomitantly used drug(s) so that the risk of overlapping toxicities have been 





and appropriate management based on existing guidelines such as the WHO TB treatment 
guidelines (365) may avoid chronic consequences. In the current study, only ten patients 
(28.6%) recovered spontaneously whereas seven (20.0%) died and the outcome of more than 
half of the patients was unknown. Although progression to chronic DIH was not observed in 
our study, early assessment of the pattern of DIH is vital for preventing progression to 
chronicity and even death (136, 348).   
The drug classes commonly implicated in DIH were anti-TB and ART, which is in line with 
other studies (138, 162, 343, 348). Most of the DIH-related hospitalisations were associated 
with anti-TB drugs, primarily isoniazid in the current study. There were a number of factors 
influencing the toxicity of isoniazid. As with other hepatotoxicity studies (162, 339, 366, 367), 
many DIH patients were underweight. The depletion of glutathione stores in malnourished 
patients increases vulnerability to oxidative liver injury (368). Some patients had increased 
susceptibility to isoniazid/pyrazinamide-associated hepatotoxicity because of concomitant 
retroviral infection leading to a mild inflammatory reaction and increased pharmacokinetic 
drug interactions (369). Polymorphisms of the key enzymes in the metabolic pathway of 
isoniazid, N-acetyltransferase 2 and microsomal enzyme cytochrome P4502E1, influence 
isoniazid-induced hepatotoxicity through increased formation of toxic metabolites (370). A 
study conducted by Yimer et al. (271) in Ethiopian patients on ART and anti-TB drugs revealed 
a greater proportion of the slow acetylator phenotype compared to other populations that may 
have increased the risk for isoniazid-related hepatotoxicity. Additionally, fixed dose anti-TB 
drugs (predominantly isoniazid) were unintentionally overdosed in eleven patients based on 
their body weight, which could have contributed to severe DIH.  
We found the median time to the occurrence of DIH was within the first 3 weeks of suspected 





study (362). The WHO  recommends initiation of ART within 8 weeks of initiation of anti-TB 
therapy or within 2 weeks in TB patients with a CD4 count of less than 50 cells/mm3 (365). 
However, concomitant use of anti-TB agents and ART leads to concerns about drug 
interactions, clinical deterioration from immune reconstitution inflammatory syndrome, and 
overlapping toxicities. Conversely, delays in ART initiation in TB patients may result in AIDS-
related illness and death (365). The decision regarding initiation of either therapy at the 
recommended time as per WHO (365) and Ethiopian treatment guidelines for concomitant 
TB/HIV infection requires a pre-treatment evaluation by a multidisciplinary team involving 
physicians, nurses, pharmacists, and other health professionals. Our findings and the limited 
related literature (354-356) suggest that this pre-treatment evaluation should include, but not 
be limited to, screening for pre-existing liver disease, history of excess alcohol consumption, 
previous ADR history, nutritional status, baseline serology for chronic viral infections 
(hepatitis B, C and HIV), and assessment of the benefit of empirical treatment initiation of anti-
TB/ART versus the risk of adverse outcomes.  
Given the majority of DIH-related hospitalisation and mortality occurred in patients receiving 
anti-TB agents (especially isoniazid and pyrazinamide) and ART, principally in underweight 
patients with pre-existing liver diseases, the following approaches could be considered to 
minimise the occurrence of preventable DIH:  
• Patients should be educated about the importance of follow-up visits for monitoring and 
educated about the signs and symptoms of hepatotoxicity (371). For patients taking anti-
TB and ART, the liver enzyme levels should be determined before initiation of therapy and 
closely monitored especially in the first three weeks of therapy. This can be achieved 





enzymes should be continued for at least medication refilling visits with special attention 
to patients with malnutrition, pre-existing liver diseases and previous ADR history. 
• Determining baseline body weight/BMI before initiation of the treatment, and throughout 
therapy. Dosing of each regimen should be individualised according to clinical condition 
and body weight. Furthermore, weight loss of 2 kg or more within 4 weeks during TB 
treatment is a risk factor for DIH (372). Therefore, the weight of patients taking anti-TB 
drugs should be measured at least at each visit for medication refilling and appropriate 
interventions should be considered when the patient is at risk for serious reactions. An 
adequate intake of nutrients is important for the integrity of liver metabolism and 
minimising the hepatotoxic effect of isoniazid and other anti-TB drugs, as the cytochrome 
P450 enzyme system is affected by malnourished states (373, 374).  
• Pharmacovigilance/post-marketing surveillance should be integrated with the innovative 
community-based health extension program (254, 375) with a focus on clinic/home-based 
therapy observation especially for patients at risk of ADRs. This should be conducted under 
clinically trained pharmacists’ supervision from primary (health centres and primary 
hospitals), secondary (general hospitals), and tertiary (specialised and referral hospitals) 
healthcare levels for patients using drugs for chronic diseases. All patients receiving drug 
therapy for chronic illnesses including TB/HIV should be linked with their respective 
village’s health extension program for close monitoring, and referral (if potential ADRs 
suspected) for appropriate management. One option would be a scheduled regular home-
based medication review process through health extension packages by clinically trained 
pharmacists. In addition, training and continuous supervision should be given to health 
extension workers on procedures to minimise the risk of complications by early assessment.  
The main limitations of our study include lack of liver biopsy for diagnosing DIH. Causality 





consistent history and supporting laboratory data. Proving the diagnosis would require 
rechallenge with the suspected drug by the treating physician to see if a similar reaction 
recurred, however, this approach was not applied for some patients due to potentially severe 
deleterious outcomes and lack of guideline for re-initiation. We did not observe the progression 
of DIH to detect chronic DIH. Hepatotoxicity suspected to be caused by herbal remedies was 
not typically recorded due to the common practice of packaging multiple agents together, lack 
of dose standardisation, recall bias and impurity of products, which may have resulted in 
underestimation of the rate of DIH-related admissions. There was possible bias resulting from 
exclusion of some patients with hepatic encephalopathy that might be associated with severe 
DIH. As the study findings mainly depended on the patient characteristics and DIH detection 
methods, the results of this study should be generalised to other settings with caution. Despite 
its limitations, our study is important to clinicians and policy makers, as it revealed the anti-
TB and ART drugs were commonly implicated in DIH-related hospitalisation and mortality for 
community-dwelling Ethiopian patients. Our study provided a detailed picture of clinical 
presentations and biochemical patterns due to its prospective methodology. In addition, we 
have identified low BMI, pre-existing liver disease, unintentional overdosing, and previous 
ADR history as risks for severe DIH; this suggests the need for education of both health 
professionals and patients to raise awareness of the need for early detection and initiation of 
suitable treatment to prevent complications or death. Our yearlong sampling in a teaching and 
referral hospital serving a population of 15 million avoided the bias associated with anti-
infective use patterns due to seasonal variation.  
5.6 Conclusion 
DIH is an important cause of hospitalisation and mortality, with most cases cholestatic in 





should be given to patients taking anti-TB and ART, particularly those who are underweight, 
with pre-existing liver disease, and a previous ADR history. Further prospective longitudinal 
studies with a large sample size should be conducted to assess the impact of infectious diseases 
(TB, HIV, and viral hepatitis), genetics, malnutrition, use of alcohol, and herbal remedies on 

















6. General discussion and conclusion 
6.1 Principal findings 
This thesis represents a substantial step forward for researchers in sub-Saharan Africa, 
including Ethiopia, on the burden of ADR-related hospital admissions and mortality, where 
such data are scarce. The thesis is comprised of a review and a significant prospective 
observational study with several analyses that provided several novel findings to add to the 
literature. The review revealed that the prevalence of ADR-related hospital admissions and 
mortality vary from 0.2% to 54.5% and 0.1% to 10.0%, respectively. The main findings from 
the prospective study were that the rates of ADR-related hospitalisation and mortality were 
10.3% (or 3.4% of all medical admissions) and 1.5%, respectively. Drug-induced 
hepatotoxicity followed by acute kidney injury were the major ADRs implicated in both 
hospital admissions and mortality. Drugs commonly associated with both hospital admissions 
and mortality were anti-TB drugs followed by ART and cardiovascular agents. In addition, 
patients with lower body mass index, pre-existing renal and liver diseases, history of previous 
ADRs, multiple comorbidities and drugs were found to be independent predictors of ADR-
related hospital admission with an area under the receiver operator curve of 79.0% (95% CI 
73.9%-84.1%). Overall, the extent of ADR-related hospitalisation in adult patients was a 
substantial public health problem, with a significant number of fatal ADRs in patients 
presenting to hospital. 
6.2 The burden of ADR-related hospital admissions and associated factors 
ADRs were a common reason for hospital admission, with a substantial number of ADR-





admissions and mortality are a considerable burden to the adult population in both developed 
and developing countries, particularly in susceptible patient groups such as the elderly, patients 
with multiple comorbidities, and in developing countries, patients with HIV/AIDS taking ART. 
Our prospective study has also confirmed a comparable prevalence of ADR-related hospital 
admission and mortality in patients included in the study. Specifically, these findings were 
further augmented by comparable studies from developed (16, 30) and developing countries 
(35, 101) with regard to ADR-related hospital admissions. Similarly, ADR-related mortality 
was comparable to previously published studies that were conducted in South Africa (23), Iran 
(331) and India (64). It is clear that the burden of ADRs are an important public health problem 
demanding additional medical care irrespective of the differences in population socio-
demographics, disease characteristics, drug therapy used, healthcare systems and, ethnic 
origins in both developing and developed countries.  
The analyses conducted in this thesis found that the major ADRs suspected to be implicated in 
hospital admissions and deaths were DIH followed by AKI and electrolyte disorders, in 
contrast to ADRs reported from developed world, such as GI bleeding (99, 105), cardiovascular 
disorders (16, 30, 32, 93, 94) and electrolyte and metabolic disturbances (9, 16, 58, 94). In 
contrast to the findings from studies conducted in developed countries (10, 40), where the 
major causative agents were anticoagulants and cardiovascular agents, the drugs most 
commonly suspected of causing ADR-related hospital admissions and deaths were anti-TB and 
ART. This reflects the difference in disease distribution, population demographics, and drug 
therapy used between the study population in Ethiopia and developed countries. In addition, 
ADR-related hospital admissions and deaths occurred commonly in patients with various 
combinations of TB, HIV/AIDS, low BMI, and pre-existing liver diseases in contrast to the 
developed world cardiovascular diseases and cancers (9, 11, 17). There are multiple reasons 





infectious diseases (TB or HIV or co-infection of both) and non-communicable chronic 
diseases, malnutrition, or as a consequence of HIV or TB, and use of multiple drugs with 
potential for interactions. Additionally, the presence of a substantial number of patients with 
pre-existing liver and kidney diseases might have increased the opportunity to derange 
pharmacokinetics, which might have led to drug interactions, serious ADRs, and finally death.  
6.2.1 Anti-TB drug-related hospital admissions and mortality   
Tuberculosis is a major public health problem in Ethiopia with the prevalence of 211 per 
100,000 of the population, of whom 13% were HIV co-infected (300). TB is also a leading 
cause of morbidity, hospital admission and death in Ethiopia (376, 377). In this thesis, the 
prospective observational study found that anti-TB drugs, particularly isoniazid followed by 
pyrazinamide, were the major drugs implicated in ADR-related hospitalisation and mortality. 
Of 1,001 patients, 3.6% were admitted with anti-TB drug-related ADRs (mainly hepatotoxicity) 
and 0.7% died from anti-TB drug suspected ADRs. Of 207 TB infected patients included in 
this study, 61 (29.5%) were TB/HIV co-infected and taking concomitant anti-TB and 
antiretroviral therapies. Approximately one-third of these had ADRs, which is in-line with 
other studies (378, 379). Patients with advanced liver disease were at increased risk of 
developing ADRs, particularly in patients taking anti-TB drugs as was similarly found by 
Gaude et al. (380). Our findings revealed that underweight patients (<18.5kg/m2) were at higher 
risk for ADR-related hospital admission and mortality than patients with normal weight. 
Previous studies revealed that malnutrition is a common health problem in developing 
countries including Ethiopia (196, 381) and important risk factor for ADR-related 
hospitalisation, especially in TB patients (162, 382, 383). Anti-TB induced hepatotoxicity is 
known to be an important reason for termination of anti-TB regimens (384) and prolongation 
of hospital stays with additional medical costs (385). ADRs due to first line anti-TB drugs are 





(386). At the same time, alternative agents may have higher complications with toxicity, and 
are often less effective. More importantly, ADRs due to anti-TB medication contribute to the 
prolongation of treatment duration, relapse of infection, drug resistance, treatment failure, and 
even death (387). In addition, anti-TB drug induced liver injury is a common cause for acute 
liver failure (133, 134), posing a challenge to the management of TB patients and TB control.  
6.2.2 ART-related hospital admissions and mortality  
The prevalence of HIV among the Ethiopian adult population was estimated to be 1.0% with 
national ART coverage of 52.0% (301).  Following anti-TB agents, ART, particularly tenofovir, 
efavirenz and nevirapine, were the second most important group of agents implicated in ADR-
related hospital admission and mortality. Overall, 2.2% of patients were admitted with ART-
related ADRs and 0.6% of patients died from ART-related ADRs. There are a number of 
precipitating factors to this finding. These include the presence of larger number of patients 
taking relatively toxic agents, such as efavirenz and tenofovir in the ART regimen (388), a 
greater number of HIV patients who present with a complicated disease state (378, 389), and a 
larger number of patients with concomitant TB, HIV, and malnutrition with an 
immunocompromised state (389, 390). In addition, lack of continuous clinical/laboratory 
monitoring of drug therapy and skilled professionals at the follow-up clinics could have 
resulted in failure in early identification (or delay in diagnosis) of specific ADRs and hence 
increased ADR severity (270, 390, 391).  
The presence of a larger number of patients with late clinical presentation of HIV or TB/HIV 
co-infection might have increased medical complexity, number of comorbidities (due to 
advanced and complicated AIDS stage) and medications used (392). In addition, the population 
in the study area is known to have higher than the country’s average HIV prevalence (393), 





factors for the occurrence of more ART-related ADRs. For instance, out of 108 HIV/AIDS 
infected patients included in this study, 61 (56.5%) were classified as either WHO clinical stage 
III and IV. The main diagnoisis in patients presenting with clinical stage III were pulmonary 
TB and severe bacterial infections. The main diagnoisis in patients presented with clinical stage 
IV were extrapulmonary TB, Pneumocystis (jirovecii) pneumonia and extrapulmonary 
cryptococcal meningitis. Finally, all the above clinical conditions could have led to poor 
immune recovery and increased likelihood of ART-related ADRs (395). In line with our 
prospective study, previous studies have revealed that ART-related ADRs are the major reason 
for modification and/or discontinuation of therapy (388, 396), hospitalisation (23, 101), life 
threatening reactions demanding intensive care (397), and mortality (65). ADRs associated 
with ART have thus become the most important limiting factor to the successful treatment of 
HIV and other opportunistic infections in community dwelling patients on chronic drug 
treatment follow up, especially in developing countries (398, 399).  
6.3 Research implications 
There are multiple strategies for preventing ADR-related hospitalisation and the associated 
burden described in the literature. Some of these include focusing on the patient care process 
using different intervention strategies, such as pharmacy-led interventions (230), monitoring 
ongoing drug therapy (225), preventing drug interactions (222), and highlighting the patients 
at high risk for ADRs (213). Highlighting the patients at high risk for ADRs depends on several 
factors, such as the disease characteristics and population demographics (9, 14, 23, 100), 
complexity of diseases and medications prescribed (9, 14, 94), healthcare systems (104), and 
ethnic origin (168, 250) of the study population. Medical practitioners often lack awareness of 
factors contributing to ADR-related hospitalisations (251, 252). To overcome this, 
identification and reporting of factors contributing to ADR-related hospitalisation for 





(199, 200). Studies, mainly from developed countries (9, 14), have identified several predictors 
of ADR-related hospital admissions, however, there is scanty data in the developing countries 
including Ethiopia. Hence, we identified six independent predictors of ADR-related hospital 
admission with a fair to good predicting capacity of 79.0% (Figure 3.1), although these 
predictors were not validated in similar or other populations. The sensitivity and specificity of 
the ADR risk prediction in AUROC were 59.2% and 86.6%, respectively, suggesting that it 
could moderately rule-in patients at risk of ADRs and strongly rule-out those patients not at 
risk of ADRs, respectively. This was further augmented by an ADR preventability assessment 
using Schumock and Thornton’s preventability assessment criteria, in which the majority of 
the ADR-related hospitalisations were preventable provided these risk factors were reviewed 
and monitored closely. This is, therefore, a novel finding in developing countries including 
Ethiopia, suggesting a higher burden of malnutrition and rising prevalence of chronic illnesses, 
such as renal and liver diseases demanding multiple medications. In addition, the study will 
reinvigorate medical practitioners in enhancing early identification of patients at higher risk for 
ADRs, promote safe and rational use of medicines through consideration of dosage regimen 
individualisation, and close monitoring.  
The vast majority of cases of ADR-related hospital admission and mortality were preventable 
based on Schumock and Thornton criteria (201). Most of the ADRs identified were type A 
(pharmacologically predictable or dose-related), and resulted from an exaggeration of a drug’s 
normal pharmacological action when given in the usual therapeutic dose. The majority of 
ADRs, therefore, are well known prior to product authorisation and are listed in product 
labelling. More importantly, some dose-related ADRs may reflect a lack of knowledge about 
pharmacokinetics and pharmacodynamics in patients with malnutrition, renal and liver 
diseases, who constituted a substantial number of patients; these risk factors were reported to 





malnutrition in adults has not been studied in detail; however, available limited studies (400, 
401) have shown that medical conditions, such as HIV, TB, renal and liver disease are 
important precipitating factors that need special focus. In addition, use of isoniazid in 
malnourished patients increases susceptibility to ADRs due to increased formation of toxic 
metabolites (370) and depletion of glutathione stores that increases vulnerability to oxidative 
liver injury (368). In general, the high proportion of preventable ADRs highlights the 
importance of improving medication use, particularly in vulnerable patient groups, such as 
patients with renal and liver diseases, TB/HIV, and malnutrition.  
In this thesis, overall findings highlight the need to focus on pre-treatment evaluation of 
community dwelling patients, particularly patients with TB/HIV co-infection taking 
concomitant anti-TB drugs and ART, pre-existing renal and liver disease, and malnutrition, in 
order to reduce drug-related adverse outcomes including death. Our findings and the limited 
related literature (354-356) suggest that this pre-treatment evaluation should include, but not 
be limited to, implementation of practical aspects of a multidisciplinary care approach that 
focus on screening for pre-existing renal and liver disease and nutritional status and assessment 
of the benefit of empirical treatment initiation versus the risk of adverse outcomes. This should 
be followed by patient monitoring, adherence to existing treatment protocols, improving of 
patient education, strengthening of clinic/home-based directly observed therapy, and the health 
extension program in the case of Ethiopia. Patients should be closely monitored in a 
multidisciplinary team approach during their treatment follow-up period and linked with their 
respective village’s health extension program for continuous monitoring, and referral (if 
potential ADRs suspected) for appropriate management. One component of continuous patient 
monitoring would be implementing a scheduled regular home-based medication review process 





training and supervision should be given to health extension workers on procedures of early 
assessment to reduce ADR-related complications. 
The findings of this thesis are relevant to healthcare authorities, program leaders, policy makers, 
and researchers as the series of analyses have revealed several important findings regarding 
ADR-related hospital admission and mortality in sub-Saharan Africa in general and Ethiopia 
in particular, where there is scanty data. The results will aid policy makers and healthcare 
system managers to develop efficient strategies to reduce the burden of ADR-related hospital 
admission on the healthcare system. The results will encourage pharmaceutical regulatory 
authorities to implement pharmacovigilance/post-marketing surveillance in routine clinical 
practice in different healthcare levels. The findings of this thesis also encourage a 
multidisciplinary team approach with the involvement of clinically trained pharmacists in the 
direct patient care process. As an epidemiological study, it identified ADR as an important 
public health problem causing significant morbidity, hospital admissions and deaths, so this 
could encourage researchers to consider multicentre longitudinal studies with interventional 
strategies to identify root causes of ADRs and reduce the ADR-related burden.  
6.4 Strengths and limitations 
The use of recognised and previously published criteria for assessment of ADR causality, type, 
severity, and preventability might increase the robustness of the method employed in the 
current study. Yet there is no universally accepted method for ADR assessment, as there is still 
ongoing debate and no consensus among researchers and regulatory authorities (402). 
Consequently, this might have led to over/under-estimation of the burden of ADRs. We used a 
three-step process to assess ADR causality, type, severity, and preventability; evaluating 
individual patient’s clinical and laboratory parameters with regard to suspected ADR(s), using 





classification, modified Hartwig et al. severity scale and Schumock and Thornton 
preventability criteria) followed by consensus review between experts. Therefore, use of these 
mixed approaches helped mitigate the subjectivity associated with interpretation of the 
causality, type, severity, and preventability of the ADRs and further increased the robustness 
of the results. Previous researchers (116, 213) have applied a similar approach. The adoption 
of the widely used WHO definition of ADR (21) has enabled direct comparisons with multiple 
studies.  
Most importantly, our study provided a detailed picture of clinical presentations, 
sociodemographic and biochemical patterns of each case due to its prospective methodology. 
The prospective identification of ADRs immediately upon admission by clinical experts has 
allowed for relatively accurate estimation of the problem in the study setting. Our yearlong 
sampling in a teaching and referral hospital serving a population of 15 million avoided the bias 
associated with anti-infective use patterns due to seasonal variation. Our study is important to 
clinicians and policy makers, as it revealed the anti-TB and ART drugs were commonly 
implicated in ADR-related hospitalisation and mortality for community-dwelling Ethiopian 
patients. In addition, we have identified several risk factors for ADR-related hospital 
admissions and mortality, suggesting the need for education of both health professionals and 
patients to raise awareness of the need for early detection and initiation of suitable treatment to 
prevent complications or death.  
There are several limitations in this work. These limitations could inform researchers and 
medical practitioners in the area of medication safety to improve planning of future studies in 
order to maximise the generalisability and validity of the findings. Due to logistic and time 
limitations, our study was conducted only in one centre so may lack direct generalisability to 





ADR causality assessment is inherently difficult, thus the diagnosis was a clinical one, based 
on a consistent history and supporting laboratory data. For instance, there was lack of liver 
biopsy for diagnosing DIH. Proving the diagnosis of ADRs would require rechallenge with the 
suspected drug by the treating physician to see if a similar reaction recurred, however, this 
approach was not applied for some patients due to potentially severe deleterious outcomes and 
lack of guidelines for re-initiation. We did not observe the progression of ADRs to detect 
chronic ADRs due to the nature of the study. ADRs suspected to be caused by commonly used 
over-the-counter medicines, contraceptives, topical agents, and herbal remedies were not 
commonly recorded in detail in drug histories, which may have resulted in underestimation of 
the true rate of ADR-related admissions. A large number of patients were excluded from the 
study due to their inability to be interviewed as a result of health or other reasons which may 
have also resulted in underestimation of the true rate of ADR-related admissions. The 
characteristics (socio-demographic and clinical conditions) of the excluded patients were not 
collected in the current study, which might be an important potential source of bias for readers 
who want to differentiate these group of patients from the study patients. Additionally, patients 
may have died due to ADRs prior to hospital admission, resulting in underestimation of the 
true ADR-related death rate. As the study findings mainly depended on the patient 
demographics, pre-existing diseases characteristics, drug therapy used and ADR detection 
methods, the results of this study should be generalised to other settings with caution.  
Another limitation of the current work was the inability to measure ADR-related economic 
impact on the healthcare system and individual patient as part of the outcomes of the study. 
The estimation of ADR-related costs would help strengthen the argument to support the 
implementation of the intervention strategies through a reasonable prioritisation, which could 
help reduce the overall costs. Therefore, future work in this area will need specific evaluation 





could allow us to fully understand the economic impact of interventions aimed at reducing 
harm due to ADRs. 
6.5 Future research directions 
More research is needed into intervention strategies to help reduce ADR-related hospitalisation 
and mortality. However, key areas that demand urgent interventions based on our study 
findings include patients taking anti-TB drugs (isoniazid and pyrazinamide) and ART 
(tenofovir, efavirenz and nevirapine), with a special focus on patients with malnutrition, 
previous ADR history, and pre-existing renal and liver diseases. Patients with cardiovascular 
disorders taking furosemide, enalapril, atorvastatin, warfarin and heparin also require special 
consideration. Given our findings that the majority of events occurred in patients receiving 
treatment for chronic infectious and non-communicable diseases, ADR risk assessment and 
intervention strategies should focus on these groups of patients to minimise the occurrence of 
preventable ADR-related hospitalisation and mortality in Ethiopia, noting that measuring the 
effectiveness of such interventions is an area requiring further research.  
In summary, this thesis has provided the most robust estimate of the extent and nature of the 
burden of ADR-related hospital admission and mortality in Ethiopian patients. Given the 
overburdening of the growing healthcare system with ADR-related hospitalisation and 
mortality, urgent work is required to:  
• investigate the impact of genetics, malnutrition, and chronic infectious and non-
communicable diseases on the acquisition and outcomes of ADRs; 
• develop robust methods for prevention of the occurrence of ADRs in the future; 





• evaluate the impact of ADR prevention strategies with the ultimate goal of preventing or 
reducing the risk of acquiring ADRs, improving patient outcomes, and minimising ADR-
related costs to the healthcare system. 
Considering the significant problem of ADR-related admission and mortality and lack of 
universally accepted standardised methods for assessing ADR causality, type, severity, and 
preventability, there is a need to develop robust standardised methods in order to accurately 
estimate the worldwide epidemiology and financial costs of the problem to the health care 
system. 
6.6 Thesis conclusion 
Our study provided several novel findings regarding hospitalisation and mortality related to 
ADRs in Ethiopian patients. Our work revealed that the extent of ADR-related hospitalisation 
in adults is an important public health problem, with a significant number of fatal ADRs in 
patients presenting to hospital. Well-known reactions to commonly used drugs, such as anti-
TB drugs, ART and cardiovascular agents, are the most frequently occurring ADRs in patients 
presenting to hospital, suggesting that strategies for their prevention should be identifiable. The 
ADR-related hospitalisation risk prediction demonstrated some ability to identify patients at 
higher risk for ADRs, such as patients with a lower BMI, previous ADR history, renal and liver 
diseases, and multiple comorbidities and medications. Therefore, consideration of these risk 
factors by medical practitioners during assessment of patients at emergency and chronic care 
centres might help distinguish patients who are at higher risk of ADR-related hospitalisation. 
Healthcare professionals, particularly physicians, pharmacists, and nurses should work more 
effectively as a multidisciplinary team to identify, prevent, and manage the ADR-related 







1. Pugatch M, Torstensson D, Laufer M. The evolution of pharmacovigilance - Pugatch 
consilium:Labeling, packaging and pharmacopeia standards: Novartis Pharmaceuticals 
Corporation 2015. Via  http://www.pugatch-
consilium.com/reports/The%20Evolution%20of%20Pharmacovigilance.pdf. 
2. Sammons HM, Choonara I. Clinical trials of medication in children, 1996-2002. 
European Journal of Clinical Pharmacology. 2005;61(2):165-7. doi:10.1007/s00228-005-
0894-9. 
3. Gallagher RM, Mason JR, Bird KA, et al. Adverse drug reactions causing admission 
to a paediatric hospital. PLoS One. 2012;7 (12):e50127. doi:10.1371/journal.pone.0050127 
4. McBride WG. Teratogenic action of thalidomide. Lancet. 1978;1(8078):1362.  
5. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with 
selective COX-2 inhibitors. Journal of American Medical Association. 2001;286 (8):954-9.  
6. World Health Organization. Safety monitoring of medicinal products: Guidelines for 
setting up and running a pharmacovigilance centre. Uppsala: Uppsala Monitoring Centre, 
World Health Organization; 2000.  
7. Levy M, Kewitz H, Altwein W, Hillebrand J, Eliakim M. Hospital admissions due to 
adverse drug reactions: A comparative study from Jerusalem and Berlin. European Journal of 
Clinical Pharmacology. 1980;17(1):25-31.  
8. Levy M, Lipshitz M, Eliakim M. Hospital admissions due to adverse drug reactions. 





9. Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital 
admissions: Results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). 
Journal of the American Geriatrics Society. 2002;50(12):1962-8.  
10. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of 
admission to hospital: Prospective analysis of 18 820 patients. British Medical Journal. 
2004;329(7456):15-9.  
11. Van der Hooft CS, Dieleman JP, Siemes C, et al. Adverse drug reaction-related 
hospitalisations: A population-based cohort study. Pharmacoepidemiology and Drug Safety. 
2008;17(4):365-71.  
12. Van der Hooft CS, Sturkenboom MC, Van Grootheest K, Kingma HJ, Stricker BH. 
Adverse drug reaction-related hospitalisations: A nationwide study in The Netherlands. Drug 
Safety. 2006;29(2):161-8.  
13. Varallo FR, Capucho HC, Planeta CS, Mastroianni PC. Possible adverse drug events 
leading to hospital admission in a Brazilian teaching hospital. Clinics. 2014;69(3):163-7. 
doi:10.6061/clinics/2014(03)03 
14. Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with 
adverse drug reactions following hospital admission: A prospective analysis of 907 patients 
in two German university hospitals. Drug Safety. 2008;31(9):789-98.  
15. Carrasco-Garrido P, de Andres LA, Barrera VH, de Miguel GA, Jimenez-Garcia R. 
Trends of adverse drug reactions related-hospitalizations in Spain (2001-2006). BMC Health 





16. Alexopoulou A, Dourakis SP, Mantzoukis D, et al. Adverse drug reactions as a cause 
of hospital admissions: A 6-month experience in a single center in Greece. European Journal 
of Internal Medicine. 2008;19(7):505-10. doi:10.1016/j.ejim.2007.06.030. 
17. Patel H, Bell D, Molokhia M, et al. Trends in hospital admissions for adverse drug 
reactions in England: Analysis of national hospital episode statistics 1998-2005. BMC 
Clinical Pharmacology. 2007;7:9. doi:10.1186/1472-6904-7-9. 
18. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse 
drug reactions in a department of general medicine. British Journal of Clinical 
Pharmacology. 1998;45(3):301-8.  
19. Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Drug-related hospital 
admissions: a review of Australian studies published 1988-1996. The Medical Journal of 
Australia. 1998;168(8):405-8.  
20. Pouyanne P, Haramburu F, Imbs JL, Begaud B. Admissions to hospital caused by 
adverse drug reactions: Cross sectional incidence study. French Pharmacovigilance Centres. 
British Medical Journal. 2000;320(7241):1036.  
21. World Health Organisation. International drug monitoring: The role of national 
centres. Report of a World Health Organisation meeting. World Health Organization 
technical report series. 1972;498:1-25.  
22. Angamo MT, Chalmers L, Curtain CM, Bereznicki LR. Adverse-Drug-Reaction-
Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence 





23. Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI. Adverse 
drug reactions in adult medical inpatients in a South African hospital serving a community 
with a high HIV/AIDS prevalence: Prospective observational study. British Journal of 
Clinical Pharmacology. 2008;65(3):396-406. doi:10.1111/j.1365-2125.2007.03034.x. 
24. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and 
management. The Lancet. 2000;356(9237):1255-9. doi:10.1016/s0140-6736(00)02799-9 
25. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: A clinician's 
guide to terminology, documentation, and reporting. Annals of Internal Medicine. 
2004;140(10):795-801.  
26. National Coordinating Council (NCC) for Medication Error Reporting and Prevention 
(MERP). via http://www.ihi.org/resources/Pages/OtherWebsites/NCCMERP.aspx. Accessed 
on Oct 2018. 
27. Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and 
medication errors: Detection and classification methods. Quality & Safety in Health Care. 
2004;13(4):306-14. doi:10.1136/qhc.13.4.306. 
28. Sonal Sekhar M, Adheena Mary C, Anju PG, Hamsa NA. Study on drug related 
hospital admissions in a tertiary care hospital in South India. Saudi Pharmaceutical Journal : 
SPJ : The Official Publication of the Saudi Pharmaceutical Society. 2011;19(4):273-8. 
doi:10.1016/j.jsps.2011.04.004. 
29. Varallo FR, Lima MFR, Galduroz JCF, Mastroianni PC. Adverse drug reaction as 
cause of hospital admission of elderly people: A Pilot study. Latin American Journal of 





30. Ahern F, Sahm LJ, Lynch D, McCarthy S. Determining the frequency and 
preventability of adverse drug reaction-related admissions to an Irish University Hospital: A 
cross-sectional study. Emergency Medicine Journal : EMJ. 2014;31(1):24-9. 
doi:10.1136/emermed-2012-201945. 
31. Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability 
of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 
1756 patients. Drug Safety. 2008;31(6):545-56.  
32. Green CF, Mottram DR, Rowe PH, Pirmohamed M. Adverse drug reactions as a 
cause of admission to an acute medical assessment unit: A pilot study. Journal of Clinical 
Pharmacy and Therapeutics. 2000;25(5):355-61.  
33. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse 
drug reactions. Annals of Pharmacotherapy. 2002;36(9):1331-6.  
34. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of 
the prevalence and economic burden of adverse drug reactions presenting to the medical 
emergency department of a tertiary referral centre: A prospective study. BMC Clinical 
Pharmacology. 2007;7:8. doi:10.1186/1472-6904-7-8. 
35. Alvarez PA, Bril F, Castro V, et al. Adverse drug reactions as a reason for admission 
to an internal medicine ward in Argentina. The International Journal of Risk & Safety in 
Medicine. 2013;25(3):185-92. doi:10.3233/jrs-130596. 
36. Shepherd G, Mohorn P, Yacoub K, May DW. Adverse drug reaction deaths reported 






37. Chen YC, Fan JS, Hsu TF, et al. Detection of patients presenting with adverse drug 
events in the emergency department. Internal Medicine Journal. 2012;42(6):651-7. 
doi:10.1111/j.1445-5994.2011.02684.x. 
38. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug 
reactions. British Medical Journal.1998;316(7140):1295-8.  
39. Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction 
related admissions according to method of detection, admission urgency and medical 
department specialty. BMC Clinical Pharmacology. 2009;9:8. doi:10.1186/1472-6904-9-8. 
40. Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug 
reactions: A population based study. British Journal of Clinical Pharmacology. 
2008;65(4):573-9. 
41. Davies EC, Green CF, Mottram DR, Rowe PH, Pirmohamed M. Emergency re-
admissions to hospital due to adverse drug reactions within 1 year of the index admission. 
British Journal of Clinical Pharmacology. 2010;70(5):749-55. doi:10.1111/j.1365-
2125.2010.03751.x. 
42. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian 
hospital--their severity and cost involved. Pharmacoepidemiology and Drug Safety. 
2003;12(8):687-92. doi:10.1002/pds.871. 
43. Pouyanne P, Haramburu F, Imbs JL, Bégaud B. Admissions to hospital caused by 






44. Jones JK. Adverse drug reactions in the community health setting: Approaches to 
recognizing, counseling, and reporting. Family & Community Health. 1982;5(2):58-67.  
45. Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug 
reactions during hospitalisation : Computerised monitoring versus stimulated spontaneous 
reporting. Drug Safety. 2000;22(2):161-8. doi:10.2165/00002018-200022020-00007. 
46. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in 
reporting adverse drug reactions. American Journal of Hospital Pharmacy. 1992;49(9):2229-
32.  
47. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. 
Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-
episodes. PLoS One. 2009;4(2):e4439.  
48. Padmavathi S,  Manimekalai K, Ambujam S. Causality, severity and preventability 
assessment of adverse cutaneous drug reaction: A prospective observational study in a 
tertiary care hospital. Journal of Clinical and Diagnostic Research : JCDR. 2013;7(12):2765-
7. doi:10.7860/jcdr/2013/7430.3753 
49. Arulmani R, Rajendran S, Suresh B. Adverse drug reaction monitoring in a secondary 
care hospital in South India. British Journal of Clinical Pharmacology. 2008;65(2):210-6.  
50. Calderon-Ospina C, Bustamante-Rojas C. The DoTS classification is a useful way to 
classify adverse drug reactions: A preliminary study in hospitalized patients. The 






51. Lobo MG, Pinheiro SM, Castro JG, Momente VG, Pranchevicius MC. Adverse drug 
reaction monitoring: Support for pharmacovigilance at a tertiary care hospital in Northern 
Brazil. BMC Pharmacology & Toxicology. 2013;14:5. doi:10.1186/2050-6511-14-5. 
52. Mannesse CK, Derkx FH, de Ridder MA, Man in 't Veld AJ, van der Cammen TJ. 
Contribution of adverse drug reactions to hospital admission of older patients. Age and 
Ageing. 2000;29(1):35-9.  
53. Mohebbi N, Shalviri G, Salarifar M, Salamzadeh J, Gholami K. Adverse drug 
reactions induced by cardiovascular drugs in cardiovascular care unit patients. 
Pharmacoepidemiology and Drug Safety. 2010;19(9):889-94. doi:10.1002/pds.1916. 
54. Ponte ML, Ragusa M, Armenteros C, Wachs A. Importance of pharmacovigilance in 
current medical practice. Medicina. 2013;73(1):35-8. 
55. Pourseyed S, Fattahi F, Pourpak Z, et al. Adverse drug reactions in patients in an 
Iranian department of internal medicine. Pharmacoepidemiology and Drug Safety. 
2009;18(2):104-10. doi:10.1002/pds.1663. 
56. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A 
systematic review of the prospective and retrospective studies. Bandolier Extra. 2002:1-15.  
57. Burgess CL, Holman CD, Satti AG. Adverse drug reactions in older Australians, 
1981-2002. The Medical Journal of Australia. 2005;182(6):267-70.  
58. Rottenkolber D, Schmiedl S, Rottenkolber M, et al. Adverse drug reactions in 
Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiology and 





59. Byrne DW, France DJ, Johnston PE, et al. Assessment of adverse drug events among 
patients in a tertiary care medical center. American Journal of Health System Pharmacists . 
2006;63 (22): 2218-27.  
60. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United 
States in years 1970-2002. Journal of the American Medical Association. 2005;294:1255-9.  
61. Hodgkinson MR, Dirnbauer NJ, Larmour I. Identification of adverse drug reactions 
using the ICD-10 Australian Modification Clinical Coding Surveillance. Journal of 
Pharmacy Practice and Research. 2009;39(1):19-23.  
62. Zoppi M, Braunschweig S, Kuenzi UP, Maibach R, Hoigne R. Incidence of lethal 
adverse drug reactions in the comprehensive hospital drug monitoring, a 20-year survey, 
1974-1993, based on the data of Berne/St. Gallen. European Journal of Clinical 
Pharmacology. 2000;56(5):427-30.  
63. Juntti-Patinen L, Neuvonen PJ. Drug-related deaths in a university central hospital. 
European Journal of Clinical Pharmacology. 2002;58(7):479-82. doi:10.1007/s00228-002-
0501-2. 
64. Vora MB, Trivedi HR, Shah BK, Tripathi CB. Adverse drug reactions in inpatients of 
internal medicine wards at a tertiary care hospital: A prospective cohort study. Journal Of 
Pharmacology & Pharmacotherapeutics. 2011;2(1):21-5. doi:10.4103/0976-500x.77102. 
65. Mouton JP, Mehta U, Parrish AG, et al. Mortality from adverse drug reactions in adult 
medical inpatients at four hospitals in South Africa: A cross-sectional survey. British Journal 





66. Noblat AC, Noblat LA, Toledo LA, et al. Prevalence of hospital admission due to 
adverse drug reaction in Salvador, Bahia. Revista da Associacao Medica Brasileira (1992). 
2011;57(1):42-5. 
67. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in 
hospitalized patients. Excess length of stay, extra costs, and attributable mortality. Journal of 
the American Medical Association. 1997;277(4):301-6. 
68. Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug 
reactions among elderly patients in Ontario emergency departments: A retrospective study. 
Drug Safety. 2012;35(9):769-81. doi:10.2165/11599540-000000000-00000. 
69. Breckenridge A. The burden of adverse drug events. British Journal of Clinical 
Pharmacology. 2015;80(4):785-7. doi:10.1111/bcp.12507. 
70. Rothschild JM, Federico FA, Gandhi TK, Kaushal R, Williams DH, Bates DW. 
Analysis of medication-related malpractice claims: Causes, preventability, and costs. 
Archives of Internal Medicine. 2002;162(21):2414-20.  
71. Studdert DM, Thomas EJ, Burstin HR, Zbar BI, Orav EJ, Brennan TA. Negligent care 
and malpractice claiming behavior in Utah and Colorado. Medical Care. 2000;38(3):250-60.  
72. Anderson JA, Adkinson NF, Jr. Allergic reactions to drugs and biologic agents. 
Journal of the American Medical Association. 1987;258(20):2891-9.  
73. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. Journal of the 
American Medical Association. 1997;278(22):1895-906.  
74. Executive summary of disease management of drug hypersensitivity: A practice 





and immunology, and the joint council of allergy, asthma and immunology. Annals of 
Allergy, Asthma and Immunology. 1999;83:665–700. Via 
https://www.ncbi.nlm.nih.gov/pubmed/10616910.  
75. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, 
ed. Textbook of adverse drug reactions, 2nd edn. Oxford: Oxford University Press. 1981:11.  
76. von Euler M, Eliasson E, Ohlen G, Bergman U. Adverse drug reactions causing 
hospitalization can be monitored from computerized medical records and thereby indicate the 
quality of drug utilization. Pharmacoepidemiology and Drug Safety. 2006;15(3):179-84. 
doi:10.1002/pds.1154. 
77. Tribin˜o G, Maldonado C, Segura O, Dı´az J. Direct costs and clinical aspects of 
adverse drug reactions in patients admitted to a level 3 hospital internal medicine ward. 
Biomedica. 2006;26:31-41. 
78. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William 
Withering Lecture 1994. Journal of the Royal College of Physicians of London. 
1995;29(1):41-9.  
79. Aronson JK. Drug therapy. In: Haslett C, Chilvers ER, Boon NA, Colledge NR, Jaa 
H, editors. Davidson's principles and practice of medicine. 19th ed ed. Edinburgh: Elsevier 
Science; 2002. 
80. Aronson JK, Ferner RE. Joining the DoTS: New approach to classifying adverse drug 
reactions. British Medical Journal. 2003;327(7425):1222-5. doi:10.1136/bmj.327.7425.1222. 
81. Zaki SA. Adverse drug reaction and causality assessment scales. Lung India : Official 





82. Gaurav Chhabra. Causality assessment,methods,pharmacovigilance: UIPS, Panjab 
University (Pharmacology) 2017. 
83. Hutchinson TA, Lane DA. Standardized methods of causality assessment for 
suspected adverse drug reactions. Journal of Chronic Diseases. 1986;39(11):857-60.  
84. World Health Organisation. The use of the WHO-UMC system for standardised case 
causality assessment via http://who-umc.org/Graphics/24734.pdf.  
85. Irey NS. Teaching monograph. Tissue reactions to drugs. The American Journal of 
Pathology. 1976;82(3):613-47.  
86. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. 
Clinical Pharmacology and Therapeutics. 1977;21(3):247-54.  
87. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the 
operational assessment of adverse drug reactions. Background, description, and instructions 
for use. Journal of American Medical Association. 1979;242(7):623-32.  
88. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of 
adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981;30(2):239-45.  
89. Khan LM, Al-Harthi SE, Osman AM, Sattar MA, Ali AS. Dilemmas of the causality 
assessment tools in the diagnosis of adverse drug reactions. Saudi Pharmaceutical Journal: 
SPJ : The Official Publication of the Saudi Pharmaceutical Society. 2016;24(4):485-93. 
doi:10.1016/j.jsps.2015.01.010 
90. Busto U, Naranjo CA, Sellers EM. Comparison of two recently published algorithms 
for assessing the probability of adverse drug reactions. British Journal of  Clinical 





91. Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple 
algorithm for assessment of adverse drug events. Clinical Pharmacology and Therapeutics. 
1995;58(6):692-8. doi:10.1016/0009-9236(95)90026-8 
92. Routledge P. A. Adverse drug reactions and interactions: Mechanisms, risk factors, 
detection, management and prevention. In: John Talbot., Waller. P, editors. Stephens’ 
detection of new adverse drug reactions 5th  ed: John Wiley & Sons, Ltd.; 2004. 
93. Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability 
of adverse drug reactions as cause of admission to a Geriatric Unit: A prospective study of 
1756 patients. Drug Safety. 2008;31(6):545-56. doi:10.2165/00002018-200831060-00009. 
94. Hofer-Dueckelmann C, Prinz E, Beindl W, et al. Adverse drug reactions (ADRs) 
associated with hospital admissions : Elderly female patients are at highest risk. International 
Journal of Clinical Pharmacology and Therapeutics. 2011;49(10):577-86.  
95. Hopf Y, Watson M, Williams D. Adverse-drug-reaction related admissions to a 
hospital in Scotland. Pharmacy World Science. 2008;30(6):854-62. doi:10.1007/s11096-008-
9240-5. 
96. Olivier P, Bertrand L, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. 
Hospitalizations because of adverse drug reactions in elderly patients admitted through the 
emergency department: A prospective survey. Drugs & Aging. 2009;26(6):475-82. 
doi:10.2165/00002512-200926060-00004. 
97. Ruiter R, Visser LE, Rodenburg EM, Trifiro G, Ziere G, Stricker BH. Adverse drug 
reaction-related hospitalizations in persons aged 55 years and over: A population-based study 






98. Pedros C, Quintana B, Rebolledo M, Porta N, Vallano A, Arnau JM. Prevalence, risk 
factors and main features of adverse drug reactions leading to hospital admission. European 
Journal of Clinical Pharmacology. 2014;70(3):361-7. doi:10.1007/s00228-013-1630-5. 
99. van der Hooft CS, Dieleman JP, Siemes C, et al. Adverse drug reaction‐related 
hospitalisations: A population‐based cohort study. Pharmacoepidemiology and Drug Safety. 
2008;17(4):365-71. 
100. Sánchez Muñoz-Torrero JF, Barquilla P, Velasco R, et al. Adverse drug reactions in 
internal medicine units and associated risk factors. European Journal of Clinical 
Pharmacology. 2010;66(12):1257-64.  
101. Mouton JP, Njuguna C, Kramer N, et al. Adverse Drug Reactions Causing Admission 
to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa. Medicine. 
2016;95(19):e3437. doi:10.1097/md.0000000000003437. 
102. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to 
emergency department visits for adverse drug events in older adults. Annals of Internal 
Medicine. 2007;147(11):755-65.  
103. Hartholt KA, van der Velde N, Looman CW, et al. Adverse drug reactions related 
hospital admissions in persons aged 60 years and over, The Netherlands, 1981-2007: Less 
rapid increase, different drugs. PLoS One. 2010;5(11):e13977. 
doi:10.1371/journal.pone.0013977. 
104. Perez Menendez-Conde C, Bermejo Vicedo T, Delgado Silveira E, Carretero Accame 
E. Adverse drug reactions which provoke hospital admission. Farmacia Hospitalaria : 
Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia 





105. Schneeweiss S, Hasford J, Gottler M, Hoffmann A, Riethling AK, Avorn J. 
Admissions caused by adverse drug events to internal medicine and emergency departments 
in hospitals: A longitudinal population-based study. European Journal of Clinical 
Pharmacology. 2002;58(4):285-91. doi:10.1007/s00228-002-0467-0. 
106. Lazarou J, Pomeranz B, Corey P. Incidence of Adverse drug reactions in hospitalised 
patients. A Meta-analysis of prospective studies. Journal of the American Medical 
Association. 1998;279(15):1200-5.  
107. Varallo FR, Capucho HC, Planeta CD, Mastroianni PD. Possible adverse drug events 
leading to hospital admission in a Brazilian teaching hospital. Clinics. 2014;69(3):163-7. 
doi:10.6061/clinics/2014(03)03. 
108. Walsh D, Lavan A, Cushing AM, Williams D. Adverse drug reactions as a cause of 
admission to a University Teaching Hospital. Irish Journal of Medical Science. 
2013;182:S282-S.  
109. Tipping B, Kalula S, Badri M. The burden and risk factors for adverse drug events in 
older patients: A prospective cross-sectional study. South African medical journal = Suid-
Afrikaanse Tydskrif vir Geneeskunde. 2006;96(12):1255-9.  




111. The Danish medicines agency’s prevention of medication errors’ network. report on 





working group 2008-10. Copenhagen: The Danish Medicines Agency’s Prevention of 
Medication Errors Network. 2011. 
112. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. The 
New England Journal of Medicine. 2003;348(16):1556-64. doi:10.1056/NEJMsa020703. 
113. Mens H, Katzenstein TL. Hepatic failure due to nevirapine treatment for HIV 
infection. Ugeskrift for Laeger. 2005;167(46):4359.  
114. Jha AK, Kuperman GJ, Rittenberg E, Teich JM, Bates DW. Identifying hospital 
admissions due to adverse drug events using a computer-based monitor. 
Pharmacoepidemiology and Drug Safety. 2001;10(2):113-9. doi:10.1002/pds.568. 
115. Hallas J, Worm J, Beck-Nielsen J, et al. Drug related events and drug utilization in 
patients admitted to a geriatric hospital department. Danish Medical Bulletin. 
1991;38(5):417-20.  
116. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug 
events in nursing homes. The American Journal of Medicine. 2000;109(2):87-94.  
117. Howard R, Avery A, Slavenburg S, et al. Which drugs cause preventable admissions 
to hospital? A systematic review. British Journal of Clinical Pharmacology. 2007;63(2):136-
47.  
118. Bigby J, Dunn J, Goldman L, et al. Assessing the preventability of emergency 
hospital admissions. A method for evaluating the quality of medical care in a primary care 





119. Ruths S, Straand J, Nygaard HA. Multidisciplinary medication review in nursing 
home residents: what are the most significant drug-related problems? The Bergen District 
Nursing Home (BEDNURS) study. Quality & Safety in Health Care. 2003;12(3):176-80.  
120. Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse 
drug reactions in geriatric nursing home residents. American Journal of Geriatrics 
Pharmacotherapy. 2006;4(1):36-41. doi:10.1016/j.amjopharm.2006.03.002. 
121. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The incidence and severity 
of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 
2003;138(3):161-7.  
122. Hardmeier B, Braunschweig S, Cavallaro M, et al. Adverse drug events caused by 
medication errors in medical inpatients. Swiss Medical Weekly. 2004;134(45-46):664-70. 
doi:2004/45/smw-10801. 
123. National board of health, 2009 annual report: The Danish patient safety 




124. Holm E, Brorson SW, Kruse JS et al. Medicines most frequently involved in serious 
adverse drug events. Journal of the Danish Medical Association. 2004;45.  
125. Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for 
preventable drug related admissions to a medical admissions unit: Observational study. 





126. Hallas J, Gram LF, Grodum E, et al. Drug related admissions to medical wards: A 
population based survey. British Journal of Clinical Pharmacology. 1992;33(1):61-8.  
127. Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two 
large academic long-term care facilities. The American Journal of Medicine. 
2005;118(3):251-8. doi:10.1016/j.amjmed.2004.09.018. 
128. Nebeker JR, Hoffman JM, Weir CR, Bennett CL, Hurdle JF. High rates of adverse 
drug events in a highly computerized hospital. Archives of Internal Medicine. 
2005;165(10):1111-6. doi:10.1001/archinte.165.10.1111. 
129. Chrischilles EA, Segar ET, Wallace RB. Self-reported adverse drug reactions and 
related resource use. A study of community-dwelling persons 65 years of age and older. 
Annals of Internal Medicine. 1992;117(8):634-40.  
130. Dartnell JG, Anderson RP, Chohan V, et al. Hospitalisation for adverse events related 
to drug therapy: incidence, avoidability and costs. The Medical Journal of Australia. 
1996;164(11):659-62.  
131. Parameswaran Nair N, Chalmers L, Bereznicki BJ, et al. Adverse drug reaction-
related hospitalizations in elderly australians: A Prospective cross-sectional study in two 
Tasmanian Hospitals. Drug Safety. 2017;40(7):597-606. doi:10.1007/s40264-017-0528-z 
132. Holt MP, Ju C. Mechanisms of drug-induced liver injury. The AAPS Journal: An 
Official Journal of the American Association of Pharmaceutical Scientists. 2006;8(1):E48-54. 
doi:10.1208/aapsj080106. 
133. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: Results of a US 





134. Lee WM. Drug-induced acute liver failure. Clinical Liver Disease. 2013;17(4):575-
86, viii. doi:10.1016/j.cld.2013.07.001. 
135. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious 
adverse drug reactions: Current progress and challenges. Nature Reviews. Drug Discovery. 
2007;6(11):904-16. doi:10.1038/nrd2423. 
136. Haque T, Sasatomi E, Hayashi PH. Drug-induced liver injury: Pattern recognition and 
future directions. Gut and Liver. 2016;10(1):27-36. doi:10.5009/gnl15114. 
137. Carey EJ, Vargas HE, Douglas DD, et al. Inpatient admissions for drug-induced liver 
injury: results from a single center. Digestive Diseases and Sciences. 2008;53(7):1977-82. 
doi:10.1007/s10620-008-0250-x. 
138. Ghabril M, Chalasani N, Bjornsson E. Drug-induced liver injury: A clinical update. 
Current Opinion in Gastroenterology. 2010;26(3):222-6. 
doi:10.1097/MOG.0b013e3283383c7c. 
139. Björnsson ES. Hepatotoxicity by drugs: The most common implicated agents. 
International Journal of Molecular Sciences. 2016;17(2). doi:10.3390/ijms17020224. 
140. Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: 
Clinical features, therapy, and outcomes. Cell Biochemistry and Biophysics. 2012;64(2):77-
83. doi:10.1007/s12013-012-9373-y. 
141. Benichou C. Criteria of drug-induced liver disorders. Report of an international 





142. Bussieres JF, Habra M. Application of International Consensus Meeting Criteria for 
classifying drug-induced liver disorders. Annals of Pharmacotherapy. 1995;29(9):875-8. 
doi:10.1177/106002809502900910. 
143. Mueller BA. Acute renal failure. In: Pharmacotherapy. 6th ed. New York, NY 
McGraw-Hill; 2005;781-90. 
144. Hannah RH, Brundige ML, Lindsay L. Drug-induced acute renal failure. US 
Pharmacy. Nephrology. 2007;32(3):45-50.  
145. Schetz M, Dasta J, Goldstein S, Golper T. Drug-induced acute kidney injury. Current 
Opinion in Critical Care. 2005;11(6):555-65.  
146. Ghane Shahrbaf F, Assadi F. Drug-induced renal disorders. Journal of Renal Injury 
Prevention. 2015;4(3):57-60. doi:10.12861/jrip.2015.12. 
147. Angamo MT, Curtain CM, Chalmers L, Yilma D, Bereznicki L. Predictors of adverse 
drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional 
study. PLoS One. 2017;12(10):e0186631. doi:10.1371/journal.pone.0186631 
148. Koselj M, Kveder R, Bren AF, Rott T. Acute renal failure in patients with drug-
induced acute interstitial nephritis. Renal Failure. 1993;15(1):69-72.  
149. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Critical 
Care Medicine. 2008;36(4 Suppl):S216-23. doi:10.1097/CCM.0b013e318168e375. 
150. Agostini JV, Han L, Tinetti ME. The relationship between number of medications and 






151. Camargo AL, Cardoso Ferreira MB, Heineck I. Adverse drug reactions: A cohort 
study in internal medicine units at a university hospital. European Journal of Clinical 
Pharmacology. 2006;62:143-9.  
152. Dormann H, Neubert A, Criegee‐Rieck M, et al. Readmissions and adverse drug 
reactions in internal medicine: the economic impact. Journal of Internal Medicine. 
2004;255(6):653-63. 
153. Hakkarainen KM, Andersson Sundell K, Petzold M, Hagg S. Methods for assessing 
the preventability of adverse drug events: A systematic review. Drug Safety. 2012;35(2):105-
26. doi:10.2165/11596570-000000000-00000. 
154. Sikdar KC, Alaghehbandan R, MacDonald D, et al. Adverse drug events in adult 
patients leading to emergency department visits. Annals of Pharmacotherapy. 
2010;44(4):641-9. doi:10.1345/aph.1M416. 
155. Trifirò G, Calogero G, Ippolito FM, et al. Adverse drug events in emergency 
department population: a prospective Italian study. Pharmacoepidemiology and Drug Safety. 
2005;14(5):333-40. 
156. Tumwikirize WA, Ogwal-Okeng JW, Vernby A, et.al. Adverse drug reactions in 
patients admitted on internal medicine wards in a district and regional hospital in Uganda. 
African Health Sciences. 2011;11(1):72-8.  
157. Aljadhey H, Mahmoud MA, Mayet A, et al. Incidence of adverse drug events in an 
academic hospital: A prospective cohort study. International Journal for Quality in Health 






158. Baena MI, Fajardo PC, Pintor-Marmol A, et al. Negative clinical outcomes of 
medication resulting in emergency department visits. European Journal of Clinical 
Pharmacology. 2014;70(1):79-87. doi:10.1007/s00228-013-1562-0. 
159. Boockvar K, Fishman E, Kyriacou CK, Monias A, Gavi S, Cortes T. Adverse events 
due to discontinuations in drug use and dose changes in patients transferred between acute 
and long-term care facilities. Archives of Internal Medicine. 2004;164(5):545-50. 
doi:10.1001/archinte.164.5.545. 
160. Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission 
in the elderly. Internal Medicine Journal. 2001;31(4):199-205.  
161. Devi P, Kamath DY, Anthony N, Santosh S, Dias B. Patterns, predictors and 
preventability of adverse drug reactions in the coronary care unit of a tertiary care hospital. 
European Journal of Clinical Pharmacology. 2012;68(4):427-33. doi:10.1007/s00228-011-
1138-9. 
162. Hassen AA, Belachew T, Yami  A, Ayen WY. Anti-Tuberculosis Drug induced 
hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: 
Nested case-control study. PLoS One. 2013;8(5):e64622. 
doi:doi:10.1371/journal.pone.0064622. 
163. Kongkaew C, Hann M, Mandal J, et al. Risk factors for hospital admissions 
associated with adverse drug events. Pharmacotherapy. 2013;33(8):827-37. 
doi:10.1002/phar.1287. 
164. Roulet L, Asseray N, Dary M, Chiffoleau A, Potel G, Ballereau F. Implementing a 





International Journal of Clinical Pharmacy. 2012;34(6):902-10. doi:10.1007/s11096-012-
9691-6. 
165. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. Evaluation of 
patient-related factors associated with causality, preventability, predictability and severity of 
hepatotoxicity during antituberclosis treatment. Pharmacological Research. 2005;51(4):353-
8.  
166. Mjorndal T, Boman MD, Hagg S, et al. Adverse drug reactions as a cause for 
admissions to a department of internal medicine. Pharmacoepidemiology and Drug Safety. 
2002;11(1):65-72. doi:10.1002/pds.667. 
167. Hellden A, Bergman U, von Euler M, Hentschke M, Odar-Cederlof I, Ohlen G. 
Adverse drug reactions and impaired renal function in elderly patients admitted to the 
emergency department: a retrospective study. Drugs & Aging. 2009;26(7):595-606. 
doi:10.2165/11315790-000000000-00000. 
168. Alomar MJ. Factors affecting the development of adverse drug reactions (Review 
article). Saudi Pharmaceutical Journal : SPJ : The Official Publication of the Saudi 
Pharmaceutical Society. 2014;22(2):83-94. doi:10.1016/j.jsps.2013.02.003. 
169. Zopf Y, Rabe C, Neubert A, et al. Women encounter ADRs more often than do men. 
European Journal of Clinical Pharmacology. 2008;64(10):999-1004. doi:10.1007/s00228-
008-0494-6. 
170. Hug BL, Witkowski DJ, Sox CM, et al. Adverse drug event rates in six community 
hospitals and the potential impact of computerized physician order entry for prevention. 





171. Rodenburg EM, Stricker BH, Visser LE. Sex differences in cardiovascular drug-
induced adverse reactions causing hospital admissions. British Journal of Clinical 
Pharmacology. 2012;74(6):1045-52. doi:10.1111/j.1365-2125.2012.04310.x. 
172. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug 
metabolizing enzymes. Molecular Pharmacology. 2009;76(2):215-28. 
doi:10.1124/mol.109.056705. 
173. El-Eraky H, Thomas SH. Effects of sex on the pharmacokinetic and 
pharmacodynamic properties of quinidine. British Journal of Clinical Pharmacology. 
2003;56(2):198-204. 
174. Mitchell SC, Smith RL, Waring RH. The menstrual cycle and drug metabolism. 
Current Drug Metabolism. 2009;10(5):499-507.  
175. Ensom MH. Gender-based differences and menstrual cycle-related changes in specific 
diseases: Implications for pharmacotherapy. Pharmacotherapy. 2000;20(5):523-39.  
176. Zhang M, Holman CDJ, Price SD, Sanfilippo FM, Preen DB, Bulsara. Comorbidity 
and repeat admission to hospital for adverse drug reactions in older adults: Retrospective 
cohort study. British Medical Journal. 2009;338. doi:10.1136/bmj.a2752. 
177. Franz CC, Egger S, Born C, Ratz Bravo AE, Krahenbuhl S. Potential drug-drug 
interactions and adverse drug reactions in patients with liver cirrhosis. European Journal of 
Clinical Pharmacology. 2012;68(2):179-88. doi:10.1007/s00228-011-1105-5. 
178. Zuckerman MJ, Menzies IS, Ho H, et al. Assessment of intestinal permeability and 
absorption in cirrhotic patients with ascites using combined sugar probes. Digestive Diseases 





179. Blaschke TF, Rubin PC. Hepatic first-pass metabolism in liver disease. Clinical 
Pharmacokinetics. 1979;4(6):423-32.  
180. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in 
patients with liver disease. Drug Safety. 2005;28(6):529-45.  
181. Gonzalez M, Goracci L, Cruciani G, Poggesi I. Some considerations on the 
predictions of pharmacokinetic alterations in subjects with liver disease. Expert Opinion on 
Drug Metabolism & Toxicology. 2014;10(10):1397-408. 
doi:10.1517/17425255.2014.952628. 
182. Franz CC, Hildbrand C, Born C, Egger S, Ratz Bravo AE, Krahenbuhl S. Dose 
adjustment in patients with liver cirrhosis: impact on adverse drug reactions and 
hospitalizations. European Journal of Clinical Pharmacology. 2013;69 (8):1565-73. 
doi:10.1007/s00228-013-1502-z. 
183. Olyaei AJ, Steffl JL. A quantitative approach to drug dosing in chronic kidney 
disease. Blood Purification. 2011;31(1-3):138-45. doi:10.1159/000321857. 
184. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and 
pharmacodynamics: basic principles and practical applications. British Journal of Clinical 
Pharmacology. 2004;57(1):6-14.  
185. Fink JC, Brown J, Hsu VD, Seliger SL, Walker L, Zhan M. CKD as an 
underrecognized threat to patient safety. American Journal of Kidney Diseases : The Official 






186. Caamano F, Pedone C, Zuccala G, Carbonin P. Socio-demographic factors related to 
the prevalence of adverse drug reaction at hospital admission in an elderly population. 
Archives of Gerontology and Geriatrics. 2005;40(1):45-52. 
doi:10.1016/j.archger.2004.05.005. 
187. Hoigne R, Sollberger J, Zoppi M, et al. Significance of age, sex, kidney function, 
atopy and number of prescriptions for the occurrence of adverse drug reactions, studied by 
multivariate statistical methods. Results from the Comprehensive Hospital Drug Monitoring 
Berne (CHDMB). Schweizerische medizinische Wochenschrift. 1984;114(49):1854-7.  
188. Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between 
drugs of abuse and antiretroviral medications: Implications and management for clinical 
practice. Expert Review of Clinical Pharmacology. 2008;1(1):115-27. 
doi:10.1586/17512433.1.1.115. 
189. Krupski A, Campbell K, Joesch JM, Lucenko BA, Roy-Byrne P. Impact of access to 
recovery services on alcohol/drug treatment outcomes. Journal of Substance Abuse 
Treatment. 2009;37(4):435-42. doi:10.1016/j.jsat.2009.05.007. 
190. Kim BH, Yi S, Kim J, et al. Influence of alcohol on the hemodynamic effects and 
pharmacokinetic properties of mirodenafil: A single-dose, randomized-sequence, open-label, 
crossover study in healthy male volunteers in Korea. Clinical Therapeutics. 2009;31(6):1234-
43. doi:10.1016/j.clinthera.2009.06.008. 
191. Onder G, Landi F, Della Vedova C, et al. Moderate alcohol consumption and adverse 






192. Przybylski G, Dabrowska A, Trzcinska H. Alcoholism and other socio-demographic 
risk factors for adverse TB-drug reactions and unsuccessful tuberculosis treatment - data from 
ten years' observation at the Regional Centre of Pulmonology, Bydgoszcz, Poland. Medical 
Science Monitor : International Medical Journal of Experimental and Clinical Research. 
2014;20:444-53. doi:10.12659/msm.890012. 
193. Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S. Tuberculosis and Nutrition. 
Lung India : Official Organ of Indian Chest Society. 2009;26(1):9-16. doi:10.4103/0970-
2113.45198. 
194. Tverdal A. Body mass index and incidence of tuberculosis. European Journal of 
Respiratory Diseases. 1986;69(5):355-62.  
195. Sudre P, ten Dam G, Kochi A. Tuberculosis: A global overview of the situation today. 
Bulletin of the World Health Organisation. 1992;70(2):149-59.  
196. Krishnaswamy K. Drug metabolism and pharmacokinetics in malutrition. Clinical 
Pharmacokinetics. 1978;3(3):216-40.  
197. Pamela M. Undernutrition in hospital: Causes and consequences. Hospial Pharmacist. 
2006;13:353-8.  
198. Purnak T, Yilmaz Y. Liver disease and malnutrition. Best practice & research. 
Clinical Gastroenterology. 2013;27(4):619-29. doi:10.1016/j.bpg.2013.06.018. 
199. Dimie O, Reginald OO, Haruna MM, et al. Morbidity andMortality Patterns of 
Hospitalised Adult HIV/AIDS Patients in the Era of Highly Active Antiretroviral Therapy: A 






200. Henry NL, Marie-Solange D, Simeon-Pierre C, et al. Adverse drug reactions of 
Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General 
Hospital, Douala, Cameroon: a cross sectional study. The Pan African Medical Journal. 
2012;12(87):1-7. 
201. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. 
Hospital Pharmacy. 1992;27(6):538.  
202. Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of 
definitions and intensity of data collection, and the possibility of prevention. Journal of 
Internal Medicine. 1990;228(2):83-90.  
203. Letrilliart L, Hanslik T, Biour M, Fagot JP, Guiguet M, Flahault A. Postdischarge 
adverse drug reactions in primary care originating from hospital care in France: A nationwide 
prospective study. Drug Safety. 2001;24(10):781-92.  
204. Thomas EJ, Lipsitz SR, Studdert DM, et al. The reliability of medical record review 
for estimating adverse event rates. Annals of Internal Medicine. 2002;136(11):812-6.   
205. Snyder RA, Abarca J, Meza JL, et.al. Reliability evaluation of the adapted national 
coordinating council medication error reporting and prevention (NCC MERP) index. 
Pharmacoepidemiology and Drug Safety. 2007;16(9):1006-13.  
206. Farcas A, Sinpetrean A, Mogosan C, et al. Adverse drug reactions detected by 
stimulated spontaneous reporting in an internal medicine department in Romania. European 





207. Rommers MK, Teepe-Twiss IM, Guchelaar HJ. Preventing adverse drug events in 
hospital practice: an overview. Pharmacoepidemiology and Drug Safety. 2007;16(10):1129-
35. doi:10.1002/pds.1440. 
208. Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to 
assess risk of adverse drug reactions among in-hospital patients 65 years or older: The 
GerontoNet ADR risk score. Archives of Internal Medicine. 2010;170(13):1142-8. 
doi:10.1001/archinternmed.2010.153. 
209. Tangiisuran B, Scutt G, Stevenson J, et al. Development and validation of a risk 
model for predicting adverse drug reactions in older people during hospital stay: Brighton 
Adverse Drug Reactions Risk (BADRI) Model. PLoS One. 2014;9(10):e111254. 
doi:10.1371/journal.pone.0111254. 
210. Elnicki RA, Schmitt JP. Contribution of patient and hospital characteristics to adverse 
patient incidents. Health Services Research. 1980;15(4):397-414.  
211. Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in 
hospitalized patients. ADE Prevention Study Group. Archives of Internal Medicine. 
1999;159(21):2553-60.   
212. Johnston PE, France DJ, Byrne DW, et al. Assessment of adverse drug events among 
patients in a tertiary care medical center. American Journal of Health-System Pharmacy : 
AJHP : Official Journal of the American Society of Health-System Pharmacists. 
2006;63(22):2218-27. doi:10.2146/ajhp050405. 
213. Parameswaran Nair N, Chalmers L, Connolly M, et al. Prediction of hospitalization 
due to adverse drug reactions in elderly community-dwelling patients (The PADR-EC Score). 





214. USAID/SPS (Strengthening Pharmaceutical System) program. Safety of Medicines in 
Sub-Saharan Africa: Assessment of Pharmacovigilance Systems and their Performance. 
2011. Via https://africapv2012.files.wordpress.com/2012/05/day-1_2_findings-from-the-ssa-
study_nwokike.pdf.  
215. Smith CC, Bennett PM, Pearce HM, et al. Adverse drug reactions in a hospital general 
medical unit meriting notification to the Committee on Safety of Medicines. British Journal 
of Clinical Pharmacology. 1996;42(4):423-9.  
216. Cox AR, Anton C, Goh CH, Easter M, Langford NJ, Ferner RE. Adverse drug 
reactions in patients admitted to hospital identified by discharge ICD-10 codes and by 
spontaneous reports. British Journal of Clinical Pharmacology. 2001;52(3):337-9.  
217. Molokhia M, Tanna S, Bell D. Improving reporting of adverse drug reactions: 
Systematic review. Clinical Epidemiology. 2009;1:75-92.  
218. Baniasadi S, Habibi M, Haghgoo R, et al. Increasing the number of adverse drug 
reactions reporting: The role of clinical pharmacy residents. Iranian Journal of 
Pharmaceutical Research : IJPR. 2014;13(1):291-7.  
219. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its 
drug and food interactions. Archives of Internal Medicine. 2005;165(10):1095-106. 
doi:10.1001/archinte.165.10.1095. 
220. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug 
interactions among elderly patients hospitalized for drug toxicity. Journal of Amerivcan 





221. Chumney EC, Robinson LC. The effects of pharmacist interventions on patients with 
polypharmacy. Pharmacy Practice (Granada). 2006;4(3):103-9.   
222. Nuckols TK, Smith-Spangler C, Morton SC, et al. The effectiveness of computerized 
order entry at reducing preventable adverse drug events and medication errors in hospital 
settings: A systematic review and meta-analysis. Systematic Reviews. 2014;3:56. 
doi:10.1186/2046-4053-3-56. 
223. Steinman MA, Handler SM, Gurwitz JH, Schiff GD, Covinsky KE. Beyond the 
prescription: medication monitoring and adverse drug events in older adults. Journal of the 
American Geriatrics Society. 2011;59(8):1513-20. doi:10.1111/j.1532-5415.2011.03500.x. 
224. Kang JS, Lee MH. Overview of therapeutic drug monitoring. The Korean Journal of 
Internal Medicine. 2009;24(1):1-10. doi:10.3904/kjim.2009.24.1.1. 
225. Monitoring drug therapy: Three steps for pharmacists. American Pharmacists 
Association. Available from. Via. https://www.pharmacytoday.org/article/S1042-
0991(15)31950-2/fulltext. 
226. Margaret Duguid. The importance of medication reconciliation for patients and 
practitioners. Australian Prescriber. 2012;35(1):15-9. doi:10.18773/austprescr.2012.007 
227. Rozich JD, Howard RJ, Justeson JM, Macken PD, Lindsay ME, Resar RK. 
Standardisation as a mechanism to improve safety in health care. Joint Commission Journal 
on Quality and Safety. 2004;30(1):5-14.  
228. Gleason KM, Groszek JM, Sullivan C, Rooney D, Barnard C, Noskin GA. 





hospitalized patients. American Journal of Health-System Pharmacy : AJHP : Official 
Journal of the American Society of Health-System Pharmacists. 2004;61(16):1689-95.  
229. Mekonnen AB, McLachlan AJ, Brien JA. Pharmacy-led medication reconciliation 
programmes at hospital transitions: A systematic review and meta-analysis. Journal of 
Clinical Pharmacy and Therapeutics. 2016;41(2):128-44. doi:10.1111/jcpt.12364. 
230. Gray SL, Hart LA, Perera S, Semla TP, Schmader KE, Hanlon JT. Meta-analysis of 
Interventions to Reduce Adverse Drug Reactions in Older Adults. Journal of the American 
Geriatrics Society. 2017. doi:10.1111/jgs.15195. 
231. Thomas R, Huntley AL, Mann M, et al. Pharmacist-led interventions to reduce 
unplanned admissions for older people: a systematic review and meta-analysis of randomised 
controlled trials. Age and Ageing. 2014;43(2):174-87. doi:10.1093/ageing/aft169. 
232. Chen TF. Pharmacist-Led Home Medicines Review and Residential Medication 
Management Review: The Australian Model. Drugs & Aging. 2016;33(3):199-204. 
doi:10.1007/s40266-016-0357-2 
233. Furniss L, Burns A, Craig SK, Scobie S, Cooke J, Faragher B. Effects of a 
pharmacist's medication review in nursing homes. Randomised controlled trial. The British 
Journal of Psychiatry : The Journal of Mental Science. 2000;176:563-7.  
234. Nishtala PS, Hilmer SN, McLachlan AJ, Hannan PJ, Chen TF. Impact of residential 
medication management reviews on drug burden index in aged-care homes: A retrospective 





235. Christensen D, Trygstad T, Sullivan R, Garmise J, Wegner SE. A pharmacy 
management intervention for optimizing drug therapy for nursing home patients. American 
Journal of Geriatric Pharmacotherapy. 2004;2(4):248-56.  
236. Etzel JV, Brocavich JM, Rousseau M. Impact of the development of a 
multidisciplinary adverse drug reaction committee. Hospital Pharmacy. 1995;30(12):1083-7.  
237. Pretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse drug 
events in older adults. American family physician. 2013;87(5):331-6.  
238. O'Connor MN, O'Sullivan D, Gallagher PF, Eustace J, Byrne S, O'Mahony D. 
Prevention of hospital-acquired adverse drug reactions in older people using screening tool of 
older persons' prescriptions and screening tool to alert to right treatment Criteria: A cluster 
randomized controlled trial. Journal of the American Geriatrics Society. 2016;64(8):1558-66. 
doi:10.1111/jgs.14312 
239. American Geriatrics Society 2015 Updated Beers criteria for potentially inappropriate 
medication use in older adults. Journal of the American Geriatrics Society. 
2015;63(11):2227-46. doi:10.1111/jgs.13702. 
240. American Geriatrics Society updated Beers criteria for potentially inappropriate 
medication use in older adults. Journal of the American Geriatrics Society. 2012;60(4):616-
31. doi:10.1111/j.1532-5415.2012.03923.x. 
241. Hamilton H, Gallagher P, Ryan C, Byrne S, O'Mahony D. Potentially inappropriate 
medications defined by STOPP criteria and the risk of adverse drug events in older 






242. Vishwas HN, Harugeri A, Parthasarathi G, Ramesh M. Potentially inappropriate 
medication use in Indian elderly: comparison of Beers' criteria and Screening Tool of Older 
Persons' potentially inappropriate Prescriptions. Geriatrics & Gerontology International. 
2012;12(3):506-14. doi:10.1111/j.1447-0594.2011.00806.x. 
243. Hanlon JT, Schmader KE. What types of inappropriate prescribing predict adverse 
drug reactions in older adults? Annals of Pharmacotherapy. 2010;44(6):1110-1. 
doi:10.1345/aph.1P182. 
244. Hanlon JT, Schmader KE. The medication appropriateness index at 20: Where it 
started, where it has been, and where it may be going. Drugs & Aging. 2013;30(11):893-900. 
doi:10.1007/s40266-013-0118-4. 
245. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy 
appropriateness. Journal of Clinical Epidemiology. 1992;45(10):1045-51.  
246. Khong TK, Singer DR. Adverse drug reactions: Current issues and strategies for 
prevention and management. Expert Opinion on Pharmacotherapy. 2002;3(9):1289-300. 
doi:10.1517/14656566.3.9.1289. 
247. Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry 
and a team intervention on prevention of serious medication errors. Journal of Amrican 
Medical Association. 1998;280(15):1311-6.   
248. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry 
and clinical decision support systems on medication safety: A systematic review. Archives of 
Internal Medicine. 2003;163(12):1409-16. doi:10.1001/archinte.163.12.1409. 





250. McDowell SE, Coleman JJ, Ferner R. Systematic review and meta-analysis of ethnic 
differences in risks of adverse reactions to drugs used in cardiovascular medicine. British 
Medical Journal 2006;332(7551):1177-81.  
251. Aziz Z, Siang TC, Badarudin NS. Reporting of adverse drug reactions: Predictors of 
under-reporting in Malaysia. Pharmacoepidemiology and Drug Safety. 2007;16(2):223-8. 
doi:10.1002/pds.1313. 
252. Rehan HS, Vasudev K, Tripathi CD. Adverse drug reaction monitoring: Knowledge, 
attitude and practices of medical students and prescribers. The National Medical Journal of 
India. 2002;15(1):24-6.  
253. Federal Democratic Republic of Ethiopia Ministry of Health. Health Sector 
Development Program IV 2010/11 – 2014/15 2010. via 
http://www.nationalplanningcycles.org/sites/default/files/country_docs/Ethiopia/ethiopia_hsd
p_iv_final_draft_2010_-2015.pdf. Accessed on Oct 2018.  
254. Banteyerga H. Ethiopia's health extension program: Improving health through 
community involvement. MEDICC review. 2011;13(3):46-9.  
255. Ministry of Health. Quarterly Health Bulletin. Policy and Practice: Information for 
Action. Addis Ababa, Ethiopia: Federal Democratic Republic of Ethiopia Ministry of Health. 
2013. 
256. Ethiopia’s Health Extension Program. Via 
http://www2.pathfinder.org/site/DocServer/CBRHAs__HEWs_REVISED_REPRINT__2_.p





257. Federal Democratic Republic of Ethiopia Ministry of Health. Guideline for 
implementation of a patient referral system. 2010. 
258. Jimma University Specialised Hospital. https://www.ju.edu.et/jimma-university-
specialized-hospital-jush. Accessed on 28 December 2016 at 12:39PM. 
259. Ethiopian Food Medicine, Health Adminstration and Control authority (FMHACA). 
Guideline for adverse drug events monitoring (Pharmacovigilance). FMHACA . 2014.  
260.    Ermias A, Gurmesa G, Mesfin M, Mengistu A. Adverse Drug Reaction Monitoring in 
Ethiopia: Analysis of case reports, 2002-2007. Ethiopian Journal of Health Development. 
2011;25(2):168-73.  
261. Members of the WHO Programme for International Drug Monitoring. Via 
https://www.who-umc.org/global-pharmacovigilance/members/who-programme-members/. 
Accessed on Oct 2018. . 
262. Gurmesa LT, Dedefo MG. Factors Affecting adverse drug reaction reporting of 
healthcare professionals and their knowledge, attitude, and practice towards adr reporting in 
Nekemte Town, West Ethiopia. Biomed Research International. 2016;2016:5728462. 
doi:10.1155/2016/5728462 
263. Seid MA, Kasahun AE, Mante BM, Gebremariam SN. Healthcare professionals' 
knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health 
center level in Ethiopia. International Journal of Clinical Pharmacy. 2018;40(4):895-902. 
doi:10.1007/s11096-018-0682-0 
264. Shanko H, Abdela J. Knowledge, attitudes, and practices of health care professionals 





Eastern Ethiopia: A Cross-sectional study. Hospital Pharmacy. 2018;53(3):177-87. 
doi:10.1177/0018578717737430 
265. Doherty J M. Algorithms for assessing the probability of an adverse drug reaction. 
2009. 
266. Melmon KL. Preventable drug reactions causes and cures. The New England Journal 
of Medicine. 1971;284(24):1361-8. doi:10.1056/nejm197106172842408 
267. Wester K, Jonsson AK, Spigset O, Druid H, Hagg S. Incidence of fatal adverse drug 
reactions: a population based study. British Journal of Clinical Pharmacology. 
2008;65(4):573-9. doi:10.1111/j.1365-2125.2007.03064.x. 
268. United Nations Acquired Immunodeficiency Syndrome (UNAIDS) global update 
2016. Via: http://www.who.int/ hiv/mediacentre/news/global-aids-update-2016-news/en/. 
Accessed on 24 June 2017. 
269. Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS. Specific features of medicines 
safety and pharmacovigilance in Africa. Therapeutic Advances in Drug Safety. 2012;3(1):25-
34. doi:10.1177/2042098611425695. 
270. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse 
effects of highly active antiretroviral therapy in developing countries. Clinical Infectious 
Diseases : An Official Publication of the Infectious Diseases Society of America. 
2007;45(8):1093-101. doi:10.1086/521150. 
271. Yimer G, Ueda N, Habtewold A, et al. Pharmacogenetic & pharmacokinetic 





in TB-HIV infected patients. PLoS One. 2011;6(12):e27810. 
doi:10.1371/journal.pone.0027810. 
272. Aminkeng F, Ross CJ, Rassekh SR, et al. Higher frequency of genetic variants 
conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and 
tuberculosis in persons of African descent. The Pharmacogenomics Journal. 2014;14(2):160-
70. doi:10.1038/tpj.2013.13. 
273. Van Olmen J, Schellevis F, Van Damme W, Kegels G, Rasschaert F. Management of 
chronic diseases in sub-Saharan Africa: Cross-fertilisation between HIV/AIDS and diabetes 
care. Journal of Tropical Medicine. 2012;2012:349312. doi:10.1155/2012/349312. 
274. Misganaw A, Mariam DH, Ali A, Araya T. Epidemiology of major non-
communicable diseases in Ethiopia: a systematic review. Journal of Health, Population, and 
Nutrition. 2014;32(1):1-13.  
275. Hunchak C, Teklu S, Meshkat N, Meaney C, Puchalski Ritchie L. Patterns and 
predictors of early mortality among emergency department patients in Addis Ababa, 
Ethiopia. BMC Research Notes. 2015;8:605. doi:10.1186/s13104-015-1592-z. 
276. Misganaw A, Mariam DH, Araya T, Ayele K. Patterns of mortality in public and 
private hospitals of Addis Ababa, Ethiopia. BMC Public Health. 2012;12:1007. 
doi:10.1186/1471-2458-12-1007. 
277. Ethiopian Federal Ministry of Health HIV/AIDS Prevention and Control Office 
Country progress report in HIV/AIDS response. Addis Ababa: Ethiopian Federal Ministry of 





278. Netsanet WW, Gandham NVR. Health extension program in Ethiopia. Universal 
health coverage studies series (UNICO) No.10. The World Bank, Washington DC; 2013. Via 
http://documents.worldbank.org/curated/en/356621468032070256/Ethiopia-The-health-
extension-program-in-Ethiopia.  
279. Gedle D, Gelaw B, Muluye D, Mesele M. Prevalence of malnutrition and its 
associated factors among adult people living with HIV/AIDS receiving anti-retroviral therapy 
at Butajira Hospital, southern Ethiopia. BMC Nutrition. 2015;1(1):5. doi:10.1186/2055-0928-
1-5. 
280. Dargie B, Tesfaye G, Worku A. Prevalence and associated factors of undernutrition 
among adult tuberculosis patients in some selected public health facilities of Addis Ababa, 
Ethiopia: a cross-sectional study. BMC Nutrition. 2016;2(1):7. doi:10.1186/s40795-016-
0046-x. 
281. European Commission. Pharmacovigilance impact assessment.2008.via 
http://ec.europa.eu/health/files/pharmacos/pharmpack_12_2008/pharmacovigilance-ia-
vol1_en.pdf.  
282 Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence 
and risk factors for adverse drug reactions in the elderly in the acute care setting. Clinical 
Interventions in Aging. 2014;9:2079-86. doi:10.2147/cia.s71178. 
283. World Health Organisation. Safety of Medicine: A guide to detecting and reporting 
adverse drug reaction.WHO. Geneva. 2002. 
284. Al Hamid A, Ghaleb M, Aljadhey H, Aslanpour Z. A systematic review of 
hospitalization resulting from medicine-related problems in adult patients. British Journal of 





285. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): A 
meta-analysis of observational studies. Pharmacy World Sciences. 2002;24(2):46-54.  
286. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse 
drug reactions: A systematic review of prospective observational studies. Annals of 
Pharmacotherapy. 2008;42(7):1017-25.  
287. CIA. Country comparison: Life expectancy at birth. 2015.Via 
https://www.cia.gov/library/publications/the-world-factbook/rankorder/2102rank.html. 
Accessed on June 9, 2016 at 5:50PM.  
288. WHO. Counterfeit Medicines: An update on estimates.2006. 
http://www.who.int/medicines/services/counterfeit/impact/The New Estimates 
Counterfeit.pdf. Accessed on June,2016. 
289. World Bank. Comparing levels of development.2000. Via 
http://www.worldbank.org/depweb/beyond/beyondco/beg_02.pdf. Accessed on Decemeber 
22, 2015 at 3:00PM. 
290. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for 
adverse drug events in older Americans. New England Journal of Medicine. 
2011;365(21):2002-12.  
291. Chen YC, Fan JS, Chen MH, et al. Risk factors associated with adverse drug events 






292. Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Begaud B. Adverse drug reactions 
in a department of systemic diseases-oriented internal medicine: Prevalence, incidence, direct 
costs and avoidability. European Journal of Clinical Pharmacology. 2000;56(2):181-6.  
293. Matanovic SM, Vlahovic-Palcevski V. Potentially inappropriate prescribing to the 
elderly: comparison of new protocol to Beers criteria with relation to hospitalizations for 
ADRs. European Journal of Clinical Pharmacology. 2014;70(4):483-90. 
doi:10.1007/s00228-014-1648-3. 
294. Walsh D, Lavan A, Cushen AM, Williams D. Adverse drug reactions as a cause of 
admission to a Dublin-based university teaching hospital. Irish Journal of Medical Science. 
2015;184(2):441-7. doi:10.1007/s11845-014-1140-1. 
295. Zhong W, Maradit-Kremers H, St Sauver JL, et al. Age and sex patterns of drug 
prescribing in a defined American population. Mayo Clinic Proceedings. 2013;88(7):697-
707. doi:10.1016/j.mayocp.2013.04.021. 
296. Gill K, Pande R, Malhotra A. Women deliver for development. Lancet (London, 
England). 2007;370(9595):1347-57. doi:10.1016/s0140-6736(07)61577-3. 
297. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. 
Pharmacotherapy. 2006;26(5):601-8. doi:10.1592/phco.26.5.601. 
298. Thomas EJ, Lipsitz SR, Studdert DM, al. e. The reliability of medical record review 
for estimating adverse event rates. Annals of Internal Medicine. 2002;136(11):812-6.  
299. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional 
burden of disease and risk factors, 2001: Systematic analysis of population health data. 





300. World Health Organisation. Tuberculosis progress in Ethipia. Via  
http://www.afro.who.int/en/ethiopia/country-programmes/topics/4481-tuberculosis.html. 
Accessed on 24 June 2017. 
301. Wang H, Wolock TM, Carter A, et al. Estimates of global, regional, and national 
incidence, prevalence, and mortality of HIV, 1980-2015: The global burden of disease study 
2015. The lancet. HIV. 2016;3(8):e361-87. doi:10.1016/s2352-3018(16)30087-x. 
302. World Health Organisation. Noncommunicable Diseases (NCD) Country Profiles 
2014. Via http://www.afro.who.int/en/ethiopia/country-programmes/topics/4591-ethiopia-
non-communicable-diseases-ncd.html. Accessed on 10 Feb 2017 at 9:11am.  
303. Mamo Y, Seid E, Adams S, Gardiner A, Parry E. A primary healthcare approach to 
the management of chronic disease in Ethiopia: an example for other countries. Clinical 
Medicine (London, England). 2007;7(3):228-31.  
304. Gebretekle GB, Serbessa MK. Exploration of over the counter sales of antibiotics in 
community pharmacies of Addis Ababa, Ethiopia: Pharmacy professionals' perspective. 
Antimicrobial Resistance and Infection Control. 2016;5:2. doi:10.1186/s13756-016-0101-z. 
305. Tegegne GT, Gaddisa T , Kefale B, et al. Drug therapy problem and contributing 
factors among ambulatory hypertensive patients in Ambo General Hospital, West 
Shoa,Ethiopia. Global Journal of Medical Research. 2015;15(4):20-6.  
306. Oumer S. Irrational use of medications among elderly patients in an Ethiopian referral 






307. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM. Frequency of and risk 
factors for preventable medication-related hospital admissions in the Netherlands. Archives of 
Internal Medicine. 2008;168(17):1890-6. doi:10.1001/archinternmed.2008.3. 
308. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic 
dysfunction. European Journal of Clinical Pharmacology. 2008;64(12):1147-61. 
doi:10.1007/s00228-008-0553-z. 
309. Getahun W, Gedif T, Tesfaye F. Regular Khat (Catha edulis) chewing is associated 
with elevated diastolic blood pressure among adults in Butajira, Ethiopia: A comparative 
study. BMC Public Health. 2010;10:390. doi:10.1186/1471-2458-10-390. 
310. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug 
data coding and analysis in epidemiologic studies. European Journal of Epidemiology. 
1994;10(4):405-11.  
311. Classification Committee of the World Organisation of Family Doctors (WICC) 1998. 
ICPC-2: International Classification of Primary Care. 2nd edn. Oxford: Oxford University 
Press.1998. 
312. Wawruch M, Zikavska M, Wsolova L, et al. Adverse drug reactions related to 
hospital admission in Slovak elderly patients. Archives of Gerontology and Geriatrics. 
2009;48(2):186-90. doi:10.1016/j.archger.2008.01.004. 
313. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: 
Misleading, but manageable. Clinical Interventions in Aging. 2008;3(2):383-9.  
314. Department of health and human services. National heart, lung, and blood institute. 





315. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165-80. 
doi:10.1016/s0140-6736(11)60178-5. 
316. Reuben A. Hy's law. Hepatology. 2004;39(2):574-8. doi:10.1002/hep.20081. 
317. World Health Organisation. Treatment of Tuberculosis: Guidelines for national 
programmes. 4th edition. Switzerland, Geneva, World Health Organisation; 2010. Via 
http://www.who.int/tb/publications/tb_treatmentguidelines/en/. 
318. British National Formulary 67 (BNF). Joint formulary committee, Pharmaceutical 
Press; 2014. 
319. Up-To-Date 19.3. Via http://freemedicalresources.blogspot.com.au/ 2012/08/use-
uptodate-database-offline-with-your.html. 
320. Robin X, Turck N, Hainard A, et al. pROC: An open-source package for R and S+ to 
analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. doi:10.1186/1471-
2105-12-77. 
321. Belachew T. Are we ready for the rising silent epidemic of metabolic syndrome and 
chronic non-communicable disease in Ethiopia? Ethiopian Journal of Health Sciences. 
2015;25(1):1-2. 
322. AIDS resource centre. Via 
http://www.etharc.org/index.php/resources/healthstat/hivaids-estimates-and-projections-in-
ethiopia-2011-2016. Accessed on 09 January 2017.  
323. Sharif-Askari FS, Syed Sulaiman SA, Saheb Sharif-Askari N, Al Sayed Hussain A. 





with chronic kidney disease. PLoS One. 2014;9(4):e95991. 
doi:10.1371/journal.pone.0095991. 
324. Corsonello A, Onder G, Bustacchini S, et al. Estimating renal function to reduce the 
risk of adverse drug reactions. Drug Safety. 2012;35 Suppl 1:47-54. doi:10.1007/bf03319102. 
325. Zeeh J, Platt D. The aging liver: Structural and functional changes and their 
consequences for drug treatment in old age. Gerontology. 2002;48(3):121-7. doi:52829. 
326. Manley HJ, McClaran ML, Overbay DK, et al. Factors associated with medication-
related problems in ambulatory hemodialysis patients. American Journal of Kidney 
Diseases : The Official Journal of the National Kidney Foundation. 2003;41(2):386-93. 
doi:10.1053/ajkd.2003.50048. 
327. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug 
reactions in Europe: A review of recent observational studies. Drug Safety. 2015;38(5):437-
53. doi:10.1007/s40264-015-0281-0. 
328. Ali EE. Health care financing in Ethiopia: Implications on access to essential 
medicines. Value in Health Regional Issues. 2014;4:37-40.Via 
http://www.valuehealthregionalissues.com/article/S2212-1099%2814%2900049-1/pdf 
Accessed on 22 June 2017 at 4:53pm.  
329. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 
prognostic comorbidity in longitudinal studies: Development and validation. Journal of 





330. Michael JA, Sandra LKG, Pamela LS, Ananth MA, Amy LS. Comparing drug-drug 
interaction severity ratings between bedside clinicians and proprietary databases, ISRN 
critical care. Hindawi. 2013;2013:1-6. doi:10.5402/2013/347346. 
331. Zargarzadeh AH, Emami MH, Hosseini F. Drug-related hospital admissions in a 
generic pharmaceutical system. Clinical and Experimental Pharmacology & Physiology. 
2007;34(5-6):494-8. doi:10.1111/j.1440-1681.2007.04600.x. 
332. Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected 
patients: A double-edged sword? Journal of the American Society of Nephrology : JASN. 
2013;24(10):1519-27. doi:10.1681/asn.2012080857. 
333. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review 
and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. 
Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of 
America. 2010;51(5):496-505. doi:10.1086/655681. 
334. Mulenga L, Musonda P, Mwango A, et al. Effect of baseline renal function on 
tenofovir-containing antiretroviral therapy outcomes in Zambia. Clinical Infectious 
Diseases : An Official Publication of the Infectious Diseases Society of America. 
2014;58(10):1473-80. doi:10.1093/cid/ciu117. 
335. Leone R, Sottosanti L, Luisa Iorio M, et al. Drug-related deaths: An analysis of the 
Italian spontaneous reporting database. Drug Safety. 2008;31(8):703-13.  
336. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene 






337. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene 
as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 
2002;35(4):883-9. doi:10.1053/jhep.2002.32102. 
338. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen 
R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. Journal of 
Gastroenterology and Hepatology. 2008;23(2):192-202. doi:10.1111/j.1440-
1746.2007.05207.x. 
339. Fernandez-Villar A, Sopena B, Fernandez-Villar J, et al. The influence of risk factors 
on the severity of anti-tuberculosis drug-induced hepatotoxicity. The International Journal of 
Tuberculosis and Lung Disease : The Official Journal of the International Union Against 
Tuberculosis and Lung Disease. 2004;8(12):1499-505.  
340. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. British 
Journal of Clinical Pharmacology. 2011;71(5):659-71. doi:10.1111/j.1365-
2125.2010.03784.x. 
341. Lee WM. Drug-induced hepatotoxicity. The New England journal of medicine. 
1995;333(17):1118-27. doi:10.1056/nejm199510263331706. 
342. Bjornsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO 
database. Digestive and Liver Disease : Official Journal of the Italian Society of 
Gastroenterology and the Italian Association for the Study of the Liver. 2006;38(1):33-8. 
doi:10.1016/j.dld.2005.06.004. 
343. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a 





344. Council for International Organizations of Medical Sciences. Working group on drug 
induced liver injury. Geneva. Council for International Organisations of Medical Sciences. 
2017. Via https://cioms.ch/working_groups/dili/. 
345. Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Current Opinion 
in Gastroenterology. 2008;24(3):287-97. doi:10.1097/MOG.0b013e3282f9764b. 
346. Takikawa H. Recent status of drug-induced liver injury. Hepatology Research : The 
Official Journal of The Japan Society of Hepatology. 2009;39(1):1-6. doi:10.1111/j.1872-
034X.2008.00400.x. 
347. Hayashi PH, Chalasani NP. Increasing impact of drug‐induced liver injury. Clinical 
Liver Disease. 2015;5(6):136-8.  
348. Devarbhavi H. An Update on Drug-induced Liver Injury. Journal of Clinical and 
Experimental Hepatology. 2012;2(3):247-59. doi:10.1016/j.jceh.2012.05.002. 
349. Hussaini SH, O'Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: A major cause 
of drug-induced jaundice in southwest England. European Journal of Gastroenterology & 
Hepatology. 2007;19(1):15-20. doi:10.1097/01.meg.0000250581.77865.68. 
350. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. 
Single-center experience with drug-induced liver injury from India: Causes, outcome, 
prognosis, and predictors of mortality. The American Journal of Gastroenterology. 
2010;105(11):2396-404. doi:10.1038/ajg.2010.287. 
351. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute 






352. Idilman R, Bektas M, Cinar K, et al. The characteristics and clinical outcome of drug-
induced liver injury: A single-center experience. Journal of Clinical Gastroenterology. 
2010;44(6):e128-32. doi:10.1097/MCG.0b013e3181c5e9cc. 
353. Friis H, Andreasen PB. Drug-induced hepatic injury: An analysis of 1100 cases 
reported to the Danish Committee on adverse drug reactions between 1978 and 1987. Journal 
of Internal Medicine. 1992;232(2):133-8.  
354. Andrade RJ, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega MC, 
Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for 
gastroenterologists. World Journal of Gastroenterology. 2007;13(3):329-40.  
355. Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: 
Interactions between drug properties and host factors. Journal of Hepatology. 
2015;63(2):503-14. doi:10.1016/j.jhep.2015.04.016. 
356. Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case characterization, 
clinical features and risk factors in drug-induced liver injury. International Journal of 
Molecular Sciences. 2016;17(5). doi:10.3390/ijms17050714. 
357. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-
induced liver injury. World Journal of Gastroenterology. 2008;14(44):6774-85.  
358. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype 






359. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver 
injury in a Swedish University hospital out-patient hepatology clinic. Alimentary 
Pharmacology & Therapeutics. 2006;24(8):1187-95. doi:10.1111/j.1365-2036.2006.03117.x. 
360. Woo HJ, Kim HY, Choi ES, et al. Drug-induced liver injury: A 2-year retrospective 
study of 1169 hospitalized patients in a single medical center. Phytomedicine : International 
Journal of Phytotherapy and Phytopharmacology. 2015;22(13):1201-5. 
doi:10.1016/j.phymed.2015.10.002. 
361. Sobhonslidsuk A, Poovorawan K, Soonthornworasiri N, Pan-Ngum W, Phaosawasdi 
K. The incidence, presentation, outcomes, risk of mortality and economic data of drug-
induced liver injury from a national database in Thailand: A population-base study. BMC 
Gastroenterology. 2016;16(1):135. doi:10.1186/s12876-016-0550-0. 
362. Wondwossen A, Waqtola C, Gemeda A. Incidence of antituberculosis-drug-induced 
hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South 
Ethiopia: A cohort study. International Journal of Mycobacteriology. 2016;5(1):14-20. 
doi:10.1016/j.ijmyco.2015.10.002. 
363. Yimer G, Gry M, Amogne W, et al. Evaluation of patterns of liver toxicity in patients 
on antiretroviral and anti-tuberculosis drugs: A prospective four arm observational study in 
ethiopian patients. PLoS One. 2014;9(4):e94271. doi:10.1371/journal.pone.0094271 
364. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: 






365. World Health Organisation. Treatment of tuberculosis: Guidelines for treatment of 
drug-susceptible tuberculosis and patient care update. Switzerland, World Health 
Organisation; 2017. p. 13-5. 
366. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical 
and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis 
treatment. American Journal of Respiratory and Critical Care Medicine. 2002;166(7):916-9. 
doi:10.1164/rccm.2108091. 
367. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular 
medicines and assessment of risk factors. Annals of Pharmacotherapy. 2004;38(6):1074-9. 
doi:10.1345/aph.1D525. 
368. Parris M. Kidd. Glutathione: Systemic protectant against oxidative and ree radical 
damage. Via 
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.372.839&rep=rep1&type=pdf. 
369. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis: Potential 
role in idiosyncratic drug reactions. Toxicology. 2002;181-182:55-63.  
370. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: 
Mechanisms and management. Journal of Clinical and Experimental Hepatology. 
2013;3(1):37-49. doi:10.1016/j.jceh.2012.12.001. 
371. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid 
preventive therapy: A 7-year survey from a public health tuberculosis clinic. Journal of 





372. Warmelink I, ten Hacken NH, van der Werf TS, van Altena R. Weight loss during 
tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. The British 
Journal of Nutrition. 2011;105(3):400-8. doi:10.1017/s0007114510003636. 
373. Buchanan N, Eyberg C, Davis MD. Isoniazid pharmacokinetics in kwashiorkor. South 
African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde. 1979;56(8):299-300.  
374. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. 
Clinical Pharmacokinetics. 1996;31(1):47-64. doi:10.2165/00003088-199631010-00004. 
375. Fetene N, Linnander E, Fekadu B, et al. The Ethiopian health extension program and 
variation in health systems performance: What matters? PLoS One. 2016;11(5):e0156438. 
doi:10.1371/journal.pone.0156438 
376. Kebede AH, Alebachew Z, Tsegaye F, Lemma E, Abebe A, Agonafir M, et al. The 
first population-based national tuberculosis prevalence survey in Ethiopia, 2010-2011. The 
International Journal of Tuberculosis and Lung Disease : The Official Journal of the 
International Union Against Tuberculosis and Lung Disease. 2014;18(6):635-9. 
377. Federal Ministry of Helath.Tuberculosis, Leprosy and TB/HIV Prevention and 
Control Program Manual. Addis Ababa: 2008.Via 
http://www.who.int/hiv/pub/guidelines/ethiopia_tb.pdf. 
378. Gesesew H, Tsehaineh B, Massa D, Tesfay A, Kahsay H, Mwanri L. The prevalence 
and associated factors for delayed presentation for HIV care among tuberculosis/HIV co-
infected patients in Southwest Ethiopia: A retrospective observational cohort. Infectious 





379. Mitku AA, Dessie ZG, Muluneh EK, Workie DL. Prevalence and associated factors 
of TB/HIV co-infection among HIV Infected patients in Amhara region, Ethiopia. African 
Health Sciences. 2016;16(2):588-95. doi:10.4314/ahs.v16i2.29. 
380. Gaude GS, Chaudhury A, Hattiholi J. Drug-induced hepatitis and the risk factors for 
liver injury in pulmonary tuberculosis patients. Journal of Family Medicine and Primary 
Care. 2015;4(2):238-43. doi:10.4103/2249-4863.154661. 
381. Mulu H, Hamza L, Alemseged F. Prevalence of malnutrition and associated factors 
among hospitalized patients with acquired immunodeficiency syndrome in Jimma University 
Specialized Hospital, Ethiopia. Ethiopian Journal of Health Sciences. 2016;26(3):217-26.  
382. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. 
Clinical profile and reintroduction of therapy. Journal of Clinical Gastroenterology. 
1996;22(3):211-4. 
383. Golemba AS, Ferreyra FG, Martearena RE, Achinelli FR, Rovai GB. Drug-induced 
hepatotoxicity and tuberculosis in a hospital from the Argentinian northeast: Cross-sectional 
study. Medwave. 2015;15(4):e6135. doi:10.5867/medwave.2015.04.6135. 
384. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin 
and pyrazinamide in patients hospitalized for pulmonary tuberculosis. The European 
Respiratory Journal. 1996;9(10):2026-30. 
385. Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the 
outcome of patients with fulminant or subfulminant liver failure during antituberculous 





386. Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor 
adherence to tuberculosis treatment. Bulletin of the World Health Organization. 
2008;86(3):B-d. 
387. Kaona FA, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to 
treatment adherence and knowledge of TB transmission among patients on TB treatment. 
BMC Public Health. 2004;4:68. doi:10.1186/1471-2458-4-68. 
388. Gudina EK, Teklu AM, Berhan A, et al. Magnitude of Antiretroviral drug toxicity in 
adult HIV patients in Ethiopia: A cohort study at seven teaching hospitals. Ethiopian Journal 
of Health Sciences. 2017;27(Suppl 1):39-52.  
389. Gesesew HA, Ward P, Woldemichael K, Mwanri L. Late presentation for HIV care in 
Southwest Ethiopia in 2003-2015: Prevalence, trend, outcomes and risk factors. BMC 
Infectious Diseases. 2018;18(1):59. doi:10.1186/s12879-018-2971-6. 
390. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. Antiretroviral therapy-
associated toxicities in the resource-poor world: The challenge of a limited formulary. The 
Journal of Infectious Diseases. 2007;196 Suppl 3:S449-56. doi:10.1086/521112. 
391. Yunihastuti E, Widhani A, Karjadi TH. Drug hypersensitivity in human 
immunodeficiency virus-infected patient: Challenging diagnosis and management. Asia 
Pacific Allergy. 2014;4(1):54-67. doi:10.5415/apallergy.2014.4.1.54. 
392. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly 






393. CSA, ICF. Ethiopian Demographic Health Survey 2011, vol. 2012. Addis Ababa and 
Calverton: Central Statistical Agency (Ethiopia) and ICF International. p. 17–27. 
394. Ali E, Woldie M. Reasons and outcomes of admissions to the medical wards of 
Jimma University Specialized Hospital, Southwest Ethiopia. Ethiopian Journal of Health 
Sciences. 2010;20(2):113-20.  
395. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count 
restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clinical 
Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 
2009;48(6):787-94. doi:10.1086/597093. 
396. Jima YT, Angamo MT, Wabe NT. Causes for antiretroviral regimen change among 
HIV/AIDS patients in Addis Ababa, Ethiopia. Tanzania Journal of Health Research. 
2013;15(1):1-9.  
397. Pau AK. Antiretroviral therapy-associated serious and life-threatening toxicities. 
Current Infectious Disease Reports. 2003;5(5):429-38.  
398. Hartmann M. The side effects of antiretroviral therapy. Der Hautarzt; Zeitschrift fur 
Dermatologie, Venerologie, und verwandte Gebiete. 2006;57(11):969-74. 
doi:10.1007/s00105-006-1240-6. 
399. Shet A, Antony J, Arumugam K, Kumar Dodderi S, Rodrigues R, DeCosta A. 
Influence of adverse drug reactions on treatment success: Prospective cohort analysis of HIV-






400. De Bandt JP. Understanding the pathophysiology of malnutrition for better treatment. 
Annales Pharmaceutiques Francaises. 2015;73(5):332-5. doi:10.1016/j.pharma.2015.03.002. 
401. Roque M, Salva A, Vellas B. Malnutrition in community-dwelling adults with 
dementia (NutriAlz Trial). The Journal of Nutrition, Health & Aging. 2013;17(4):295-9. 
doi:10.1007/s12603-012-0401-9. 
402. Smyth RM, Gargon E, Kirkham J, et al. Adverse drug reactions in children: A 





















Title: “Adverse Drug Reaction Related Admissions to Jimma University Specialised 
Hospital, Southwest Ethiopia: Clinical Burdens and Determinants” 
You are invited to participate in a research study, conducted by the University of Tasmania, 
School of Medicine. You are selected as a possible participant in this research because you are 
18 years of age or older, and are admitted to a medical ward of the Jimma University 
Specialised Hospital (JUSH) between 01 May 2015 to 31 August 2016. 
Before you decide whether or not you wish to participate in this study, it is important for you 
to understand why the research is being done and what it will involve. Please take the time to 
read (or to be read) the following information carefully and discuss it with others if you wish. 
NB: This form was used after translation into local languages, Amharic and Afan Oromo, as 
explained in the methodology. 
1. What is the background of this study? 
Complications related to medicines are an increasingly important health concern. Detection of 
these complications (known as ‘adverse drug reactions (ADRs)) in hospitals provides an 
important measure of the burden of drug related morbidity on the healthcare system and also 
recognition of drug safety as a major public health priority.   
Private Bay 26 Hobart 
Tasmania Australia 7001 
Phone (03) 6226 2190 







    
     









2. What is an adverse drug reaction (ADR)? 
An adverse drug reaction is a response to a drug which occurs at doses normally used in man. 
Most are predictable and are known as side effects. Common examples include skin rash caused 
by antibiotics and drowsiness caused by some anti-allergy medicines. 
3. What is the purpose of this study? 
This study aims to assess the clinical burden of adverse drug reaction-related hospital 
admissions; determine the incidence rate of severe and preventable ADRs, and identify risk 
indicators for ADRs for patients admitted in medical wards in Ethiopia. The hope is that ADR 
risk score will be used to help identify people living in the community who have a high chance 
of ADRs, so that they can receive additional care and attention from healthcare professionals 
to reduce their chance of ending up in hospital. 
This project forms a part of Mulugeta Angamo’s PhD thesis. 
4. What does this study involve? 
If you agree to participate in this study, you can indicate that you want to be involved in using 
the attached Participant Consent Form. The study will be conducted over 12 months from 01 
May 2015 to 31 August 2016. 
This study consists of two parts. Firstly you will be interviewed with a short questionnaire 
regarding any recent changes to your drug therapy, how you take your medicines, alcohol use, 
smoking status, khat chewing habit and previous ADRs. The interview will last not more than 
30 minutes. Secondly, your medical records at the Jimma University Specialized Hospital 
(JUSH) will be reviewed to determine whether you experienced an ADR and what factors 





5. What are the risks associated with these procedures? 
You are unlikely to experience any discomfort during this procedure. If you experience some 
discomfort during the interview process, it may be due to the following reasons 
a) Possible discomfort due to the underlying medical condition. 
b) Possible discomfort due to not understanding clearly the scientific reasons for the questions 
being asked. 
c) Discomfort trying to remember the events before admission or medication history asked 
about by the research officer. 
If you find that you are becoming distressed during the interview, you are free to either end the 
interview or ask the researcher to move the discussion in another direction. If necessary, we 
will arrange for you to see a counsellor at no expense to you. 
6. What are the benefits of this study? 
Your participation may contribute to a better understanding of ADRs occurring in adults and 
elderly people. This may lead to future improvements in ADR prediction for people like you, 
with the aim of reducing the risks of ADRs for these people. This study also assists health 
practitioners to identify people who are at increased risk of ADRs and promote safer use of 
medicines, with a subsequent reduction in the associated costs of admissions due to ADRs or 
prolongation of hospital stay. 
7. What happens if I don’t want to take part in the study? 
Participation is entirely voluntary. It is completely up to you whether or not you participate. If 
you decide not to participate, it will not affect your future care. 
8. How will my confidentiality be protected? 
199 
Of the people treating you, only the research pharmacist will know whether or not you are 
participating in this study. All information will be treated in a confidential manner and all data, 
including your personal information, will be coded against a unique identifying number so your 
personal information will be protected. Your name and any other personal information will not 
be used in reports or publications resulting from this study. All of the information collected as 
part of this research will be kept in secure storage in the School of Medicine and will be 
destroyed after a period of 10 years in line with University of Tasmania regulations. 
9. Will I benefit from the study?
This study aims to further medical knowledge and may prevent adult and elderly people 
experiencing ADRs in the future; however, it may not directly benefit you. 
10. What should I do if I want to discuss this study further before I decide?
When you have read this information, if you have any queries regarding this study or your 
participation in this study, please do not hesitate to contact one of the study investigators listed 
below: 
Mulugeta Angamo (PhD candidate) 
Telephone: 04        ; Email: mulugeta.angamo@utas.edu.au 
Professor Luke Bereznicki (Deputy Head, School of Medicine) 
Telephone: 04        ; Email: Luke.Bereznicki@utas.edu.au 
Dr Leanne Chalmers (Lecturer, Pharmacy, School of Medicine) 
Telephone: 04        ; Email: Leanne.Chalmers@utas.edu.au 
Dr Colin Curtain (Pharmacy Practice course coordinator) 
Telephone: +61 3 6226 1096; Email: Colin.Curtain@utas.edu.au 
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Dr Daniel Yilma (Internist, Department of Internal Medicine, Jimma University, Ethiopia) 
Telephone: +25          ; Email: @     .com     
11. Who should I contact if I have concerns about the conduct of this study?
This project has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee. If you have any concerns of an ethical nature, or complaints about the manner in 
which the study is conducted, you may contact the Executive Officer of the Human Research 
Ethics Committee (Tasmania) Network on (03) 6226 7479 or human.ethics@utas.edu.au. The 
Executive Officer is the person nominated to receive complaints from research participants.   
Please quote the ethics reference number H0014718 and/or RPGC/58/2015. 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. 









Title of Project: “Adverse Drug Reaction Related Admissions to Jimma University 
Specialized Hospital, Southwest Ethiopia: Clinical Burdens and Determinants” 
1. I acknowledge that the nature, purpose and contemplated effects of the project so far as it 
affects me, have been fully explained to my satisfaction by the research worker and my 
consent is given voluntarily.  
2. The details of the project methods have also been explained to me, including the 
anticipated length of time it will take and an indication of any discomfort, which may be 
expected.  I understand that my involvement means that the research officer has my 
permission to collect information from my medical records, and that I will be asked to 
participate in an interview with the research officer. 
3. I understand that these are the following risks or possible discomfort: 
• Possible discomfort due to the underlying medical condition. 
• Possible discomfort due to not understanding clearly the scientific reasons for 
the questions being asked. 
• Discomfort trying to remember the events before admission or medication 
history asked about by the research officer. 
 
Private Bay 26 Hobart 
Tasmania Australia 7001 
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I am aware that if I become distressed during the interview, I may either end the interview or 
ask the researcher to move the discussion in another direction. If necessary, counselling will 
be arranged for me at no expense to me. 
4. Although I understand that the purpose of this research project is to improve the quality of 
medical care, it has also been explained that my involvement may not be of any benefit to 
me. 
5. I have been given the opportunity to have a member of my family or friend present while 
the project was explained to me. 
6. I am informed that no information regarding any medical history will be divulged and the 
results of any analyses involving me will not be published so as to reveal my identity. 
7. I understand that my involvement in the project will not affect my relationship with my 
medical advisers in their management of my health. My withdrawal will not affect my legal 
rights, my medical care or my relationship with the hospital or my doctors. 
8. I understand that I will be given a signed copy of this patient information sheet and consent 
form.  I am not giving up my legal rights by signing this consent form. 
9. I understand that the study will be conducted in accordance with the latest versions of the 
National Statement on Ethical Conduct in Human Research 2007 and applicable privacy 
laws. 
Name of participant_________________________________ 
 





10. I have explained this project and the implications of participation in it to this volunteer 
and I believe that the consent is informed and that he/she understands the implications of 
participation. 
Name of investigator:  Mulugeta Angamo 



























Appendix C. Data collection tool   
Section I: Socio-demographic and life style characteristics 
                                                          Patient card number_________________________ 
1. Admission date _____________________(dd/mm/yyyy) 
2. Discharge date______________________(dd/mm/yyyy) 
3. Age_______________ 
4. Gender:   a) Male               b) Female 
5. Weight(Kg) _____________ 
6. Height(m)_____________ 
7. Educational status: 
a) Illiterate  
b) Primary school 
c) Secondary school 
d) College and above  
8. Marital status: 
a) Single  
b) Married  
c) Widowed 
d) Divorced  
9. Job/ Occupation: 
a) Farmer 
b) Merchant 
c) Government employee 
d) Non-government employee 
e) Private employee 
f) Private technical works (e.g. 
carpenter ) 
g) Retired  
h) Student 
i) Others, specify _______________
10. Residence/Place of living: 
a) Rural village b) Urban (city or town)
11. Living status  





c) Living alone d) Other, specify________________
12. How often do you consume alcohol (Beer, Wine, “Tella”,”Tejji”, “Katikalla”, etc)? 
a) Usually( daily ) 
b) Sometimes (2-4 times per week) 
c)  Rarely (≤1 times per week)  
d) Not at all  
e) Unknown  
13. Do you smoke cigarette? 
a) Yes b) No  c) Unknown 
If YES, how many cigarette per day ___________________________ 
14. Khat chewing habit: 
a) Regular (≥4 times per week) 
b) Sometimes (2-3 times per week) 
c) Rarely (≤1 times per week) 
d) Not chew khat  
e) Unknown 
15. Do you use herbal/alternative medicine in your home or among practitioners?  
a) Yes b) No  c) Unknown 
If YES, the name of the herb/product___________________________________ 
Section II: Patient’s Cognition, daily Activity and Medication adherence (Interviews) 
16. Abbreviated Mental Test (AMT): Used for cognitive status assessment  
S. No Questions  Yes=1 No =0 
1.  How old are you?   
2.  What is the time (nearest hour)?   
3.  Address for recall at the end of test – this should be repeated by 
the patient, e.g. Ferenji Arada 
  
4.  What year is it?   





6.  Can the patient recognise two relevant persons (e.g. 
Nurse/Doctor) 
  
7.  What was the date of your birth?   
8.  When was Ethio-Eritrean War?   
9.  Who is the present Prime Minister?   
10.  Count down from 20 to 1 (no errors, no cues)   
                                                    Total Correct sum  ______/10 
NB: A score of less than 7 suggests cognitive impairment. 
17. Barthel Index (BI) of Activities of Daily Living  
 Variables  With help Independent  
1 Feeding (if food needs to be cut up)  5 10 
2 Moving from wheelchair to bed and return (includes 
sitting up in bed) 
5-10 15 
3 Personal toilet (wash face, comb hair, shave, clean teeth) 0 5 
4 Getting on and off toilet (handling clothes, wipe, flush) 5 10 
5 Bathing self 0 5 
6 Walking on level surface(or if unable to walk, propel 
wheelchair) 





7 Ascend and descend stairs 5 10 
8 Dressing(includes tying shoes, fastening fasteners) 5 10 
9 Controlling bowels 5 10 
10 Controlling bladder 5 10 





Notice: A patient scoring 100 BI is continent, feds himself, dresses himself, gets up out bed 
and chairs, bathes himself, walks at least a block, and can ascend and descend stairs.  
18. Morisky 8-Item Medication Adherence scale   
No. Morisky 8-Item Medication Adherence Questionnaire Answer 
1 Do you sometimes forget to take your medicine?  Yes       No 
2 People sometimes miss taking their medicines for reasons other than 
forgetting. Thinking over the past 2 weeks, were there any days 
when you did not take your medicine? 
 Yes       No 
3 Have you ever cut back or stopped taking your medicine without 
telling your doctor because you felt worse when you took it? 
 Yes       No 
4 When you travel or leave home, do you sometimes forget to bring 
along your medicine?  
 Yes       No 
   5 Did you take all your medicines yesterday?  Yes       No 
6 When you feel like your symptoms are under control, do you 
sometimes stop taking your medicine? 
 Yes       No 
7 Taking medicine every day is a real inconvenience for some people. 
Do you ever feel hassled about sticking to your treatment plan? 
 Yes       No 
 
   8 How often do you have difficulty remembering to take all your 
medicine?  
 Never/rarely 
 Once in a while 
  Sometimes 
  Usually 
  All the time 
                                          Total Correct sum ______/8 






Section III: Medical and medication related data (Medical Record Review) 
19. Chief compliant for current admission is : 
_____________________________________________________________________ 
20. Pertinent history of present illness: 
___________________________________________________________________________
___________________________________________________________________________ 




22. Was the patient following up for chronic care at ambulatory care clinic? 
                a) Yes               b) No          c) unknown 
23. Was the patient admitted in the last 3 months?   
      a) Yes      b) No     c) unknown  
If YES, reasons for admission______________________________________________ and 
Number of admissions________________            
24. Does the patient have documented or reported drug allergy/hypersensitivity history, e.g. to 
Penicillin, Aspirin?  
                  a) Yes                          b) No                      c) unknown 
If YES, for which drug/agent_______________________________________________ 
25. Does the patient have documented or reported ADR history? 
                      a) Yes                    b) No                       c) unknown 
If YES, for which drug/agent ______________________________________________ 





The Charlson Co-Morbidity Index* Yes No Classic score Updated 
AIDS   +6 +4 
Cerebrovascular disease (excluding hemiplegia)   +1 +0 
Chronic respiratory disease (e.g. asthma, COPD, bronchitis)   +1 +1 
Congestive heart failure   +1 +2 
Connective tissue disease (e.g. SLE, rheumatoid arthritis, 
scleroderma, Sjogren’s disease, osteoarthritis, etc.) 
  +1 +1 
Dementia   +1 +2 
Hemiplegia or paraplegia   +2 +2 
Any malignancy including Leukaemia  and Lymphoma   +2   +2 
Myocardial infarction   +1 +0 
Peripheral vascular disease   +1         + 0 
Peptic ulcer disease   +1 + 0 
Diabetes mellitus without end organ damage       +1 + 0 
Diabetes mellitus with end organ damage         +2 +1 






    +1 +2 
Moderate or severe liver disease (e.g. cirrhosis with portal HT 
+/- variceal bleeding) 
     +3 +4 
Renal diseases          +2 +1 
Metastatic solid tumour         +6 +6 
                                                              Total score:   
Age of patient 









2. Age 41-50 years: 1 points 
3. Age 51-60 years: 2 points 
4. Age 61-70 years: 3 points 
5. Age 71-80 years: 4 points 






    +1 
    +2 
    +3 
       +4 
       +5 
                                                         Total score, including age factor   
*Note: The following comorbid conditions are mutually exclusive: diabetes with chronic complications 
and diabetes without chronic complications; mild and moderate/sever liver disease; and any malignancy 
and metastatic solid tumour 
 
27. Pertinent Laboratory/Biochemical investigation results that could be helpful for ADR 
diagnosis (write the laboratory investigation result in-front of respective parameters if it 
was performed as per the patient clinical indication )  
 
Laboratory parameters  
Laboratory investigations vs normal reference values   
At Admission (if any 
between 0 to 24 hrs of 
admission)   
Reference values (Bases on Koda-Kimble, et 
al. Applied therapeutics book) 
Renal function test 
a) Scr  0.6-1.2mg/dl 
b) BUN  8-18 mg/dl 
c) eGFR  75-125ml/min  
Liver function test 
a) AST  0-35 IU/L 





c) ALP   30 – 120 U/L 
d) Bilirubin-total  0.1–1.0 mg/dL   
e) Bilirubin-direct   0-0.2mg/dL 
f) Serum albumin   3.5 – 5 g/dL 
Complete Blood Count(CBC)  
a) WBC count  3.2-9.8x103cell/mm3 
b) RBC count  4.2-5.9x106 for M&3.5-5x106 cells/mm3 
forF 
c) Neutrophils   54%-62% 
d) Bands   3%-5% 
e) Lymphocytes   25%-33% 
f) Monocytes   3%-7% 
g) Eosinophils   1%-3% 
h) Basophils   <1% 
i) Hgb  14-18g/dL for M &12-16 g/dL for females 
j) HCT  39-49% for M &33-43% for F 
k) MCV  76 to 100 μm3 
l) MCH  27 to 33pg 
m) MCHC  33- 37g/dL 
n) PLT  130-400x103/ mm3 
Coagulation Test 
a) INR  2.0-3.0 for AF/DVT/VHD 
b) aPTT  35 to 45 to seconds 





a) TG  <160 mg/dL 
b) Total Cholest  <200 mg/dL 
c) LDL  70–160 mg/dL 
d) HDL  >45 mg/dL 
Cardiac function  
a) Troponin I  <0.03 ng/mL 
b) CK-MB  0–12 units/L 
Electrolyte test  
a) Na+  135 - 145 mEq/L 
b) K+  3.5 – 5.0 mEq/L 
c) Ca+  8.8 – 10.2 mg/dl 
Glycaemic level  
a) FPG  70 – 110 mg/dl 
b) RPG  140-180mg/dl 
Vital signs  
a) Temperature   
b) BP   
c) PR   




































28. List of medications (including OTC medications and contraceptive pills)  used prior to the current hospital admissions 
Name of the prescription only drug  Yes   No Dose   Frequency Date started  Date stopped  Routes Remark  
1.        
2.        
3.        
4.        
5.        
6.        
7.        
Name of Contraceptives  Yes       No Dose   Frequency Date started  Date stopped  Routes Remark  
8.        
9.        
Name of OTC drugs   Yes       No Dose   Frequency Date started  Date stopped  Routes Remark  
10.        
11.        





Section IV: Summary of ADR Case note  






30. What are the pertinent clinical and laboratory abnormalities for suspected corresponding 
drug(s)? 
Pertinent suspected drug related reactions 
(after interviewing of patient and 
reviewing of patient medical record) i.e. 




Corresponding suspected list 
of drug(s) patient taking at 
admission 
1)    
 
 
2)    
 
3)   
 
 











31. Suspected drug outcomes  
a) Drug stopped  
b) Drug withheld  
c) Drug continued  
d) Drug substituted 
e) Dose reduced 
f) Antidote or counteracting agent administered  
g) Unknown  
32. ADR outcome: 
a) Fatal                    
b) Not yet recovered  
c) Partially recovered                     
d) Recovered                     
e) Unknown    
Section V: ADR Causality, Severity, Type and Preventability assessment  
33. Causality assessment for each of the suspected drug on Q30 above 




Scores for suspected  
drug(s) in Q31 
(1) (2) (3) (4) 
1. Are there previous conclusive reports on this reaction?  +1 0 0     
2. Did the adverse reaction appear after the suspected drug 
was administered?  
+2 -1 0     
3. Did the adverse reaction improve when the drug was 
discontinued or a specific antagonist was administered?  





4. Did the adverse reaction reappear when the drug was 
readministered?  
+2 -1 0     
5. Are there alternative causes that could on their own have 
caused the reaction?  
-1 +2 0     
6. Did the reaction reappear when a placebo was given?  -1 +1 0     
7. Was the drug detected in blood or other fluids in 
concentrations known to be toxic?  
+1 0 0     
8. Was the reaction more severe when the dose was 
increased or less severe when the dose was decreased?  
+1 0 0     
9. Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure?  
+1 0 0     
10. Was the adverse reaction confirmed by any objective 
evidence?  
+1 0 0     
Total Score:        
 
34. List of drug(s) implicated in causing ADR 
List of drug(s)  List of corresponding ADRs 
1)   
2)   
3)   







35. Type of ADR based on Rawlins classification (Tick “√” in the most appropriate box taking 
into consideration of ADR listed in Q34)  
ADR type Reaction (1) Reaction (2) Reaction (3) Reaction (4) 
a) Type A (Dose dependent, 
pharmacological and 
predictable) 
    
b) Type  B (Dose independent, 
bizarre and non-predictable)  
    
 
36. Is there clinically significant interactions between or among drugs used by the patient at 
admission? This question should be answered by checking interactions in MICROMEDEX 
drug interaction checker and based on existing evidences.  
a) Yes                      b) No                             c) Unknown  
If YES, the severity level of interaction is: 
a) Contraindicated (Avoid combination)-means the drugs are contraindicated for concurrent 
use 
b) Major (Consider therapy modification) -means the interaction may be life threatening 
and/or require medical intervention to minimise or prevent serious adverse events 
c) Moderate (Monitor therapy)-means the interaction may result in exacerbation of the 
patient’s condition and/or require an alteration in therapy 
d) Minor (No action is needed) – means the interaction would have limited clinical effects. 
May include an increase in the frequency or severity of the side effects, but generally it 
would not require a major alteration in therapy 





37. Severity of ADR based on modified Hartwig and Siegel scale (Tick √ in the most appropriate level  for ADR listed in Q34)  
Severity scale  Severity 
Level  
Description of the above identified reaction(s)  Reaction (1) Reaction (2) Reaction (3) Reaction (4) 
a) Mild  Level 1 The ADR requires no change in treatment with the suspected 
drug.                                                              Yes       No 
    
Level 2 The ADR requires that the suspected drug be withheld, 
discontinued or otherwise changed.               Yes       No 
    
b) Moderate  Level 3 The ADR requires that the suspected drug be withheld, 
discontinued or otherwise changed, and/ or an antidote or other 
treatment is required. There is no increase in length of stay.  
                                                                         Yes       No 
    
Level 4 (a) Any level 3 ADR that increases length of stay by at least one day. 
                                                                         Yes       No 
    
Level 4 (b) The ADR is the reason for admission.             Yes       No     
c) Severe  Level 5 Any level 4 ADR that requires intensive medical care.  
                                                                              Yes       No 
    
Level 6 The ADR causes permanent harm to the patient.  Yes       No     
Level 7(a) The ADR directly leads to the death of the patient.  Yes   No                                                                                







38. Preventability of ADR based on Schumock and Thornton scale (Tick √ in the most appropriate preventability scale bases on the ADR listed in 
Q 34). Notice: Answering “yes” to one or more of the questions in section “a” implies that an ADR is DEFINITELY preventable and If answers 
are all negative to section “a”, then proceed to Section “b”. Answering “yes” to one or more of the questions in section “b” implies that an 
ADR is PROBABLY preventable and if the answers are all negative to section “b”, then proceed to Section “c”. In Section “c” the ADR is 
NOT preventable  




1. Was there a history of allergy or previous reactions to the drug?             
 Yes       No 
2. Was the drug involved inappropriate for the patient’s clinical 
condition?       Yes       No 
3. Was the dose, route or frequency of administration 
inappropriate for the patient’s age, weight or disease state? 
                         Yes       No 
4. Was a toxic serum drug concentration (or laboratory 
monitoring test) documented?  Yes       No 





5. Was there a known treatment for the adverse drug reaction?  




6. Was required therapeutic drug monitoring or other necessary 
laboratory tests not performed?                        Yes       No 
7. Was a drug interaction involved in the ADR?  Yes       No 
8. Was poor compliance involved in the ADR?    Yes       No 
9. Were preventative measures not prescribed or administered to 
the patient?                                                        Yes       No 
    
















































Appendix F. ADR preventability factors  
Of 119 ADR-related admissions, 106 (89.1%) ADRs in 92 patients were suspected to be 
preventable according to Schumock et al. preventability assessment criteria. The leading 
preventability factors identified were inadequate monitoring of therapies (73.3%), presence of 
drug interactions (65.0%), not prescribing preventive measures (58.3%), presence of poor 
medication compliance (30.5%) and presence of previous ADR history (24.4%) (Fig 1). The 
majority (75.5%) of the reactions involved >1 Schumock et al. preventability assessment factor.  
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Appendix G. ADR severity, outcomes and length of hospital stay   
According to the Hartwig severity scale, 95 (79.8%) of the ADRs were reasons for hospital 
admission and/or increased LOS by at least one day, 6 (5.0%) of the ADRs required intensive 
medical care, 3 (2.5%) caused permanent harm to the patient and 15 (12.6%) led to death 
directly or indirectly. Of the 119 ADRs, 58 (48.7%) were not recovered at discharge whereas 
46 (38.7%) ADR cases were fully recovered (Table 1). 
One hundred and nineteen ADRs resulted in 1,565 hospital days (1,319 days for moderate 
ADRs and 246 days for severe ADRs), which was 11.6% of overall admissions (i.e. 13,520 
days). The overall median (IQR) LOS for patients with ADRs was 12 (9-20) days. The median 
(IQR) LOS was shorter for patients with severe ADRs than patients with moderate ADRs and 
patients without ADRs, 10 (4.5-12) days versus 13 (9-21) days versus 11 (8-16) days, 
respectively. Overall, ADRs prolonged hospital stay by approximately two days.   
Appendix G Table. Hartwig severity scale and outcomes of the patients hospitalised with 
ADRs 
ADR severity level  N (%) 
ADR was a reason for hospital admission and/or increased LOS by 
at least one day 
95 (79.8) 
ADR that required intensive medical care 6 (5.0) 
ADR caused permanent harm to the patient 3 (2.5) 
ADR directly or indirectly led to death 15 (12.6) 
ADR outcomes   
Fatal 15 (12.6) 
Not fully recovered 58 (48.7) 






Appendix H. Previous ADR history 
Of 1,001 patients included in this study, 41 (4.1%) patients had a previous ADR history. Of 
these 41 cases, 29 (71.0%) were documented in patients admitted with current ADRs and 61.0% 
were in females. Of the 29 previous ADR cases identified in patients hospitalised with ADRs, 
12 of them were similar in type to the current ADRs. Of 41 patients with a previous ADR 
history, ADRs were not diagnosed in 12 of them (i.e. 12 patients with previous ADR history 



















Appendix H Table. Case details of patients with previous ADR history  
Patient 
ID  
Age Gender  Previous ADR type/allergy or 
suspected drug  
Current ADR and suspected ADR 
07 27 F  Ampicillin suspected allergy  Cloxacillin suspected skin rash  
87 58 F  Glibenclamide suspected 
hypoglycemia  
Glibenclamide suspected gastritis  
130  27  F  AZT/3TC/EFV with unidentified 
ADR 
Lamivudine suspected diarrhoea  
176 50  M  Insulin suspected hypoglycemia  Insulin suspected hypoglycemia  
177  48  M  Metoprolol and enalapril with 
unidentified ADR 
Metoprolol suspected syncope  
187  40  F  Bleeding with unknown agent  Diclofenac suspected 
gastrointestinal bleeding  
278 36  F  Phenobarbital and phenytoin 
suspected osteoporosis  
Phenobarbital and phenytoin 
suspected osteomalacia  
279 38  M  Anti-TB suspected hepatotoxicity  Isoniazid and pyrazinamide 
suspected hepatotoxicity  
296  75  M  Atorvastatin and aspirin 
suspected unidentified ADR 
Atorvastatin suspected 
hepatotoxicity 
303  25  F  Tenofovir suspected 
nephrotoxicity  
Tenofovir suspected acute kidney 
injury  
304  35  F  Anti-TB suspected skin rash  Isoniazid and rifampicin suspected 
pruritic skin rash  
305  29   F  Efavirenz suspected 
hepatotoxicity  
Efavirenz suspected hepatotoxicity 




314  70  M  Glibenclamide suspected 
hypoglycemia  
Insulin and glibenclamide 
suspected hypoglycemia  
340  25  F  Efavirenz suspected nightmare  Efavirenz suspected delirium  
345  70  M  Atenolol suspected orthostatic 
hypotension  
Furosemide suspected acute 
kidney injury and metoprolol 
suspected vertigo  
374 40  F  Skin rash with unknown agent  Isoniazid and pyrazinamide 
suspected hepatotoxicity 
401  27   F  Zidovudine suspected anemia  Nevirapine suspected severe skin 
rash  
405  18 M  Skin rash with unknown agent  Diclofenac suspected acute kidney 
injury  
421  28  F  Anti-TB suspected hepatotoxicity Isoniazid and pyrazinamide 
suspected hepatotoxicity 
524  37  F  Zidovudine suspected allergic 
reaction   
Rifampicin suspected diarrhea   
550  24  M  Anti-TB suspected hepatotoxicity Isoniazid and pyrazinamide 
suspected hepatotoxicity 
659  55 F  Anti-TB suspected unidentified 
ADR 
Isoniazid and efavirenz suspected 
hepatotoxicity 
677  28  F  Co-trimoxazole suspected 
hypersensitivity reaction  
Isoniazid, pyrazinamide and 





Case details of patients with previous ADR-history cont…. 
Patient 
ID  
Age Gender  Previous ADR type/allergy and 
suspected drug  
Current ADR 
769  33 M  Anti-TB suspected unidentified 
ADR 
Isoniazid and ritonavir suspected 
hepatotoxicity 
878 25  M  Efavirenz suspected 
neuropsychiatric problem  
Efavirenz suspected delirium 
899  35  F  Medroxyprogesterone acetate 
suspected skin rash  
Medroxyprogesterone acetate 
suspected vaginal bleeding   
921  40  F  Hydrochlorothiazide suspected 
Skin rash 
Furosemide suspected acute 
kidney injury and hypocalcemia  
993  19  F  Phenytoin suspected gingival 
hyperplasia  
Phenytoin suspected gingival 
hyperplasia 
146 20  M  Anti-TB suspected skin 
pigmentation (blackening)  
No ADR suspected  
156  35  M  Epigastric pain with unknown 
agent  
No ADR suspected 
168  40  M  Nevirapine suspected skin rash  No ADR suspected 
172  80  M  Enalapril suspected dry cough  No ADR suspected 
212  80  F  Penicillin allergic  No ADR suspected 
225  32  F  Co-trimoxazole and nevirapine 
suspected skin rash  
No ADR suspected 
257  30  F  Lamivudine suspected 
vomiting  
No ADR suspected 
370  35  F  Anti-TB suspected 
hepatotoxicity 
No ADR suspected 
380  36  F  Warfarin suspected bleeding  No ADR suspected 
776  21 M  Warfarin suspected bleeding No ADR suspected 
785  35 F  Anti-TB suspected unidentified 
ADR 
No ADR suspected 
956  48  F  Unfractionated heparin 
suspected phlebitis   
No ADR suspected 
 
 
